PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20306339-0	2011	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.	Capecitabine	85-97	thymidylate synthetase	Homo sapiens	0-20
20306339-0	2011	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.	Capecitabine	85-97	thymidylate synthetase	Homo sapiens	22-26
20306339-1	2011	PURPOSE: The primary aim of this study was to characterize the 6-month overall survival and toxicity associated with second-line capecitabine treatment of advanced pancreatic cancer patients harboring the TYMS *2/*2 allele.	Capecitabine	129-141	thymidylate synthetase	Homo sapiens	205-209
20306339-5	2011	Patients with the *2/*2 TYMS polymorphism were treated with capecitabine, 1,000 mg/m2 twice daily for 14 consecutive days of a 21 day cycle.	Capecitabine	60-72	thymidylate synthetase	Homo sapiens	24-28
20306339-16	2011	Although the study was closed early, it appears capecitabine therapy in pancreatic cancer patients harboring the TYMS *2/*2 variant may be associated with increased non-hematologic toxicity.	Capecitabine	48-60	thymidylate synthetase	Homo sapiens	113-117
29147260-0	2011	Complete Remission of Advanced Gastric Cancer in Response to Chemotherapy With Docetaxel, Cisplatin and Capecitabine (dcx).	Capecitabine	104-116	doublecortin	Homo sapiens	118-121
21170649-0	2011	Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.	Capecitabine	74-86	thymidylate synthetase	Homo sapiens	0-20
21170649-0	2011	Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.	Capecitabine	74-86	thymidine phosphorylase	Homo sapiens	25-48
21170649-1	2011	PURPOSE: The primary purpose of this study was to evaluate the role of thymidylate synthase (TS) and thymidine phosphorylase (TP) as biomarkers to predict clinical outcomes of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC).	Capecitabine	176-188	thymidylate synthetase	Homo sapiens	71-91
21170649-1	2011	PURPOSE: The primary purpose of this study was to evaluate the role of thymidylate synthase (TS) and thymidine phosphorylase (TP) as biomarkers to predict clinical outcomes of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC).	Capecitabine	176-188	thymidine phosphorylase	Homo sapiens	101-124
21050273-10	2011	We conclude that oral capecitabine significantly decreases the incidence rates of recurrent SCC, BCC, and AK in SOTRs and is associated with manageable toxicity.	Capecitabine	22-34	serpin family B member 3	Homo sapiens	92-95
20656421-0	2011	Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.	Capecitabine	52-64	thymidylate synthetase	Homo sapiens	123-143
20656421-0	2011	Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.	Capecitabine	52-64	thymidine phosphorylase	Homo sapiens	148-171
21804305-1	2011	Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5"-deoxy-5-fluorocytidine (5"-DFCR), 5"-deoxy-5-fluorouridine (5"-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively.	Capecitabine	0-12	cytidine deaminase	Mus musculus	239-257
21804305-1	2011	Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5"-deoxy-5-fluorocytidine (5"-DFCR), 5"-deoxy-5-fluorouridine (5"-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively.	Capecitabine	0-12	cytidine deaminase	Mus musculus	259-262
21804305-1	2011	Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5"-deoxy-5-fluorocytidine (5"-DFCR), 5"-deoxy-5-fluorouridine (5"-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively.	Capecitabine	0-12	thymidine phosphorylase	Mus musculus	269-292
21113620-0	2011	The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.	Capecitabine	33-45	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	14-19
21113620-2	2011	It is hypothesized that capecitabine (Hoffmann-La Roche Inc.) based chemotherapy can cause overexpression of COX-2 in tumor and healthy tissue, which finally induced HFS in hands and feet.	Capecitabine	24-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	109-114
21498394-0	2011	Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.	Capecitabine	105-117	dihydropyrimidine dehydrogenase	Homo sapiens	71-75
21586171-0	2011	Thymidine Phosphorylase/beta-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.	Capecitabine	139-151	thymidine phosphorylase	Homo sapiens	0-23
21586171-7	2011	CONCLUSIONS: In Chinese advanced gastric cancer, Thymidine Phosphorylase positive & beta-tubulin III negative might predict response and prognosis to capecitabine plus paclitaxel chemotherapy.	Capecitabine	154-166	thymidine phosphorylase	Homo sapiens	49-72
21498394-1	2011	PURPOSE: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine.	Capecitabine	139-151	dihydropyrimidine dehydrogenase	Homo sapiens	34-65
21498394-1	2011	PURPOSE: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine.	Capecitabine	139-151	dihydropyrimidine dehydrogenase	Homo sapiens	67-70
21498394-3	2011	The coding region of dihydropyrimidine dehydrogenase gene (DPYD) was sequenced in 45 cases with grade 3 or more capecitabine-related toxicity and in 100 randomly selected controls (cohort).	Capecitabine	112-124	dihydropyrimidine dehydrogenase	Homo sapiens	21-52
21498394-3	2011	The coding region of dihydropyrimidine dehydrogenase gene (DPYD) was sequenced in 45 cases with grade 3 or more capecitabine-related toxicity and in 100 randomly selected controls (cohort).	Capecitabine	112-124	dihydropyrimidine dehydrogenase	Homo sapiens	59-63
21498394-12	2011	CONCLUSIONS: DPYD IVS14+1G>A and 2846A>T predict for severe toxicity to capecitabine, for which patients require dose reductions.	Capecitabine	78-90	dihydropyrimidine dehydrogenase	Homo sapiens	13-17
21756828-10	2011	The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively.	Capecitabine	37-49	protein tyrosine phosphatase receptor type U	Homo sapiens	57-60
21756828-10	2011	The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively.	Capecitabine	37-49	protein tyrosine phosphatase receptor type U	Homo sapiens	141-144
21756828-10	2011	The sensitivity to doxifluridine and capecitabine in AGS-pTP was significantly increased, as compared with that in AGS-p. IC50 values of AGS-pTP to doxifluridine and capecitabine were estimated 1.7 folds and 2.2 folds as much as that of AGS-p, respectively.	Capecitabine	166-178	protein tyrosine phosphatase receptor type U	Homo sapiens	141-144
21756828-12	2011	CONCLUSIONS: Enhancement of TP expression improves the sensitivity of gastric carcinoma cells to doxifluridine and capecitabine.	Capecitabine	115-127	thymidine phosphorylase	Homo sapiens	28-30
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Capecitabine	118-130	KRAS proto-oncogene, GTPase	Homo sapiens	36-47
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Capecitabine	118-130	KRAS proto-oncogene, GTPase	Homo sapiens	49-53
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Capecitabine	118-130	tumor protein p53	Homo sapiens	164-167
21508389-2	2011	Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes colorectal tumour cells to oxaliplatin and capecitabine in a wild-type tumour suppressor p53 (TP53)-dependent manner.	Capecitabine	118-130	tumor protein p53	Homo sapiens	169-173
21325291-0	2011	A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.	Capecitabine	66-78	cytidine deaminase	Homo sapiens	22-40
21768671-0	2011	Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.	Capecitabine	38-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	80-86
24212668-1	2011	The present article describes the ongoing (partial) remission of a female patient (41 years old) from estrogen receptor (ER)-positive/progesterone receptor (PR)-negative metastatic breast cancer in response to a combination treatment directed towards the revitalization of the mitochondrial respiratory chain (oxidative phosphorylation), the suppression of NF-kappaB as a factor triggering the inflammatory response, and chemotherapy with capecitabine.	Capecitabine	439-451	estrogen receptor 1	Homo sapiens	102-119
24212668-1	2011	The present article describes the ongoing (partial) remission of a female patient (41 years old) from estrogen receptor (ER)-positive/progesterone receptor (PR)-negative metastatic breast cancer in response to a combination treatment directed towards the revitalization of the mitochondrial respiratory chain (oxidative phosphorylation), the suppression of NF-kappaB as a factor triggering the inflammatory response, and chemotherapy with capecitabine.	Capecitabine	439-451	estrogen receptor 1	Homo sapiens	121-123
24212668-1	2011	The present article describes the ongoing (partial) remission of a female patient (41 years old) from estrogen receptor (ER)-positive/progesterone receptor (PR)-negative metastatic breast cancer in response to a combination treatment directed towards the revitalization of the mitochondrial respiratory chain (oxidative phosphorylation), the suppression of NF-kappaB as a factor triggering the inflammatory response, and chemotherapy with capecitabine.	Capecitabine	439-451	progesterone receptor	Homo sapiens	134-155
20709813-1	2011	BACKGROUND: To evaluate capecitabine-docetaxel (XT), with trastuzumab (H) in human epidermal growth factor receptor 2 (HER2)-positive disease, in inoperable locally advanced breast cancer (LABC).	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-117
20709813-1	2011	BACKGROUND: To evaluate capecitabine-docetaxel (XT), with trastuzumab (H) in human epidermal growth factor receptor 2 (HER2)-positive disease, in inoperable locally advanced breast cancer (LABC).	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-123
21498742-11	2011	CONCLUSION: The median OS of pretreated patients with HER2-negative MBC receiving capecitabine is approximately 18 months, but HER2-negative/HRe-negative patients have a low probablility of response/disease control to capecitabine and require innovative therapies.	Capecitabine	82-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
21498742-11	2011	CONCLUSION: The median OS of pretreated patients with HER2-negative MBC receiving capecitabine is approximately 18 months, but HER2-negative/HRe-negative patients have a low probablility of response/disease control to capecitabine and require innovative therapies.	Capecitabine	218-230	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
21168393-7	2011	Emodin enhances the capecitabine-induced cytotoxic effects through ERK1/2 inactivation and decreasing the Rad51 and ERCC1 protein levels induced by capecitabine.	Capecitabine	20-32	mitogen-activated protein kinase 3	Homo sapiens	67-73
21498742-0	2011	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
21498742-3	2011	Here, response, survival and prognostic factors were examined in a prospectively characterized cohort of human epidermal growth factor receptor 2 (HER2) negative MBC patients receiving capecitabine following anthracycline and taxane failure.	Capecitabine	185-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-145
21498742-3	2011	Here, response, survival and prognostic factors were examined in a prospectively characterized cohort of human epidermal growth factor receptor 2 (HER2) negative MBC patients receiving capecitabine following anthracycline and taxane failure.	Capecitabine	185-197	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
21168393-0	2011	Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.	Capecitabine	125-137	RAD51 recombinase	Homo sapiens	14-19
21168393-7	2011	Emodin enhances the capecitabine-induced cytotoxic effects through ERK1/2 inactivation and decreasing the Rad51 and ERCC1 protein levels induced by capecitabine.	Capecitabine	148-160	RAD51 recombinase	Homo sapiens	106-111
21168393-0	2011	Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.	Capecitabine	125-137	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
21168393-7	2011	Emodin enhances the capecitabine-induced cytotoxic effects through ERK1/2 inactivation and decreasing the Rad51 and ERCC1 protein levels induced by capecitabine.	Capecitabine	148-160	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	116-121
21168393-4	2011	Accordingly, we aimed to explore the molecular mechanism of emodin enhances the capecitabine-induced cytotoxicity through controlling Rad51, ERCC1, and TP expression in human non-small cell lung cancer (NSCLC).	Capecitabine	80-92	RAD51 recombinase	Homo sapiens	134-139
21168393-4	2011	Accordingly, we aimed to explore the molecular mechanism of emodin enhances the capecitabine-induced cytotoxicity through controlling Rad51, ERCC1, and TP expression in human non-small cell lung cancer (NSCLC).	Capecitabine	80-92	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	141-146
21168393-8	2011	Enhancement of ERK1/2 signaling by constitutively active MKK1/2 (MKK1/2-CA) results in increasing Rad51 and ERCC1 protein levels and cell viability in NSCLC cell lines treated with emodin and capecitabine.	Capecitabine	192-204	mitogen-activated protein kinase 3	Homo sapiens	15-21
21168393-8	2011	Enhancement of ERK1/2 signaling by constitutively active MKK1/2 (MKK1/2-CA) results in increasing Rad51 and ERCC1 protein levels and cell viability in NSCLC cell lines treated with emodin and capecitabine.	Capecitabine	192-204	mitogen-activated protein kinase kinase 1	Homo sapiens	57-63
21168393-5	2011	The results show that capecitabine increases the phosphorylation of MKK1/2-ERK1/2 and protein levels of Rad51 and ERCC1 through enhancing the protein stability.	Capecitabine	22-34	mitogen-activated protein kinase kinase 1	Homo sapiens	68-72
21168393-5	2011	The results show that capecitabine increases the phosphorylation of MKK1/2-ERK1/2 and protein levels of Rad51 and ERCC1 through enhancing the protein stability.	Capecitabine	22-34	mitogen-activated protein kinase 3	Homo sapiens	75-81
21168393-5	2011	The results show that capecitabine increases the phosphorylation of MKK1/2-ERK1/2 and protein levels of Rad51 and ERCC1 through enhancing the protein stability.	Capecitabine	22-34	RAD51 recombinase	Homo sapiens	104-109
21168393-5	2011	The results show that capecitabine increases the phosphorylation of MKK1/2-ERK1/2 and protein levels of Rad51 and ERCC1 through enhancing the protein stability.	Capecitabine	22-34	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	114-119
21168393-8	2011	Enhancement of ERK1/2 signaling by constitutively active MKK1/2 (MKK1/2-CA) results in increasing Rad51 and ERCC1 protein levels and cell viability in NSCLC cell lines treated with emodin and capecitabine.	Capecitabine	192-204	mitogen-activated protein kinase kinase 1	Homo sapiens	65-74
21168393-10	2011	We conclude that enhancing the cytotoxicity to capecitabine by emodin is mediated by down-regulation the expression of Rad51 and ERCC1 and up-regulation TP expression.	Capecitabine	47-59	RAD51 recombinase	Homo sapiens	119-124
21168393-10	2011	We conclude that enhancing the cytotoxicity to capecitabine by emodin is mediated by down-regulation the expression of Rad51 and ERCC1 and up-regulation TP expression.	Capecitabine	47-59	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	129-134
20461379-0	2011	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.	Capecitabine	40-52	NK6 homeobox 2	Mus musculus	83-87
20461379-2	2011	We report the first prospective analysis of the 3-drug combination of gemcitabine (G), docetaxel (T) and capecitabine (X) (mGTX) with schedule modification to maximize biomodulation of X.	Capecitabine	105-117	NK6 homeobox 2	Mus musculus	123-127
21224365-8	2011	RESULTS: Patients with low scores for Dll4, VEGF-C, and neuropilin-1 showed trends toward improvement in PFS associated with the addition of bevacizumab to capecitabine (P values = 0.01, 0.05, and 0.07, respectively).	Capecitabine	156-168	delta like canonical Notch ligand 4	Homo sapiens	38-42
21168393-6	2011	Depletion of endogenous Rad51 or ERCC1 expression by specific small interfering RNA transfection significantly increases capecitabine-induced cell death and growth inhibition.	Capecitabine	121-133	RAD51 recombinase	Homo sapiens	24-29
21168393-6	2011	Depletion of endogenous Rad51 or ERCC1 expression by specific small interfering RNA transfection significantly increases capecitabine-induced cell death and growth inhibition.	Capecitabine	121-133	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	33-38
20643864-1	2011	BACKGROUND: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment.	Capecitabine	276-288	TIMP metallopeptidase inhibitor 1	Homo sapiens	67-106
20643864-1	2011	BACKGROUND: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment.	Capecitabine	276-288	TIMP metallopeptidase inhibitor 1	Homo sapiens	108-114
21342034-14	2011	show the activity and safety of capecitabina at a lower dose (1000 mg/m(2) twice daily) at first-line therapy in HER2-negative metastatic breast cancer.	Capecitabine	32-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
20125120-2	2011	The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX).	Capecitabine	168-180	vascular endothelial growth factor A	Homo sapiens	78-84
21224365-8	2011	RESULTS: Patients with low scores for Dll4, VEGF-C, and neuropilin-1 showed trends toward improvement in PFS associated with the addition of bevacizumab to capecitabine (P values = 0.01, 0.05, and 0.07, respectively).	Capecitabine	156-168	neuropilin 1	Homo sapiens	56-68
21494397-9	2011	Treatment with Ixabepilone + Capecitabine in a phase II study resulted in an overall response rate (ORR) of 23% in ER/PR/HER2 negative, triple-negative breast cancer patients (TNBC) while ORR of 31% was seen in a preplanned pooled analysis of TNBC in the phase III trials of Ixabepilone + Capecitabine.	Capecitabine	29-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
21577028-0	2011	Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.	Capecitabine	37-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
20936340-0	2011	High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.	Capecitabine	61-73	transforming growth factor alpha	Homo sapiens	11-20
20936340-1	2011	Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Capecitabine	14-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-125
20936340-1	2011	Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Capecitabine	14-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
20936340-12	2011	These data suggest that TGF-alpha plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer.	Capecitabine	78-90	transforming growth factor alpha	Homo sapiens	24-33
20936340-12	2011	These data suggest that TGF-alpha plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer.	Capecitabine	78-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
21577028-12	2011	CONCLUSIONS: Heavily pretreated patients with ErbB2-positive locally advanced or metastatic breast cancer may benefit from treatment with lapatinib and capecitabine, with a low risk of cardiac toxicity.	Capecitabine	152-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-51
21160268-5	2010	No critical adverse reactions were observed, suggesting that S-1 can be useful and safe for the treatment of capecitabine-resistant recurrent breast cancer.	Capecitabine	109-121	proteasome 26S subunit, non-ATPase 1	Homo sapiens	61-64
21080742-4	2010	In patients with HER2-positive metastatic gastric cancer (n = 584), median overall survival (primary endpoint) was significantly longer for recipients of intravenous trastuzumab plus chemotherapy (comprising cisplatin and either fluorouracil or capecitabine) than in those receiving chemotherapy alone in the ToGA trial.	Capecitabine	245-257	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21
21045833-0	2010	Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.	Capecitabine	27-39	thymidine phosphorylase	Mus musculus	64-87
21160268-0	2010	[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].	Capecitabine	11-23	proteasome 26S subunit, non-ATPase 1	Homo sapiens	84-87
21142915-1	2010	AIM: To find out whether SNPs in the transporter gene ATP-binding casette B1 (ABCB1) were related to adverse effects in colorectal cancer patients treated with 5-fluorouracil (5-FU) or capecitabine.	Capecitabine	185-197	ATP binding cassette subfamily B member 1	Homo sapiens	54-76
21142915-1	2010	AIM: To find out whether SNPs in the transporter gene ATP-binding casette B1 (ABCB1) were related to adverse effects in colorectal cancer patients treated with 5-fluorouracil (5-FU) or capecitabine.	Capecitabine	185-197	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
20855840-0	2010	Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.	Capecitabine	56-68	mechanistic target of rapamycin kinase	Homo sapiens	22-26
21070441-0	2010	Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.	Capecitabine	124-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-81
21070441-3	2010	Here we report the case of a patient with brain metastases from breast cancer overexpressing HER-2 who achieved a complete radiologic response after treatment by radiation and concurrent Lapatinib and Capecitabine.	Capecitabine	201-213	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-98
21084819-0	2010	[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].	Capecitabine	94-106	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
20444849-1	2010	BACKGROUND: The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity.	Capecitabine	83-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
20542996-5	2010	Lapatinib, in combination with chemotherapeutic agents, such as capecitabine, provides clinical benefits to patients with ErbB2+ breast cancer, including patients who develop progressive disease on trastuzumab.	Capecitabine	64-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-127
20855840-11	2010	PBMC data suggested that prolonged exposure to capecitabine reduced the ridaforolimus inhibition of mTOR.	Capecitabine	47-59	mechanistic target of rapamycin kinase	Homo sapiens	100-104
20855840-13	2010	Inhibition of the target thymidylate synthase by capecitabine was unaffected.	Capecitabine	49-61	thymidylate synthetase	Homo sapiens	25-45
21162897-1	2010	OBJECTIVE: To explore the expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in low rectal cancer on neoadjuvant chemoradiotherapy with capecitabine plus radiotherapy.	Capecitabine	163-175	phosphatase and tensin homolog	Homo sapiens	98-102
19877119-0	2010	Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.	Capecitabine	136-148	dihydropyrimidine dehydrogenase	Homo sapiens	27-58
19877119-11	2010	CONCLUSIONS: TP/DPD ratio is a possible predictive factor for tumor response after concomitant preoperative chemoradiation with capecitabine in LARC.	Capecitabine	128-140	dihydropyrimidine dehydrogenase	Homo sapiens	13-19
20856879-2	2010	Human UPP activity has been a focus of cancer research due to its role in activating fluoropyrimidine nucleoside chemotherapeutic agents such as 5-fluorouracil (5-FU) and capecitabine.	Capecitabine	171-183	uridine phosphorylase 1	Homo sapiens	6-9
20944178-0	2010	Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.	Capecitabine	33-45	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
20700125-1	2010	BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell cancer.	Capecitabine	182-194	thymidine phosphorylase	Homo sapiens	65-88
20700125-1	2010	BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell cancer.	Capecitabine	182-194	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	99-144
20700125-1	2010	BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell cancer.	Capecitabine	182-194	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	146-151
20944178-9	2010	CONCLUSION: The results of the current study demonstrate that S-1 is an effective and well-tolerated treatment in patients with capecitabine-resistant MBC.	Capecitabine	128-140	proteasome 26S subunit, non-ATPase 1	Homo sapiens	62-65
20683054-4	2010	PATIENTS AND METHODS: HER-2-positive patients who had received adjuvant anthracyclines received docetaxel at 75 mg/m(2) on day 1 and capecitabine 950 mg/m(2)/day, days 1-14, every 3 weeks until disease progression or unacceptable toxicity.	Capecitabine	133-145	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-27
20618366-13	2010	The APR rate was 35% in the capecitabine group compared with 47% in the 5-FU group (P = 0.06).	Capecitabine	28-40	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	4-7
20683054-13	2010	CONCLUSION: These data confirm that the combination of trastuzumab plus capecitabine and docetaxel is highly active in patients with HER-2-overexpressing anthracycline-pretreated breast cancer, offering a significant survival benefit and is well tolerated.	Capecitabine	72-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	133-138
19551465-0	2010	Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.	Capecitabine	73-85	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	87-90
20507294-0	2010	Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.	Capecitabine	124-136	dihydropyrimidine dehydrogenase	Homo sapiens	51-55
20485287-4	2010	Capecitabine (1.250 mg m(-2) BID) was administered on days 1-14 every 21 days for at least two cycles.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	29-32
20460474-7	2010	RESULTS: The maximum tolerated dose of capecitabine was 625 mg/m2 BID.	Capecitabine	39-51	BH3 interacting domain death agonist	Homo sapiens	66-69
20226755-2	2010	The human UP type 1 (hUP1) is a molecular target for the design of inhibitors intended to boost endogenous uridine levels to rescue normal tissues from the toxicity of fluoropyrimidine nucleoside chemotherapeutic agents, such as capecitabine and 5-fluorouracil.	Capecitabine	229-241	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	21-25
20032127-0	2010	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.	Capecitabine	25-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
20414020-10	2010	Interestingly, the capecitabine response in HER2 negative-expressing patients, especially in HR(+)/HER2(-)subgroup, was significantly better than that in HER2-over-expressing patients.	Capecitabine	19-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
20414020-10	2010	Interestingly, the capecitabine response in HER2 negative-expressing patients, especially in HR(+)/HER2(-)subgroup, was significantly better than that in HER2-over-expressing patients.	Capecitabine	19-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
20414020-10	2010	Interestingly, the capecitabine response in HER2 negative-expressing patients, especially in HR(+)/HER2(-)subgroup, was significantly better than that in HER2-over-expressing patients.	Capecitabine	19-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
20414020-13	2010	Finally, it was suggested that use of capecitabine in upfront line for HER2-negative expressing cases or soft tissue metastatic cases contributed to the prolongation of time to treatment failure(TTF)and overall survival.	Capecitabine	38-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
20414020-13	2010	Finally, it was suggested that use of capecitabine in upfront line for HER2-negative expressing cases or soft tissue metastatic cases contributed to the prolongation of time to treatment failure(TTF)and overall survival.	Capecitabine	38-50	ras homolog family member H	Homo sapiens	195-198
20179708-0	2010	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.	Capecitabine	71-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
19815649-0	2010	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.	Capecitabine	53-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
19815649-1	2010	BACKGROUND: The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options.	Capecitabine	106-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
19850635-1	2010	BACKGROUND: The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX).	Capecitabine	281-293	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	171-213
22966291-3	2010	We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5"-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC.	Capecitabine	95-107	thymidine phosphorylase	Homo sapiens	14-37
20219304-0	2010	[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].	Capecitabine	27-39	dihydropyrimidine dehydrogenase	Homo sapiens	100-103
22966291-3	2010	We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5"-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC.	Capecitabine	95-107	thymidine phosphorylase	Homo sapiens	39-41
19526361-0	2010	Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.	Capecitabine	90-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
22966291-7	2010	Our present results showing a high expression of TP in BLBC indicate that capecitabine-based chemotherapy would be of benefit for patients with TNBC.	Capecitabine	74-86	thymidine phosphorylase	Homo sapiens	49-51
20146975-1	2010	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1).	Capecitabine	172-184	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
20035722-4	2010	The balance between thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) is critical to the efficacy of capecitabine.	Capecitabine	150-162	thymidylate synthetase	Homo sapiens	20-40
20035722-4	2010	The balance between thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) is critical to the efficacy of capecitabine.	Capecitabine	150-162	dihydropyrimidine dehydrogenase	Homo sapiens	47-78
20035722-4	2010	The balance between thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) is critical to the efficacy of capecitabine.	Capecitabine	150-162	dihydropyrimidine dehydrogenase	Homo sapiens	80-83
20146975-1	2010	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1).	Capecitabine	172-184	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
21779217-0	2010	Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-100
21048830-0	2010	Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
20671989-5	2010	The exact mechanism of this interaction is unknown but may be related to downregulation of cytochrome P450 2C9 by capecitabine or its metabolites.	Capecitabine	114-126	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	91-110
19287304-0	2009	Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	43-77
20071309-7	2009	In a pivotal phase III trial, a combination of lapatinib and capecitabine almost doubled time to disease progression when compared to capecitabine alone (8.4 vs. 4.1 months) in women with HER2/ErbB2-positive advanced or metastatic breast cancer previously treated with anthracyclin, taxanes and trastuzumab.	Capecitabine	61-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
20071309-7	2009	In a pivotal phase III trial, a combination of lapatinib and capecitabine almost doubled time to disease progression when compared to capecitabine alone (8.4 vs. 4.1 months) in women with HER2/ErbB2-positive advanced or metastatic breast cancer previously treated with anthracyclin, taxanes and trastuzumab.	Capecitabine	61-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-198
19287304-13	2009	Lapatinib plus capecitabine seems to have clinical activity in HER2-positive brain metastases.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
19623659-0	2009	Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.	Capecitabine	47-59	cyclin D1	Homo sapiens	77-86
19623659-6	2009	In nude mice, the combination of curcumin and capecitabine was found to be more effective than either agent alone in reducing tumor volume (p = 0.001 vs. control; p = 0.031 vs. capecitabine alone), Ki-67 proliferation index (p = 0.001 vs. control) and microvessel density marker CD31.	Capecitabine	46-58	platelet/endothelial cell adhesion molecule 1	Mus musculus	279-283
19791830-3	2009	The orally administered combination of lapatinib and capecitabine was a more effective treatment than capecitabine alone, and was a generally well tolerated, conveniently administered combination for women with trastuzumab-refractory, HER2-positive advanced or metastatic breast cancer in a clinical trial.	Capecitabine	53-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	235-239
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Capecitabine	154-166	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-41
19153829-1	2009	The randomized phase III trial EGF100151 demonstrated that the combination of lapatinib plus capecitabine (L + C) significantly improved time to progression (TTP) compared with capecitabine alone (C) in heavily pretreated patients with HER2+ (ErbB2+) advanced or metastatic breast cancer.	Capecitabine	93-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	236-240
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Capecitabine	154-166	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
19219602-0	2009	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.	Capecitabine	154-166	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-53
19822515-0	2009	Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?	Capecitabine	44-56	thymidylate synthetase	Homo sapiens	75-79
19846022-11	2009	In sensitivity analyses the ICER for lapatinib plus capecitabine compared with capecitabine monotherapy or vinorelbine monotherapy was robust to variation in assumptions.	Capecitabine	52-64	cAMP responsive element modulator	Homo sapiens	28-32
19250795-0	2009	Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.	Capecitabine	39-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
19250795-0	2009	Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.	Capecitabine	39-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-84
19250795-14	2009	CONCLUSIONS: The 22% pCR rate in a HER2-negative population suggests that addition of bevacizumab increases the activity of neoadjuvant capecitabine-docetaxel.	Capecitabine	136-148	erb-b2 receptor tyrosine kinase 2	Homo sapiens	35-39
19663627-3	2009	The TP/DPD ratio has suggested a positive correlation with the efficacy of capecitabine in human xenograft models.	Capecitabine	75-87	dihydropyrimidine dehydrogenase	Homo sapiens	7-10
19596923-1	2009	BACKGROUND: The therapeutic effects of oral capecitabine are proposed to be determined by the equilibrium of two intratumoral metabolizing enzymes, namely thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	44-56	dihydropyrimidine dehydrogenase	Homo sapiens	188-219
19661033-4	2009	We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy.	Capecitabine	129-141	CEA cell adhesion molecule 3	Homo sapiens	94-97
19661033-6	2009	More research is needed to try to explain the striking activity of capecitabine in this patient with lung adenocarcinoma and high levels of CEA and to find molecular targets to predict the response to this agent.	Capecitabine	67-79	CEA cell adhesion molecule 3	Homo sapiens	140-143
19578762-6	2009	Antitumor activity of bevacizumab in combination with capecitabine was significantly higher than that of each agent alone (COL-16-JCK, COLO 205).	Capecitabine	54-66	NIMA related kinase 8	Homo sapiens	130-133
19584872-0	2009	All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
19436196-2	2009	We hypothesized that the expression of topoisomerase I (Topo I) and thymidylate synthase (TS) may help predict the treatment response in patients undergoing irinotecan and capecitabine-based chemoradiation.	Capecitabine	172-184	thymidylate synthetase	Homo sapiens	68-88
19596923-1	2009	BACKGROUND: The therapeutic effects of oral capecitabine are proposed to be determined by the equilibrium of two intratumoral metabolizing enzymes, namely thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	44-56	dihydropyrimidine dehydrogenase	Homo sapiens	221-224
19596923-7	2009	CONCLUSION: In vitro study demonstrated that capecitabine was effective against the BT-483 and MB-MDA-231 breast carcinoma cell lines used but the significance of the status of intratumoral TP and DPD in determining its therapeutic efficacy needs further studies.	Capecitabine	45-57	dihydropyrimidine dehydrogenase	Homo sapiens	197-200
19082596-0	2009	Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.	Capecitabine	18-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
19082596-14	2009	CONCLUSION: The combination of capecitabine and trastuzumab is active and well-tolerated in patients with HER2-overexpressing breast caner resistant to both anthracyclines and taxanes.	Capecitabine	31-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110
19082596-1	2009	PURPOSE: The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes.	Capecitabine	70-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-120
18670776-9	2009	Capecitabine 450 mg bid orally was received on days 1 through 5 every week for 4 weeks, followed by a 2-week rest.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	20-23
19457654-6	2009	In conclusion, in this largest study on capecitabine with or without irinotecan to date we found a predictive value of DPD expression.	Capecitabine	40-52	dihydropyrimidine dehydrogenase	Homo sapiens	119-122
19107485-0	2009	Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.	Capecitabine	30-42	cytidine deaminase	Homo sapiens	77-95
19107485-4	2009	We then hypothesized that cytidine deaminase (CDA) extensive phenotype could be responsible for the severe toxicities observed with capecitabine.	Capecitabine	132-144	cytidine deaminase	Homo sapiens	26-44
19107485-4	2009	We then hypothesized that cytidine deaminase (CDA) extensive phenotype could be responsible for the severe toxicities observed with capecitabine.	Capecitabine	132-144	cytidine deaminase	Homo sapiens	46-49
19107485-8	2009	This case report suggest for the first time that severe toxicities with a capecitabine-containing protocol could be, at least in part, linked with an extensive-CDA syndrome.	Capecitabine	74-86	cytidine deaminase	Homo sapiens	160-163
19107485-9	2009	The case reported here suggests therefore that besides DPD, screening for CDA activity could be of interest to ensure a better safety in the handling of oral capecitabine at the bedside.	Capecitabine	158-170	cytidine deaminase	Homo sapiens	74-77
19289619-11	2009	CONCLUSION: Continuation of trastuzumab plus capecitabine showed a significant improvement in overall response and time to progression compared with capecitabine alone in women with HER-2-positive breast cancer who experienced progression during trastuzumab treatment.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	182-187
19351764-10	2009	CONCLUSION: Sarcopenia is a significant predictor of toxicity and TTP in metastatic breast cancer patients treated with capecitabine.	Capecitabine	120-132	ZFP36 ring finger protein	Homo sapiens	66-69
18807123-16	2009	CONCLUSIONS: S-1 was fairly well tolerated, but demonstrated very limited activity in capecitabine-pretreated patients who had already been exposed to anthracycline and taxane.	Capecitabine	86-98	proteasome 26S subunit, non-ATPase 1	Homo sapiens	13-16
19343004-0	2009	Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.	Capecitabine	113-125	alpha fetoprotein	Homo sapiens	0-17
19436196-2	2009	We hypothesized that the expression of topoisomerase I (Topo I) and thymidylate synthase (TS) may help predict the treatment response in patients undergoing irinotecan and capecitabine-based chemoradiation.	Capecitabine	172-184	thymidylate synthetase	Homo sapiens	90-92
19287123-0	2009	Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.	Capecitabine	37-49	dihydropyrimidine dehydrogenase	Homo sapiens	110-141
19117341-1	2009	BACKGROUND: A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression.	Capecitabine	83-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-121
19133157-0	2009	A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.	Capecitabine	64-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-98
18807123-0	2009	Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.	Capecitabine	98-110	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
18807123-2	2009	We have retrospectively examined the efficacy and safety of S-1 in patients with MBC who had been previously treated with anthracycline, taxane, and capecitabine.	Capecitabine	149-161	proteasome 26S subunit, non-ATPase 1	Homo sapiens	60-63
18807123-17	2009	It was suggested that S-1 clinically exhibited cross-resistance to capecitabine.	Capecitabine	67-79	proteasome 26S subunit, non-ATPase 1	Homo sapiens	22-25
19117293-0	2009	The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.	Capecitabine	103-115	dihydropyrimidine dehydrogenase	Homo sapiens	68-99
18997184-15	2009	The comparison of S-1 with capecitabine showed that capecitabine had a slightly higher response rate (statistically not significant) in addition to a higher rate of adverse events such as the hand-foot syndrome and diarrhea.	Capecitabine	52-64	proteasome 26S subunit, non-ATPase 1	Homo sapiens	18-21
19117293-0	2009	The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.	Capecitabine	117-123	dihydropyrimidine dehydrogenase	Homo sapiens	68-99
19117293-1	2009	OBJECTIVES: To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5"-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC).	Capecitabine	243-255	dihydropyrimidine dehydrogenase	Homo sapiens	124-127
19117293-1	2009	OBJECTIVES: To evaluate whether two molecular biomarkers, thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), could be clinically useful in predicting and improving the chemotherapeutic outcome of the oral fluoropyrimidine capecitabine (5"-DFUR or Xeloda), in the treatment of human head and neck squamous cell carcinoma (HNSCC).	Capecitabine	268-274	dihydropyrimidine dehydrogenase	Homo sapiens	124-127
19117293-9	2009	CONCLUSIONS: The results of this study suggest that HNSCC patients who would most benefit from capecitabine-based chemotherapy could be identified by examining the TP to DPD ratio of their tumors.	Capecitabine	95-107	dihydropyrimidine dehydrogenase	Homo sapiens	170-173
19366055-1	2009	BACKGROUND: Capecitabine in combination with oxaliplatin and irinotecan (COI regimen) is active and well tolerated in metastatic colorectal cancer.	Capecitabine	12-24	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	73-76
18952552-9	2008	Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy.	Capecitabine	105-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
19068453-0	2008	A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.	Capecitabine	74-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-130
19105824-2	2008	Over-expression of ERCC1 correlates with insensitivity to oxaliplatin (OX) therapy, while high thymidine phosphorylase (TP) levels predict for increased sensitivity to capecitabine (Xel).	Capecitabine	168-180	thymidine phosphorylase	Homo sapiens	95-118
19105824-2	2008	Over-expression of ERCC1 correlates with insensitivity to oxaliplatin (OX) therapy, while high thymidine phosphorylase (TP) levels predict for increased sensitivity to capecitabine (Xel).	Capecitabine	168-180	thymidine phosphorylase	Homo sapiens	120-122
18188694-2	2008	Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab.	Capecitabine	70-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
18188694-10	2008	CONCLUSION: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.	Capecitabine	41-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
19028276-2	2008	In the present study, mRNA expression of PDGFRbeta and c-kit in 33 patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy with cetuximab/capecitabine/irinotecan in correlation with the tumor regression rate was investigated.	Capecitabine	169-181	platelet derived growth factor receptor beta	Homo sapiens	41-50
18600532-2	2008	In patients treated with capecitabine or 5FU combined with other chemotherapeutic drugs, DPD activity in peripheral blood mononuclear cells was increased in patients experiencing grade I/II neutropenia.	Capecitabine	25-37	dihydropyrimidine dehydrogenase	Homo sapiens	89-92
18849320-0	2008	FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.	Capecitabine	57-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-142
18823221-6	2008	It is indicated for combination therapy with capecitabine for the treatment of patients with HER2-overexpressing LABC or MBC whose disease has progressed after receiving previous treatment with an anthracycline, a taxane, and trastuzumab.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
18690094-1	2008	The objective of this study was to investigate the relationship between the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) and the response to capecitabine in patients with advanced/recurrent gastric cancer.	Capecitabine	181-193	dihydropyrimidine dehydrogenase	Homo sapiens	156-159
18690094-8	2008	TP and DPD expression profiles are useful for predicting a response to capecitabine.	Capecitabine	71-83	dihydropyrimidine dehydrogenase	Homo sapiens	7-10
18695884-0	2008	Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.	Capecitabine	72-84	microRNA 137	Homo sapiens	23-29
18790783-9	2008	As 5-FU and the oral 5-FU prodrug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small-molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.	Capecitabine	34-46	Deoxyuridine triphosphatase	Drosophila melanogaster	170-177
18420342-6	2008	Capecitabine also showed a trend toward the induction of TSP-1.	Capecitabine	0-12	thrombospondin 1	Homo sapiens	57-62
18594531-2	2008	UGT1A1(*)28 genotype was determined in 218 patients receiving irinotecan (either first-line therapy with capecitabine or second-line as monotherapy) for metastatic colorectal cancer.	Capecitabine	105-117	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
18562256-0	2008	Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.	Capecitabine	84-96	cytidine deaminase	Homo sapiens	30-48
18525298-6	2008	Capecitabine was administered at 750 mg/m2 twice daily days 2 to 14 in cohort 1 but only on days 2 to 7 from cohort 2 due to early neutropenia and to allow for prophylactic granulocyte colony-stimulating factor (GCSF) support.	Capecitabine	0-12	colony stimulating factor 3	Homo sapiens	173-210
17882419-0	2008	Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.	Capecitabine	40-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
17882419-1	2008	PURPOSE: We retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer (MBC).	Capecitabine	105-117	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
17882419-13	2008	CONCLUSIONS: The combination therapy of trastuzumab plus capecitabine is effective and tolerable for heavily pretreated patients with HER2-positive MBC.	Capecitabine	57-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
17851564-3	2008	We hypothesized that capecitabine inhibits the synthesis of CYP2C9, which metabolizes indisulam.	Capecitabine	21-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	60-66
18768996-5	2008	Combination therapy with lapatinib and capecitabine has demonstrated superior time to progression compared with capecitabine monotherapy for the treatment of HER2-positive metastatic breast cancer refractory to anthracycline-, taxane-, and trastuzumab-containing regimens.	Capecitabine	39-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
18594499-5	2008	In a pivotal phase III trial, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression relative to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer previously treated with anthracyclines, taxanes, and trastuzumab.	Capecitabine	61-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	175-179
18473752-0	2008	A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.	Capecitabine	55-67	carboxylesterase 2	Homo sapiens	2-20
18414469-3	2008	Capecitabine was administered two times daily (BID) on days 1-14.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	47-50
18414469-9	2008	A dose of indisulam 500 mg m(-2) and capecitabine 1250 mg m(-2) BID proved to be safe at cycle 1 and 2 in nine additional patients.	Capecitabine	37-49	BH3 interacting domain death agonist	Homo sapiens	64-67
18414469-15	2008	A dose of indisulam 500 mg m(-2) and capecitabine 1250 mg m(-2) BID was considered safe in multiple treatment cycles.	Capecitabine	37-49	BH3 interacting domain death agonist	Homo sapiens	64-67
18621613-0	2008	A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.	Capecitabine	59-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
18621613-0	2008	A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.	Capecitabine	59-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-162
18473752-3	2008	The present study prospectively examined the possible relationship between the toxicity and efficacy of capecitabine and 14 different polymorphisms in CES 2, CDD, TS and DPD.	Capecitabine	104-116	carboxylesterase 2	Homo sapiens	151-156
18473752-3	2008	The present study prospectively examined the possible relationship between the toxicity and efficacy of capecitabine and 14 different polymorphisms in CES 2, CDD, TS and DPD.	Capecitabine	104-116	dihydropyrimidine dehydrogenase	Homo sapiens	170-173
18473752-7	2008	For the first time, an association between a polymorphism in the CES2 gene and the efficacy of capecitabine has been described, providing preliminary evidence of its predictive and prognostic value.	Capecitabine	95-107	carboxylesterase 2	Homo sapiens	65-69
18487908-5	2008	Lapatinib combined with capecitabine showed efficacy against HER2-positive metastatic breast cancer.	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
18473752-1	2008	Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU).	Capecitabine	0-12	carboxylesterase 2	Homo sapiens	78-96
18473752-1	2008	Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU).	Capecitabine	0-12	carboxylesterase 2	Homo sapiens	98-103
18473752-1	2008	Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU).	Capecitabine	0-12	cytidine deaminase	Homo sapiens	106-124
18473752-1	2008	Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU).	Capecitabine	0-12	cytidine deaminase	Homo sapiens	126-129
18245544-0	2008	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.	Capecitabine	96-108	thymidylate synthetase	Homo sapiens	0-20
17516068-0	2008	A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.	Capecitabine	36-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
17516068-1	2008	PURPOSE: To determine the response rate and toxicity profile of trastuzumab and capecitabine in women with HER2-overexpressing advanced breast cancer.	Capecitabine	80-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
17516068-11	2008	CONCLUSION: Trastuzumab in combination with capecitabine is highly active in women with HER2-overexpressing metastatic breast cancer and is well tolerated.	Capecitabine	44-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
18319546-0	2008	Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.	Capecitabine	110-122	dihydropyrimidine dehydrogenase	Homo sapiens	28-59
17851858-0	2008	Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.	Capecitabine	26-38	vascular endothelial growth factor A	Homo sapiens	86-90
18245544-0	2008	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.	Capecitabine	96-108	methylenetetrahydrofolate reductase	Homo sapiens	25-60
18245544-10	2008	CONCLUSIONS: This study suggests that common genetic variation in MTHFR but not TYMS may be useful for predicting toxicity from capecitabine in patients with advanced colorectal cancer.	Capecitabine	128-140	methylenetetrahydrofolate reductase	Homo sapiens	66-71
18245544-11	2008	In addition, MTHFR single nucleotide polymorphisms predicted serum folate and plasma homocysteine levels, and, combined, these factors may be important predictors of capecitabine-induced toxicity.	Capecitabine	166-178	methylenetetrahydrofolate reductase	Homo sapiens	13-18
17440727-0	2008	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.	Capecitabine	32-44	NK6 homeobox 2	Homo sapiens	46-49
17440727-4	2008	GTX consisted of capecitabine (X), 750 mg/m(2) p.o.	Capecitabine	17-29	NK6 homeobox 2	Homo sapiens	0-3
17762433-5	2007	The docetaxel dose ranged from 30 to 35 mg/m2, the oxaliplatin dose from 40 to 50 mg/m2, and the capecitabine dose from 750 to 850 mg/m2 BID.	Capecitabine	97-109	BH3 interacting domain death agonist	Homo sapiens	137-140
19037763-0	2008	Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?	Capecitabine	76-88	dihydropyrimidine dehydrogenase	Homo sapiens	101-104
19037763-6	2008	Capecitabine was substituted because of severe toxicity with 5-FU after determining that the level of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in the metabolism of fluoropyrimidines, was within normal limits.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	135-138
19002271-4	2008	Capecitabine plus docetaxel (XT) and trastuzumab with XT (HXT) are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, respectively.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
19002271-4	2008	Capecitabine plus docetaxel (XT) and trastuzumab with XT (HXT) are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, respectively.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
19002271-5	2008	The Xeloda in Neoadjuvant (XeNA) trial, an open-label, multicenter, phase II study, independently assesses the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer.	Capecitabine	4-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
19104657-1	2008	BACKGROUND: Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or capecitabine.	Capecitabine	241-253	dihydropyrimidine dehydrogenase	Homo sapiens	54-85
19104657-1	2008	BACKGROUND: Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or capecitabine.	Capecitabine	241-253	dihydropyrimidine dehydrogenase	Homo sapiens	92-96
18632519-3	2007	Capecitabine is degraded by dihydropyrimidine dehydrogenase (DPD), and a deficiency in this enzyme can increase the toxicity of capecitabine.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	28-59
18632519-3	2007	Capecitabine is degraded by dihydropyrimidine dehydrogenase (DPD), and a deficiency in this enzyme can increase the toxicity of capecitabine.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	61-64
18632519-3	2007	Capecitabine is degraded by dihydropyrimidine dehydrogenase (DPD), and a deficiency in this enzyme can increase the toxicity of capecitabine.	Capecitabine	128-140	dihydropyrimidine dehydrogenase	Homo sapiens	28-59
18632519-3	2007	Capecitabine is degraded by dihydropyrimidine dehydrogenase (DPD), and a deficiency in this enzyme can increase the toxicity of capecitabine.	Capecitabine	128-140	dihydropyrimidine dehydrogenase	Homo sapiens	61-64
17904787-12	2007	The level of COX2 and p16 after capecitabine and vinorelbine treatment was assessed with immunohistochemical methods.	Capecitabine	32-44	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	13-17
17577021-0	2007	Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.	Capecitabine	18-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	57-91
17611699-0	2007	DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.	Capecitabine	34-46	dihydropyrimidine dehydrogenase	Homo sapiens	0-3
17611699-10	2007	Higher gene expression levels of DPD were associated with resistance to capecitabine (P=0.032; Kruskal-Wallis test).	Capecitabine	72-84	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
17611699-12	2007	This pilot study suggests that intratumoral gene expression levels of DPD may be useful in predicting the clinical outcome of patients with metastatic CRC with first-line single agent capecitabine treatment.	Capecitabine	184-196	dihydropyrimidine dehydrogenase	Homo sapiens	70-73
17577021-4	2007	We have conducted a phase II study to confirm activity and feasibility of capecitabine and trastuzumab in combination in HER-2-overexpressing advanced/metastatic breast cancer.	Capecitabine	74-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-126
17577021-12	2007	CONCLUSION: These data confirm that the combination of capecitabine and trastuzumab is highly active in patients with HER-2-overexpressing anthracycline- and/or taxane-pretreated breast cancer, with only slight restrictions regarding quality of life.	Capecitabine	55-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
17640356-3	2007	Beside tumour tissue, TP is highly expressed in white blood cells, possibly causing increased hematotoxicity, when taxanes are combined with capecitabine.	Capecitabine	141-153	thymidine phosphorylase	Homo sapiens	22-24
17695515-0	2007	Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.	Capecitabine	22-34	estrogen receptor 1	Homo sapiens	74-91
17009035-0	2007	Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.	Capecitabine	0-12	interleukin 6	Mus musculus	53-57
17679920-0	2007	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
17509107-1	2007	A 63-year-old woman was diagnosed with acute myelo-monocytic leukaemia, associated with MLL gene rearrangement, 16 months after completion of oral capecitabine for metastatic colon cancer.	Capecitabine	147-159	lysine methyltransferase 2A	Homo sapiens	88-91
17009035-0	2007	Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.	Capecitabine	0-12	parathyroid hormone-like peptide	Mus musculus	62-67
17009035-9	2007	Furthermore, capecitabine lowered the levels of PTHrP and IL-6 in plasma and suppressed hypoglycemia and hypercalcemia in this model.	Capecitabine	13-25	parathyroid hormone-like peptide	Mus musculus	48-53
17009035-9	2007	Furthermore, capecitabine lowered the levels of PTHrP and IL-6 in plasma and suppressed hypoglycemia and hypercalcemia in this model.	Capecitabine	13-25	interleukin 6	Mus musculus	58-62
17009035-11	2007	CONCLUSIONS: PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models.	Capecitabine	116-128	interleukin 6	Mus musculus	190-194
17009035-11	2007	CONCLUSIONS: PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models.	Capecitabine	116-128	parathyroid hormone-like peptide	Mus musculus	199-204
17530484-11	2007	Some patients tolerated a capecitabine dose as high as 1250 mg/m(2) BID.	Capecitabine	26-38	BH3 interacting domain death agonist	Homo sapiens	68-71
17531106-0	2007	Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.	Capecitabine	75-87	mutS homolog 2	Homo sapiens	20-24
17350823-1	2007	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of chemotherapeutic agent 5-fluorouracil (5FU) and its derivatives, including capecitabine.	Capecitabine	160-172	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
17350823-1	2007	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of chemotherapeutic agent 5-fluorouracil (5FU) and its derivatives, including capecitabine.	Capecitabine	160-172	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
17531106-1	2007	PURPOSE: The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine.	Capecitabine	200-212	mutS homolog 2	Homo sapiens	112-116
17531106-5	2007	CONCLUSION: The higher gene expression of MSH2 in responders and the trend for predicting overall survival indicates a predictive value of this marker in the treatment of advanced CRC with capecitabine.	Capecitabine	189-201	mutS homolog 2	Homo sapiens	42-46
17378915-2	2007	TP cannot activate capecitabine, because capecitabine first needs conversion by carboxylesterase and cytidine deaminase into 5-deoxy-fluorouridine.	Capecitabine	41-53	cytidine deaminase	Homo sapiens	101-119
17203168-0	2007	Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.	Capecitabine	117-129	thymidylate synthetase	Homo sapiens	21-41
17203168-0	2007	Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	46-77
18846242-13	2007	Akin to 5-FU, capecitabine can also lead to severe toxicities in DPD-deficient patients.	Capecitabine	14-26	dihydropyrimidine dehydrogenase	Homo sapiens	65-68
17688376-0	2007	Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.	Capecitabine	42-54	thymidylate synthetase	Homo sapiens	72-92
17688376-0	2007	Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.	Capecitabine	42-54	thymidine phosphorylase	Homo sapiens	97-120
17688376-1	2007	This work is intended to study the effect of preoperative capecitabine and radiotherapy treatment on the levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) mRNAs in rectal carcinoma.	Capecitabine	58-70	thymidylate synthetase	Homo sapiens	115-135
17688376-1	2007	This work is intended to study the effect of preoperative capecitabine and radiotherapy treatment on the levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) mRNAs in rectal carcinoma.	Capecitabine	58-70	thymidylate synthetase	Homo sapiens	137-139
17688376-1	2007	This work is intended to study the effect of preoperative capecitabine and radiotherapy treatment on the levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) mRNAs in rectal carcinoma.	Capecitabine	58-70	thymidine phosphorylase	Homo sapiens	142-165
17688376-1	2007	This work is intended to study the effect of preoperative capecitabine and radiotherapy treatment on the levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) mRNAs in rectal carcinoma.	Capecitabine	58-70	dihydropyrimidine dehydrogenase	Homo sapiens	208-211
17688376-14	2007	TP induction is in accordance with the expected role of TP in the activation of capecitabine and the known promoting role of TP in tissue fibrosis frequently associated with tumor regression.	Capecitabine	80-92	thymidine phosphorylase	Homo sapiens	0-2
17688376-14	2007	TP induction is in accordance with the expected role of TP in the activation of capecitabine and the known promoting role of TP in tissue fibrosis frequently associated with tumor regression.	Capecitabine	80-92	thymidine phosphorylase	Homo sapiens	56-58
17688376-14	2007	TP induction is in accordance with the expected role of TP in the activation of capecitabine and the known promoting role of TP in tissue fibrosis frequently associated with tumor regression.	Capecitabine	80-92	thymidine phosphorylase	Homo sapiens	56-58
17998790-6	2007	The DLT level was reached at paclitaxel 110 mg/m2, LOHP 50 mg/m2 and capecitabine 1,000 mg/m2/day.	Capecitabine	69-81	codanin 1	Homo sapiens	4-7
18846242-14	2007	Screening patients for DPD deficiency prior to administration of 5-FU or capecitabine using UraBT could potentially lower risk of toxicity.	Capecitabine	73-85	dihydropyrimidine dehydrogenase	Homo sapiens	23-26
17241513-5	2006	Dihydropyrimidine dehydrogenase is prone to marked circadian rhythms, drug-drug interactions, and genetic polymorphisms; influence of its erratic activity on 5-FU pharmacokinetics and toxicity profile has been extensively investigated, and it is now well known that DPD deficiency leads to severe toxicities with 5-FU or possibly capecitabine exposure.	Capecitabine	330-342	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
17192538-0	2006	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Capecitabine	212-224	epidermal growth factor receptor	Homo sapiens	60-92
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Capecitabine	212-224	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-105
17192538-1	2006	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.	Capecitabine	212-224	epidermal growth factor receptor	Homo sapiens	141-173
16950593-15	2006	Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) that in refractory metastatic breast cancer doubled the response rate of capecitabine although it did not affect survival.	Capecitabine	177-189	vascular endothelial growth factor A	Homo sapiens	62-96
16950593-15	2006	Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) that in refractory metastatic breast cancer doubled the response rate of capecitabine although it did not affect survival.	Capecitabine	177-189	vascular endothelial growth factor A	Homo sapiens	98-102
16943524-0	2006	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.	Capecitabine	66-78	thymidine phosphorylase	Homo sapiens	0-23
17038885-2	2006	The aim of this study was to validate, in a routine clinical setting, a simple and rapid method to determine the DPD status in a subset of cancer patients, all presenting with life-threatening toxicities following 5-FU or capecitabine intake.	Capecitabine	222-234	dihydropyrimidine dehydrogenase	Homo sapiens	113-116
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	105-117	thymidylate synthetase	Homo sapiens	123-143
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	105-117	thymidylate synthetase	Homo sapiens	145-147
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	105-117	methylenetetrahydrofolate reductase	Homo sapiens	187-192
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	105-117	dihydropyrimidine dehydrogenase	Homo sapiens	199-230
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	105-117	dihydropyrimidine dehydrogenase	Homo sapiens	232-235
16926630-6	2006	The combination between erlotinib and docetaxel resulted in an approximately 50% reduction in thymidylate synthase activity (the molecular target of 5-fluorodeoxyuridine monophosphate, the active capecitabine anabolite) with an higher impact observed with DU145 cells than with PC3 cells.	Capecitabine	196-208	thymidylate synthetase	Homo sapiens	94-114
16755175-1	2006	OBJECTIVE: COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib.	Capecitabine	40-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	11-16
16292536-0	2006	Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.	Capecitabine	23-35	dihydropyrimidine dehydrogenase	Homo sapiens	98-130
16910885-2	2006	We report a single institution"s experience with capecitabine, a thymidylate synthase (TS) inhibitor, in the treatment of MTC and FTC.	Capecitabine	49-61	thymidylate synthetase	Homo sapiens	65-85
16910885-2	2006	We report a single institution"s experience with capecitabine, a thymidylate synthase (TS) inhibitor, in the treatment of MTC and FTC.	Capecitabine	49-61	thymidylate synthetase	Homo sapiens	87-89
16777702-4	2006	Thymidine phosphorylase (TP) is the final enzyme responsible for Capecitabine activation.	Capecitabine	65-77	thymidine phosphorylase	Homo sapiens	0-23
16438929-1	2006	Capecitabine is an oral fluoropyrimidine carbamate activated sequentially in both liver and tumor tissues by carboxylesterases, cytidine deaminase, and thymidine phosphorylase.	Capecitabine	0-12	cytidine deaminase	Homo sapiens	128-146
18221035-1	2006	Thymidine phosphorylase (TP), also known as platelet derived endothelial cell growth factor (PD-ECGF), is an enzyme involved in thymidine synthesis and degradation and exerts an angiogenic activity, whereas N4 pentyloxy-carbonyl- 5"-deoxy-5-fluorocytidine, commonly called capecitabine (CAP), is a TP-activated oral fluorpyrimidine, which generates 5-fluorouracil (5-FU) within tumours.	Capecitabine	207-255	thymidine phosphorylase	Homo sapiens	44-91
18221035-1	2006	Thymidine phosphorylase (TP), also known as platelet derived endothelial cell growth factor (PD-ECGF), is an enzyme involved in thymidine synthesis and degradation and exerts an angiogenic activity, whereas N4 pentyloxy-carbonyl- 5"-deoxy-5-fluorocytidine, commonly called capecitabine (CAP), is a TP-activated oral fluorpyrimidine, which generates 5-fluorouracil (5-FU) within tumours.	Capecitabine	207-255	thymidine phosphorylase	Homo sapiens	93-100
18221035-1	2006	Thymidine phosphorylase (TP), also known as platelet derived endothelial cell growth factor (PD-ECGF), is an enzyme involved in thymidine synthesis and degradation and exerts an angiogenic activity, whereas N4 pentyloxy-carbonyl- 5"-deoxy-5-fluorocytidine, commonly called capecitabine (CAP), is a TP-activated oral fluorpyrimidine, which generates 5-fluorouracil (5-FU) within tumours.	Capecitabine	273-285	thymidine phosphorylase	Homo sapiens	44-91
18221035-1	2006	Thymidine phosphorylase (TP), also known as platelet derived endothelial cell growth factor (PD-ECGF), is an enzyme involved in thymidine synthesis and degradation and exerts an angiogenic activity, whereas N4 pentyloxy-carbonyl- 5"-deoxy-5-fluorocytidine, commonly called capecitabine (CAP), is a TP-activated oral fluorpyrimidine, which generates 5-fluorouracil (5-FU) within tumours.	Capecitabine	273-285	thymidine phosphorylase	Homo sapiens	93-100
16397116-0	2006	Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5"-deoxy-5-fluorouridine in breast cancer cells.	Capecitabine	130-142	tumor necrosis factor	Mus musculus	55-82
16397116-1	2006	Uridine phosphorylase (UPase) has been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in the anabolism of its oral prodrug, capecitabine, through the conversion of 5"-deoxy-5-fluorouridine (5"-DFUR) into 5-FU.	Capecitabine	169-181	uridine phosphorylase 1	Mus musculus	23-28
16897968-3	2006	As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts.	Capecitabine	261-273	proteasome (prosome, macropain) 26S subunit, non-ATPase, 1	Mus musculus	19-22
16086096-9	2006	CONCLUSION: This study demonstrates antitumor activity of combination IFN-alpha/capecitabine/thalidomide in MRCC.	Capecitabine	80-92	interferon alpha 1	Homo sapiens	70-79
16396674-8	2006	CONCLUSION: Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.	Capecitabine	69-81	HCC	Homo sapiens	176-179
16353181-1	2006	BACKGROUND AND OBJECTIVES: We have investigated the regulation by mitomycin C (MMC) of thymidine phosphorylase (dThdPase) and dihydropyrimidine dehydrogenase (DPD), which enhances or reduces the efficacy of capecitabine and its metabolite 5"-deoxy-5-fluorouridine (5"-DFUR), in rectal cancer tissues.	Capecitabine	207-219	dihydropyrimidine dehydrogenase	Homo sapiens	66-157
16218935-0	2005	Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.	Capecitabine	83-95	thymidylate synthetase	Homo sapiens	34-54
16014372-7	2005	The mechanism of action for the interaction is not clear, but may be related to down-regulation of CYP2C9 by capecitabine or its metabolites or a pharmacodynamic interaction with warfarin.	Capecitabine	109-121	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	99-105
15944764-6	2005	There were inverse correlations between antitumor and DPD activities for 5"-DFUR (r=-0.79, P=0.034), capecitabine (r=-0.56, P=0.19) and 5-FU (r=-0.86, P=0.013).	Capecitabine	101-113	dihydropyrimidine dehydrogenase	Homo sapiens	54-57
16115930-1	2005	PURPOSE: Complete or partial loss of dihydropyrimidine dehydrogenase (DPD) function has been described in cancer patients with intolerance to fluoropyrimidine drugs like 5-fluorouracil (5-FU) or Xeloda.	Capecitabine	195-201	dihydropyrimidine dehydrogenase	Homo sapiens	37-68
16115930-1	2005	PURPOSE: Complete or partial loss of dihydropyrimidine dehydrogenase (DPD) function has been described in cancer patients with intolerance to fluoropyrimidine drugs like 5-fluorouracil (5-FU) or Xeloda.	Capecitabine	195-201	dihydropyrimidine dehydrogenase	Homo sapiens	70-73
15866500-9	2005	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5"-5-fluorocytidine) have shown that plasma 2"-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS).	Capecitabine	83-95	thymidylate synthetase	Homo sapiens	260-280
15894361-11	2005	The MDT of continuous capecitabine, when given with pelvic radiotherapy and weekly cisplatin, is 450 mg m2 bid.	Capecitabine	22-34	BH3 interacting domain death agonist	Homo sapiens	107-110
15894361-12	2005	CONCLUSIONS: The recommended dose of capecitabine in this combination is 300 mg/m2 bid.	Capecitabine	37-49	BH3 interacting domain death agonist	Homo sapiens	83-86
15917420-0	2005	Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.	Capecitabine	74-86	thymidine phosphorylase	Homo sapiens	0-23
15917420-1	2005	BACKGROUND: Thymidine phosphorylase (TP) is the key enzyme for capecitabine activation in tumour cells.	Capecitabine	63-75	thymidine phosphorylase	Homo sapiens	12-35
15917420-1	2005	BACKGROUND: Thymidine phosphorylase (TP) is the key enzyme for capecitabine activation in tumour cells.	Capecitabine	63-75	thymidine phosphorylase	Homo sapiens	37-39
15917420-2	2005	AIMS: To examine whether TP expression in tumour cells and stroma is predictive of the tumour response to capecitabine plus docetaxel chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).	Capecitabine	106-118	thymidine phosphorylase	Homo sapiens	25-27
15917420-7	2005	Tumour response to capecitabine/docetaxel was significantly associated with high tumour cell TP expression (p = 0.004) and low stromal TP expression (p = 0.009).	Capecitabine	19-31	thymidine phosphorylase	Homo sapiens	93-95
15917420-7	2005	Tumour response to capecitabine/docetaxel was significantly associated with high tumour cell TP expression (p = 0.004) and low stromal TP expression (p = 0.009).	Capecitabine	19-31	thymidine phosphorylase	Homo sapiens	135-137
15917420-8	2005	Moreover, high tumour cell TP expression was significantly associated with severe hand-foot syndrome, a toxic side effect of capecitabine (p = 0.01).	Capecitabine	125-137	thymidine phosphorylase	Homo sapiens	27-29
15917420-10	2005	CONCLUSIONS: In advanced NSCLC, TP expression in tumour cells and stroma is associated with tumour response to capecitabine/docetaxel chemotherapy, and might be a useful predictor of tumour response to capecitabine based chemotherapy.	Capecitabine	111-123	thymidine phosphorylase	Homo sapiens	32-34
15917420-10	2005	CONCLUSIONS: In advanced NSCLC, TP expression in tumour cells and stroma is associated with tumour response to capecitabine/docetaxel chemotherapy, and might be a useful predictor of tumour response to capecitabine based chemotherapy.	Capecitabine	202-214	thymidine phosphorylase	Homo sapiens	32-34
15729713-2	2005	The sensitivity of cancer cells to capecitabine, which is an oral, tumor-selective pre-prodrug of 5-fluorouracil may correlate better to the TP/DPD ratio than to levels of either enzyme alone.	Capecitabine	35-47	dihydropyrimidine dehydrogenase	Homo sapiens	144-147
15687373-0	2005	Hydrolysis of capecitabine to 5"-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.	Capecitabine	14-26	carboxylesterase 2	Homo sapiens	65-82
15687373-2	2005	A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil.	Capecitabine	135-147	carboxylesterase 2	Homo sapiens	59-76
15687373-2	2005	A three-step in vivo-targeted activation process requiring carboxylesterases, cytidine deaminase, and thymidine phosphorylase converts capecitabine to 5-fluorouracil.	Capecitabine	135-147	cytidine deaminase	Homo sapiens	78-96
15687373-3	2005	Carboxylesterases hydrolyze capecitabine"s carbamate side chain to form 5"-deoxy-5-fluorocytidine (5"-DFCR).	Capecitabine	28-40	carboxylesterase 2	Homo sapiens	0-17
15687373-4	2005	This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay.	Capecitabine	154-166	carboxylesterase 2	Homo sapiens	121-125
15687373-4	2005	This study examines the steady-state kinetics of recombinant human carboxylesterase isozymes carboxylesterase (CES) 1A1, CES2, and CES3 for hydrolysis of capecitabine with a liquid chromatography/mass spectroscopy assay.	Capecitabine	154-166	carboxylesterase 3	Homo sapiens	131-135
15687373-5	2005	Additionally, a spectrophotometric screening assay was utilized to identify drugs that may inhibit carboxylesterase activation of capecitabine.	Capecitabine	130-142	carboxylesterase 2	Homo sapiens	99-115
15687373-6	2005	CES1A1 and CES2 hydrolyze capecitabine to a similar extent, with catalytic efficiencies of 14.7 and 12.9 min(-1) mM(-1), respectively.	Capecitabine	26-38	carboxylesterase 2	Homo sapiens	11-15
15687373-7	2005	Little catalytic activity is detected for CES3 with capecitabine.	Capecitabine	52-64	carboxylesterase 3	Homo sapiens	42-46
15687373-12	2005	Both CES1A1 and CES2 are responsible for the activation of capecitabine, whereas CES3 plays little role in 5"-DFCR formation.	Capecitabine	59-71	carboxylesterase 2	Homo sapiens	16-20
15709193-0	2005	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.	Capecitabine	105-117	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	0-6
15721430-0	2005	Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.	Capecitabine	27-39	dihydropyrimidine dehydrogenase	Homo sapiens	146-149
15547687-5	2004	In the primary tumors, paclitaxel and S-1 displayed a significant antitumor activity, with 57 and 41%, respectively inhibition of tumor growth (p < 0.01), but capecitabine had no effect.	Capecitabine	162-174	proteasome 26S subunit, non-ATPase 1	Homo sapiens	38-41
15709193-0	2005	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.	Capecitabine	105-117	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	11-17
15709193-2	2005	We hypothesized that germline polymorphisms within genes related to drug target (thymidylate synthase) or metabolizing enzymes (UDP-glucuronosyltransferase, UGT) would impact response and toxicity to the combination of capecitabine plus irinotecan (CPT-11).	Capecitabine	219-231	thymidylate synthetase	Homo sapiens	81-101
15709193-2	2005	We hypothesized that germline polymorphisms within genes related to drug target (thymidylate synthase) or metabolizing enzymes (UDP-glucuronosyltransferase, UGT) would impact response and toxicity to the combination of capecitabine plus irinotecan (CPT-11).	Capecitabine	219-231	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	157-160
15709193-10	2005	CONCLUSIONS: These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan.	Capecitabine	149-161	UDP glucuronosyltransferase family 1 member A7	Homo sapiens	46-52
15709193-10	2005	CONCLUSIONS: These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan.	Capecitabine	149-161	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	60-66
15547687-6	2004	When S-1 and paclitaxel were combined, they synergistically caused tumor regression (tumor growth inhibition ratio 94%, p < 0.01) in mice compared to capecitabine plus paclitaxel, without any toxicity.	Capecitabine	153-165	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	5-8
15490371-0	2004	Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).	Capecitabine	73-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
15490371-0	2004	Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).	Capecitabine	87-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-33
15353299-6	2004	Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	Capecitabine	120-132	thymidylate synthetase	Homo sapiens	22-24
15634525-1	2004	OBJECTIVE: To determine the contents of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in pancreatic cancer to provide a basis for the clinical use of capecitabine in pancreatic cancer patients.	Capecitabine	175-187	dihydropyrimidine dehydrogenase	Homo sapiens	106-109
15634525-6	2004	CONCLUSION: The increased TP to DPD ratio in pancreatic cancer suggests that capecitabine could be activated by the cancer, these capable of selectively kill the tumor cells.	Capecitabine	77-89	dihydropyrimidine dehydrogenase	Homo sapiens	32-35
15305186-1	2004	The purpose of the study was to determine the maximum-tolerated dose (MTD) of oral capecitabine, combined with concurrent, standard preoperative pelvic radiotherapy, when given twice daily, from Monday to Friday throughout the course of radiotherapy, for locally advanced potentially resectable rectal cancer.	Capecitabine	83-95	metallothionein 1E	Homo sapiens	70-73
15305186-14	2004	Dose escalation of capecitabine was ceased at 2000 mg m(-2) day(-1) after reaching MTD.	Capecitabine	19-31	metallothionein 1E	Homo sapiens	83-86
15305186-19	2004	We conclude that the MTD of capecitabine was reached at a dose level of 2000 mg m(-2) day(-1), given as 1000 mg m(-2) twice daily, from Monday to Friday throughout the course of preoperative pelvic irradiation of 50.4 Gy.	Capecitabine	28-40	metallothionein 1E	Homo sapiens	21-24
15353299-6	2004	Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	Capecitabine	134-140	thymidylate synthetase	Homo sapiens	22-24
14581344-1	2003	PURPOSE: The efficacy of new oral fluoropyrimidines, including capecitabine, is improved in cells expressing high levels of thymidine phosphorylase (TP) and low levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase.	Capecitabine	63-75	thymidylate synthetase	Homo sapiens	171-191
15555291-4	2004	RESULTS: In capecitabine and TACE group: there were 1 CR, 14 PR, 5 SD and 3 PD; the overall response rate was 65.2%; the AFP and tumor reduction rates were 68.8% and 73.9%; the median survival time was 11.9 months.	Capecitabine	12-24	alpha fetoprotein	Homo sapiens	121-124
15173095-0	2004	Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.	Capecitabine	28-40	thymidine phosphorylase	Homo sapiens	85-108
15173095-1	2004	PURPOSE: Previous studies have shown that tumor response to capecitabine strongly correlates with tumor thymidine phosphorylase (TP).	Capecitabine	60-72	thymidine phosphorylase	Homo sapiens	104-127
15173095-1	2004	PURPOSE: Previous studies have shown that tumor response to capecitabine strongly correlates with tumor thymidine phosphorylase (TP).	Capecitabine	60-72	thymidine phosphorylase	Homo sapiens	129-131
15173095-3	2004	investigate the pharmacological role of TP by measuring the pharmacokinetics (PK) of capecitabine in a human bladder tumor model that was characterized by the overexpression of TP and (b).	Capecitabine	85-97	thymidine phosphorylase	Homo sapiens	40-42
15173095-4	2004	develop the use of PK measurements for capecitabine by fluorine-19 magnetic resonance spectroscopy as a noninvasive surrogate marker for determining TP levels in tumors and for predicting tumor response to capecitabine in patients.	Capecitabine	39-51	thymidine phosphorylase	Homo sapiens	149-151
15173095-13	2004	Using in vivo fluorine-19 magnetic resonance spectroscopy to mea-sure the PK of capecitabine and its intermediate metabolites in tumors may provide a noninvasive surrogate method for determining TP levels in tumors and for predicting tumor response to capecitabine in patients.	Capecitabine	80-92	thymidine phosphorylase	Homo sapiens	195-197
15134221-4	2004	The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug.	Capecitabine	205-217	thymidylate synthetase	Homo sapiens	48-68
15134221-4	2004	The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug.	Capecitabine	205-217	dihydropyrimidine dehydrogenase	Homo sapiens	131-162
15134221-4	2004	The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug.	Capecitabine	205-217	dihydropyrimidine dehydrogenase	Homo sapiens	164-167
15054447-1	2004	The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile.	Capecitabine	58-70	kallikrein related peptidase 3	Homo sapiens	156-187
14676129-9	2003	The effect of capecitabine may be attributed to the high expression of PD-ECGF in tumors.	Capecitabine	14-26	thymidine phosphorylase	Mus musculus	71-78
15071737-5	2004	RESULTS: IFN-alpha2a enhanced the sensitivity of the LCI-D20 tumor response to capecitabine treatment.	Capecitabine	79-91	interferon alpha 2	Mus musculus	9-19
15071737-10	2004	CONCLUSION: IFN-alpha2a enhanced the antitumor effect of capecitabine on HCC in nude mice, which might be ascribed to the up-regulation of TP expression in liver cancer tissues by IFN-alpha2a.	Capecitabine	57-69	interferon alpha 2	Mus musculus	12-22
15150550-2	2004	This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the effect of capecitabine through the upregulation of thymidine phosphorylase (TP), which is responsible for the metabolism of 5-fluorouracil (5-FU) and its derivatives, including capecitabine.	Capecitabine	118-130	thymidine phosphorylase	Homo sapiens	159-182
15150550-2	2004	This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the effect of capecitabine through the upregulation of thymidine phosphorylase (TP), which is responsible for the metabolism of 5-fluorouracil (5-FU) and its derivatives, including capecitabine.	Capecitabine	118-130	thymidine phosphorylase	Homo sapiens	184-186
15150550-2	2004	This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the effect of capecitabine through the upregulation of thymidine phosphorylase (TP), which is responsible for the metabolism of 5-fluorouracil (5-FU) and its derivatives, including capecitabine.	Capecitabine	285-297	thymidine phosphorylase	Homo sapiens	159-182
15150550-2	2004	This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the effect of capecitabine through the upregulation of thymidine phosphorylase (TP), which is responsible for the metabolism of 5-fluorouracil (5-FU) and its derivatives, including capecitabine.	Capecitabine	285-297	thymidine phosphorylase	Homo sapiens	184-186
15132128-8	2004	In six tumors, TP was more intense that DPD, suggesting capecitabine sensitivity.	Capecitabine	56-68	dihydropyrimidine dehydrogenase	Homo sapiens	40-43
15132128-9	2004	Only five tumors failed to express TP but four of these expressed DPD, suggesting capecitabine resistance.	Capecitabine	82-94	dihydropyrimidine dehydrogenase	Homo sapiens	66-69
14614573-9	2004	CONCLUSION: The increased TP expression and the elevated TP/DPD ratio following irradiation with up to 20 Gy may offer an increased clinical advantage to chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone.	Capecitabine	177-189	thymidine phosphorylase	Homo sapiens	26-28
14614573-9	2004	CONCLUSION: The increased TP expression and the elevated TP/DPD ratio following irradiation with up to 20 Gy may offer an increased clinical advantage to chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone.	Capecitabine	177-189	dihydropyrimidine dehydrogenase	Homo sapiens	57-63
12866042-2	2003	In our study, we examined whether the antitumor activity of capecitabine is directly affected by a modulation of dihydropyrimidine dehydrogenase (DPD).	Capecitabine	60-72	dihydropyrimidine dehydrogenase	Homo sapiens	146-149
12866042-5	2003	The HCT116 cells bearing DPD cDNA expressed about 13 times higher DPD activities than the parental HCT116 cells, and they became significantly less susceptible to capecitabine than the parental cells when transplanted into nude mice.	Capecitabine	163-175	dihydropyrimidine dehydrogenase	Homo sapiens	25-28
12866042-6	2003	Administration of RO0094889 that is converted to a DPD inhibitor 5-vinyluracil selectively in tumor tissues restored the antitumor activity of capecitabine against the tumor of the HCT116 cells carrying DPD cDNA and various tumors expressing DPD.	Capecitabine	143-155	dihydropyrimidine dehydrogenase	Homo sapiens	51-54
12866042-6	2003	Administration of RO0094889 that is converted to a DPD inhibitor 5-vinyluracil selectively in tumor tissues restored the antitumor activity of capecitabine against the tumor of the HCT116 cells carrying DPD cDNA and various tumors expressing DPD.	Capecitabine	143-155	dihydropyrimidine dehydrogenase	Homo sapiens	203-206
12866042-6	2003	Administration of RO0094889 that is converted to a DPD inhibitor 5-vinyluracil selectively in tumor tissues restored the antitumor activity of capecitabine against the tumor of the HCT116 cells carrying DPD cDNA and various tumors expressing DPD.	Capecitabine	143-155	dihydropyrimidine dehydrogenase	Homo sapiens	203-206
14657601-0	2003	Forced expression of cytidine deaminase confers sensitivity to capecitabine.	Capecitabine	63-75	cytidine deaminase	Homo sapiens	21-39
12866042-8	2003	These results indicate that the antitumor activity of capecitabine is directly affected by DPD activities in tumor tissues and therefore, the combination of capecitabine and a tumor selective DPD inhibitor, RO0094889, will be beneficial to patients who have tumors with high levels of DPD.	Capecitabine	54-66	dihydropyrimidine dehydrogenase	Homo sapiens	91-94
12866042-8	2003	These results indicate that the antitumor activity of capecitabine is directly affected by DPD activities in tumor tissues and therefore, the combination of capecitabine and a tumor selective DPD inhibitor, RO0094889, will be beneficial to patients who have tumors with high levels of DPD.	Capecitabine	54-66	dihydropyrimidine dehydrogenase	Homo sapiens	192-195
12866042-8	2003	These results indicate that the antitumor activity of capecitabine is directly affected by DPD activities in tumor tissues and therefore, the combination of capecitabine and a tumor selective DPD inhibitor, RO0094889, will be beneficial to patients who have tumors with high levels of DPD.	Capecitabine	54-66	dihydropyrimidine dehydrogenase	Homo sapiens	192-195
12866042-8	2003	These results indicate that the antitumor activity of capecitabine is directly affected by DPD activities in tumor tissues and therefore, the combination of capecitabine and a tumor selective DPD inhibitor, RO0094889, will be beneficial to patients who have tumors with high levels of DPD.	Capecitabine	157-169	dihydropyrimidine dehydrogenase	Homo sapiens	91-94
12763217-4	2003	Capecitabine was escalated from 750 mg/m(2) twice a day (bid) to 1250 mg/m(2) bid from day 1 to day 14 in four dose levels.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	57-60
12763217-4	2003	Capecitabine was escalated from 750 mg/m(2) twice a day (bid) to 1250 mg/m(2) bid from day 1 to day 14 in four dose levels.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	78-81
12763217-8	2003	A high rate of capecitabine treatment modification was required with capecitabine 1050 mg/m(2) bid (dose level 3).	Capecitabine	15-27	BH3 interacting domain death agonist	Homo sapiens	95-98
12763217-10	2003	In conclusion, we believe that capecitabine 900 mg/m(2) bid (dose level 2) is the recommended dose in combination with epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2).	Capecitabine	31-43	BH3 interacting domain death agonist	Homo sapiens	56-59
12527930-1	2003	Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the degradation of pyrimidines and pyrimidine base analogs including the anticancer drugs 5-fluorouracil (5-FU) and Xeloda.	Capecitabine	195-201	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
12527930-1	2003	Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the degradation of pyrimidines and pyrimidine base analogs including the anticancer drugs 5-fluorouracil (5-FU) and Xeloda.	Capecitabine	195-201	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
12527930-4	2003	This underlines the need for a test system for DPYD mutations in patients undergoing chemotherapy with 5-FU or with Xeloda.	Capecitabine	116-122	dihydropyrimidine dehydrogenase	Homo sapiens	47-51
12617910-0	2003	Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.	Capecitabine	143-155	dihydropyrimidine dehydrogenase	Homo sapiens	88-91
12931018-9	2003	The present finding of a wide range in these enzyme expressions in RCC suggests that a certain subpopulation with a high TP/DPD ratio has potential responsiveness to fluoropyrimidines, especially 5"-deoxy-5-fluorouridine and capecitabine.	Capecitabine	225-237	dihydropyrimidine dehydrogenase	Homo sapiens	124-127
14657601-1	2003	OBJECTIVE: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) and gemcitabine (2",2"-difluorodeoxycytidine).	Capecitabine	95-107	cytidine deaminase	Homo sapiens	11-29
14657601-1	2003	OBJECTIVE: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) and gemcitabine (2",2"-difluorodeoxycytidine).	Capecitabine	95-107	cytidine deaminase	Homo sapiens	31-34
14657601-1	2003	OBJECTIVE: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) and gemcitabine (2",2"-difluorodeoxycytidine).	Capecitabine	109-157	cytidine deaminase	Homo sapiens	11-29
14657601-1	2003	OBJECTIVE: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) and gemcitabine (2",2"-difluorodeoxycytidine).	Capecitabine	109-157	cytidine deaminase	Homo sapiens	31-34
14657601-2	2003	The purpose of the present study was to directly examine the role of CDD in tumor cells themselves in mediating the sensitivity to capecitabine compared with gemcitabine.	Capecitabine	131-143	cytidine deaminase	Homo sapiens	69-72
14657601-8	2003	CONCLUSIONS: The present study clearly showed direct evidence for the contribution of CDD in tumor cells themselves to the sensitivities to capecitabine and gemcitabine.	Capecitabine	140-152	cytidine deaminase	Homo sapiens	86-89
12351595-3	2002	Capecitabine was administered at escalating doses from 250 to 1,250 mg/m(2) bid (including weekends) for the duration of radiotherapy.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	76-79
12351595-5	2002	RESULTS: Dose-limiting grade 3 hand-foot syndrome was observed in two of six patients treated at a capecitabine dose of 1,000 mg/m(2) bid.	Capecitabine	99-111	BH3 interacting domain death agonist	Homo sapiens	134-137
12351595-10	2002	CONCLUSION: The recommended dose for phase II evaluation is capecitabine 825 mg/m(2) bid, administered without break during a conventional radiotherapy period of about 6 weeks.	Capecitabine	60-72	BH3 interacting domain death agonist	Homo sapiens	85-88
12481438-3	2002	Pharmacogenomic studies have correlated the antitumor response to Capecitabine with the expression of the drug metabolizing enzymes thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	66-78	dihydropyrimidine dehydrogenase	Homo sapiens	165-196
12481438-3	2002	Pharmacogenomic studies have correlated the antitumor response to Capecitabine with the expression of the drug metabolizing enzymes thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).	Capecitabine	66-78	dihydropyrimidine dehydrogenase	Homo sapiens	198-201
11919232-11	2002	On the basis of our toxicity experience, we recommend use of capecitabine in combination with oxaliplatin 130 mg/m(2) at an initial dose of 1,250 mg/m(2) bid in nonpretreated patients and at a dose of 1,000 mg/m(2) bid in pretreated patients.	Capecitabine	61-73	BH3 interacting domain death agonist	Homo sapiens	215-218
12481413-2	2002	More specifically, in this report, we investigated whether apoptosis induced by capecitabine was mediated by the Fas/FasL system.	Capecitabine	80-92	Fas ligand	Homo sapiens	117-121
12481413-6	2002	The striking enhancement of thymidylate synthase inhibition that we observed in cells with high TP activity was most probably at the origin of the potentiation of capecitabine antiproliferative efficacy.	Capecitabine	163-175	thymidylate synthetase	Homo sapiens	28-48
12481413-9	2002	This implication of Fas in Xeloda-induced apoptosis was next confirmed by using antagonistic anti-Fas and anti-FasL antibodies that proved to reverse capecitabine antiproliferative activity, thus highlighting the key role that Fas could play in the optimization of an antitumor response to fluoropyrimidine drugs.	Capecitabine	27-33	Fas ligand	Homo sapiens	111-115
12481413-9	2002	This implication of Fas in Xeloda-induced apoptosis was next confirmed by using antagonistic anti-Fas and anti-FasL antibodies that proved to reverse capecitabine antiproliferative activity, thus highlighting the key role that Fas could play in the optimization of an antitumor response to fluoropyrimidine drugs.	Capecitabine	150-162	Fas ligand	Homo sapiens	111-115
12481413-10	2002	Our data, therefore, show that TP plays a key role in the capecitabine activity and that the Fas/FasL system could be considered as a new determinant for Xeloda efficacy.	Capecitabine	154-160	Fas ligand	Homo sapiens	97-101
11956613-9	2002	These results suggest that TP and DPD levels in primary colorectal tumors may be a useful indicator for selecting patients likely to respond to 5"-DFUR adjuvant chemotherapy and probably capecitabine, a prodrug of 5"-DFUR.	Capecitabine	187-199	dihydropyrimidine dehydrogenase	Homo sapiens	34-37
11956089-13	2002	Considering the role of UPase in 5-FU metabolism and the elevated expression of this protein in cancer cells compared with paired normal tissues, additional investigation should be warranted to firmly establish the clinical role of UPase in the tumor selective activation of 5-FU and capecitabine.	Capecitabine	284-296	uridine phosphorylase 1	Mus musculus	232-237
12016389-6	2002	CONCLUSIONS: Our findings suggest that tamoxifen may increase chemotherapy sensitivity through TP up-regulation for treatment regimens including doxifluridine, capecitabine, and/or methotrexate.	Capecitabine	160-172	thymidine phosphorylase	Homo sapiens	95-97
12020396-2	2002	Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU.	Capecitabine	104-116	thymidine phosphorylase	Homo sapiens	0-23
12020396-2	2002	Thymidine phosphorylase (TP) converts 5"-deoxy-5-fluorouridine (5"-DFUR), an intermediate metabolite of capecitabine, to 5-FU.	Capecitabine	104-116	thymidine phosphorylase	Homo sapiens	25-27
12020396-8	2002	These results on TP status in 2 tumor cell types could provide novel information for predicting prognosis for a patient subgroup, which would receive a probable therapeutic effect from 5"-DFUR, and presumably, from adjuvant therapy of capecitabine in early-stage breast cancer.	Capecitabine	235-247	thymidine phosphorylase	Homo sapiens	17-19
11896086-0	2002	Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.	Capecitabine	49-61	FBXW7 antisense RNA 1	Homo sapiens	0-4
11935213-10	2002	However, observed additive in vivo antitumor activity clearly indicates that the clinical efficacy of the combination of trastuzumab and capecitabine/5"-dFUrd against HER-2-overexpressing breast cancer is worth investigating.	Capecitabine	137-149	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-172
12450432-1	2001	Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed).	Capecitabine	190-202	thymidylate synthetase	Homo sapiens	0-20
11801546-2	2002	We previously demonstrated that deficiency in hENT1, the most abundant and widely distributed plasma membrane nucleoside transporter in human cells, confers high-level resistance to gemcitabine toxicity in vitro, whereas the relationship between hENT1 activity and capecitabine toxicity is unknown.	Capecitabine	265-277	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	246-251
11801546-4	2002	The presence of NBMPR reduced the cytotoxic effects of 5"-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells.	Capecitabine	140-152	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	97-102
11801546-8	2002	We conclude that because hENT1 deficiency has previously been associated with nucleoside drug resistance, immunohistochemical staining of hENT1 warrants further study as a predictive tool for guiding the appropriate use of gemcitabine and capecitabine in the treatment of breast cancer.	Capecitabine	239-251	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	138-143
12018454-0	2002	Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.	Capecitabine	60-72	thymidylate synthetase	Homo sapiens	0-20
12018454-1	2002	Thymidylate synthase is a target enzyme for chemotherapeutic agents such as 5-fluorouracil and capecitabine, its oral prodrug.	Capecitabine	95-107	thymidylate synthetase	Homo sapiens	0-20
12018454-9	2002	Our data suggest that genotyping patients for the thymidylate synthase polymorphism would be useful in identifying patients who are more likely to respond to capecitabine treatment for advanced colorectal cancer.	Capecitabine	158-170	thymidylate synthetase	Homo sapiens	50-70
11977645-3	2002	Xeloda was given, as a single drug, at a dose of or 2,510 mg/m2/d, bid, for two weeks followed by one week rest as one cycle, at least for one cycle in each patient.	Capecitabine	0-6	BH3 interacting domain death agonist	Homo sapiens	67-70
12450432-1	2001	Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed).	Capecitabine	190-202	thymidylate synthetase	Homo sapiens	22-24
11286326-8	2001	The tumour-preferential activation of capecitabine to fluorouracil is explained by tissue differences in the activity of cytidine deaminase and thymidine phosphorylase, key enzymes in the conversion process.	Capecitabine	38-50	cytidine deaminase	Homo sapiens	121-139
11353816-0	2001	Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.	Capecitabine	159-171	solute carrier family 28 member 1	Homo sapiens	56-61
11353816-11	2001	This study also reports for the first time the generation of an antibody against hCNT1, which may be useful in the elucidation of the relationship between hCNT1 expression and tumor response to capecitabine treatment.	Capecitabine	194-206	solute carrier family 28 member 1	Homo sapiens	81-86
11353816-11	2001	This study also reports for the first time the generation of an antibody against hCNT1, which may be useful in the elucidation of the relationship between hCNT1 expression and tumor response to capecitabine treatment.	Capecitabine	194-206	solute carrier family 28 member 1	Homo sapiens	155-160
11291085-0	2001	Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.	Capecitabine	30-42	thymidine phosphorylase	Homo sapiens	91-114
11291085-1	2001	The purpose of the present study was to examine directly the role of thymidine phosphorylase (TP) in the sensitivity of renal cell carcinoma (RCC) to a novel fluoropyrimidine carbamate, capecitabine.	Capecitabine	186-198	thymidine phosphorylase	Homo sapiens	69-92
11291085-1	2001	The purpose of the present study was to examine directly the role of thymidine phosphorylase (TP) in the sensitivity of renal cell carcinoma (RCC) to a novel fluoropyrimidine carbamate, capecitabine.	Capecitabine	186-198	thymidine phosphorylase	Homo sapiens	94-96
11291085-11	2001	The present study clearly provides direct evidence for the role of TP in mediating the sensitivity of RCC to capecitabine.	Capecitabine	109-121	thymidine phosphorylase	Homo sapiens	67-69
11587492-6	2001	CONCLUSIONS: It was revealed that the most important factors that determine the selective production of 5-FU in tumor tissue after capecitabine administration are tumor-specific activation by dThdPase, the nonlinear elimination of 5-FU by DPD in tumor tissue, and the blood flow rate in tumors.	Capecitabine	131-143	dihydropyrimidine dehydrogenase	Homo sapiens	239-242
11218877-1	2000	OBJECTIVE: To investigate the expression of platelet-derived endothelial cell growth factor (PD-ECGF) in liver cancer and explore its related intervention with Capecitabine for the growth and metastasis of liver cancer.	Capecitabine	160-172	thymidine phosphorylase	Mus musculus	44-91
11218877-1	2000	OBJECTIVE: To investigate the expression of platelet-derived endothelial cell growth factor (PD-ECGF) in liver cancer and explore its related intervention with Capecitabine for the growth and metastasis of liver cancer.	Capecitabine	160-172	thymidine phosphorylase	Mus musculus	93-100
10097741-3	1999	Capecitabine was converted to 5"-DFUR by either human carboxyestelase or cytidine deaminase, which were mainly localized in human liver.	Capecitabine	0-12	cytidine deaminase	Homo sapiens	73-91
11504493-5	1999	The influence of tumor TP on fluoropyrimidine toxicity is variable, but capecitabine is a prodrug of fluorouracil that requires activation by TP and hence may have a higher therapeutic index than other fluoropyrimidines.	Capecitabine	72-84	thymidine phosphorylase	Homo sapiens	142-144
10853015-1	2000	Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule.	Capecitabine	162-174	dihydropyrimidine dehydrogenase	Homo sapiens	226-257
10853015-1	2000	Thymidine phosphorylase (dThdPase) is the rate-limiting enzyme that metabolizes 5"-deoxy-5-fluorouridine (5"-dFUrd, doxifluridine), an intermediate metabolite of capecitabine, to the active drug 5-fluorouracil (5-FUra), while dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra to an inactive molecule.	Capecitabine	162-174	dihydropyrimidine dehydrogenase	Homo sapiens	259-262
10853015-6	2000	The dThdPase/DPD ratio, which was reported to correlate with the susceptibility of human cancer xenografts to capecitabine, was high in esophageal, renal, breast, colorectal, and gastric cancers (median ratio of >1.5).	Capecitabine	110-122	dihydropyrimidine dehydrogenase	Homo sapiens	13-16
10595802-4	1999	Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD"s activity.	Capecitabine	65-77	dihydropyrimidine dehydrogenase	Homo sapiens	179-182
10595802-5	1999	Capecitabine, a prodrug of fluorouracil, circumvents DPD.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	53-56
9485021-6	1998	However, capecitabine was effective even in tumors with lower levels of dThdPase if DPD levels were also lower.	Capecitabine	9-21	dihydropyrimidine dehydrogenase	Homo sapiens	84-87
9485021-0	1998	Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.	Capecitabine	45-57	dihydropyrimidine dehydrogenase	Homo sapiens	120-151
9485021-11	1998	The efficacy of capecitabine would be optimized by selecting patients who have tumors with a high ratio of dThdPase to DPD activities.	Capecitabine	16-28	dihydropyrimidine dehydrogenase	Homo sapiens	119-122
21537884-3	2011	Data from 30 patients were available from a phase II study of trastuzumab and capecitabine in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes.	Capecitabine	78-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-134
33805100-0	2021	An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities.	Capecitabine	125-137	enolase superfamily member 1	Homo sapiens	96-102
33766378-1	2021	Glycosylated pH-sensitive mesoporous silica nanoparticles (MSNs) of capecitabine (CAP) were developed for targeting colorectal cancer.	Capecitabine	68-80	sorbin and SH3 domain containing 1	Rattus norvegicus	82-85
33971591-8	2021	A good correlation was found between the concentration of capecitabine detected with POCIS deployed during five days (32 +- 1 ng L-1) and the average concentrations obtained in grab samples.	Capecitabine	58-70	RAB3A interacting protein like 1	Homo sapiens	177-181
34951129-1	2022	TAS-114 is a dual deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD) inhibitor expected to widen the therapeutic index of capecitabine.	Capecitabine	151-163	dihydropyrimidine dehydrogenase	Homo sapiens	60-91
24503798-0	2013	18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.	Capecitabine	69-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
24503802-0	2013	Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.	Capecitabine	84-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
34954044-0	2022	Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.	Capecitabine	46-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-163
23689990-1	2015	BACKGROUND: The results from a phase III trial conducted outside of Japan demonstrated a significant improvement in time to progression (TTP) when lapatinib was combined with capecitabine compared with capecitabine alone in patients with HER2-positive advanced or metastatic breast cancer.	Capecitabine	175-187	erb-b2 receptor tyrosine kinase 2	Homo sapiens	238-242
34951129-1	2022	TAS-114 is a dual deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD) inhibitor expected to widen the therapeutic index of capecitabine.	Capecitabine	151-163	dihydropyrimidine dehydrogenase	Homo sapiens	93-96
34911922-5	2021	Preoperative capecitabine- based chemoradiotherapy(CRT)(50.4 Gy in 28 fractions of 1.8 Gy each)was implemented.	Capecitabine	13-25	calcitonin receptor	Homo sapiens	51-54
34947902-0	2021	Visfatin and Resveratrol Differentially Regulate the Expression of Thymidylate Synthase to Control the Sensitivity of Human Colorectal Cancer Cells to Capecitabine Cytotoxicity.	Capecitabine	151-163	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8
34947902-0	2021	Visfatin and Resveratrol Differentially Regulate the Expression of Thymidylate Synthase to Control the Sensitivity of Human Colorectal Cancer Cells to Capecitabine Cytotoxicity.	Capecitabine	151-163	thymidylate synthetase	Homo sapiens	67-87
34947902-3	2021	It has been suggested that thymidylate synthase (TYMS) level might affect the capecitabine efficacy in CRC patients, but the mechanism still needs more elucidation.	Capecitabine	78-90	thymidylate synthetase	Homo sapiens	27-47
34947902-3	2021	It has been suggested that thymidylate synthase (TYMS) level might affect the capecitabine efficacy in CRC patients, but the mechanism still needs more elucidation.	Capecitabine	78-90	thymidylate synthetase	Homo sapiens	49-53
34947902-6	2021	Thus, the aim of present study is to examine the visfatin capacity in TYMS expression and in the development of capecitabine resistance of CRC.	Capecitabine	112-124	nicotinamide phosphoribosyltransferase	Homo sapiens	49-57
34947902-8	2021	Our results found that visfatin significantly reduces the CRC sensitivity to capecitabine by controlling the TYMS expression via p38 signaling and Sp1 transcription factor.	Capecitabine	77-89	nicotinamide phosphoribosyltransferase	Homo sapiens	23-31
34947902-8	2021	Our results found that visfatin significantly reduces the CRC sensitivity to capecitabine by controlling the TYMS expression via p38 signaling and Sp1 transcription factor.	Capecitabine	77-89	thymidylate synthetase	Homo sapiens	109-113
34947902-8	2021	Our results found that visfatin significantly reduces the CRC sensitivity to capecitabine by controlling the TYMS expression via p38 signaling and Sp1 transcription factor.	Capecitabine	77-89	mitogen-activated protein kinase 14	Homo sapiens	129-132
34947902-9	2021	Moreover, resveratrol could significantly alleviate the visfatin effect on capecitabine-treated CRC cells.	Capecitabine	75-87	nicotinamide phosphoribosyltransferase	Homo sapiens	56-64
34947902-10	2021	These results provided new insights to understand the capecitabine susceptibility of CRC under a visfatin-containing environment and a possible therapeutic application of resveratrol in CRC patients with obesity.	Capecitabine	54-66	nicotinamide phosphoribosyltransferase	Homo sapiens	97-105
34506675-12	2021	IMPLICATIONS FOR PRACTICE: The syndrome of dihydropyrimidine deaminase (DPD) deficiency is an uncommon but well-described cause of severe toxicity related to fluoropyrimidine chemotherapy agents (5-fluorouracil and capecitabine).	Capecitabine	215-227	dihydropyrimidine dehydrogenase	Homo sapiens	72-75
34589134-2	2021	Administration of lapatinib with capecitabine is an effective treatment for HER2-positive metastatic BC.	Capecitabine	33-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
34380637-1	2021	PURPOSE: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C versus lapatinib + capecitabine (L+C) in 621 patients with HER2+ metastatic breast cancer (MBC) who had received {greater than or equal to}2 prior HER2-directed regimens in the metastatic setting.	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	233-237
34380637-1	2021	PURPOSE: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C versus lapatinib + capecitabine (L+C) in 621 patients with HER2+ metastatic breast cancer (MBC) who had received {greater than or equal to}2 prior HER2-directed regimens in the metastatic setting.	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	321-325
34722261-0	2021	Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.	Capecitabine	52-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-139
35489750-0	2022	Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.	Capecitabine	34-46	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
34449540-1	2021	Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
34449540-1	2021	Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
34449540-3	2021	DPYD gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine.	Capecitabine	115-127	dihydropyrimidine dehydrogenase	Homo sapiens	0-4
34318311-1	2021	A chemometrics-oriented green ultra-performance liquid chromatography-mass spectrometry/mass spectrometry method was developed and validated for the first-time simultaneous estimation of capecitabine (CAP) and lapatinib (LPB) along with imatinib (as internal standard (IS)) in rat plasma.	Capecitabine	187-199	sorbin and SH3 domain containing 1	Rattus norvegicus	201-204
34213636-4	2021	Patients with extensive invasive residual cancer after neoadjuvant therapy are at high risk for disease recurrence, and two pivotal clinical trials, CREATE-X and KATHERINE, demonstrated improved recurrence free survival with adjuvant capecitabine and ado-trastuzumab-emtansine (T-DM1) in TNBC and HER2-positive residual cancers, respectively.	Capecitabine	234-246	erb-b2 receptor tyrosine kinase 2	Homo sapiens	297-301
34234467-7	2021	Finally, the patient was treated with capecitabine combined with pyrotinib, an irreversible TKI, acting on HER2.	Capecitabine	38-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
34100299-0	2021	Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine based chemotherapy toxicity.	Capecitabine	78-90	thymidylate synthetase	Homo sapiens	32-36
34100299-1	2021	Aim: TYMS gene encodes for TS enzyme involved in 5-fluorouracil (5-FU) and capecitabine (CAP) metabolism.	Capecitabine	75-87	thymidylate synthetase	Homo sapiens	5-9
34100299-1	2021	Aim: TYMS gene encodes for TS enzyme involved in 5-fluorouracil (5-FU) and capecitabine (CAP) metabolism.	Capecitabine	89-92	thymidylate synthetase	Homo sapiens	5-9
34100299-3	2021	Materials & methods: TYMS-TSER and 3RG>C polymorphisms were analyzed by use of PCR/PCR-RFLP in 313 5-FU/CAP-treated cancer patients.	Capecitabine	104-107	thymidylate synthetase	Homo sapiens	21-25
34221179-9	2021	The HER2-specific tyrosine kinase inhibitor tucatinib when added to trastuzumab and capecitabine was shown to improve PFS and overall survival (OS) over trastuzumab and capecitabine alone in pretreated patients in the randomized HER2CLIMB trial; this benefit was apparently independent of hormone-receptor expression.	Capecitabine	84-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
34248558-3	2021	In this report, we demonstrate a case of capecitabine-related acute myeloid leukemia that was diagnosed 16 months after the completion of treatment for early-stage colon cancer, by a complex chromosome analysis 48,XY,6,del(7)(q22),+8,+13,t(13;17)(q12;p13),t(13,21)(q12;122),+mar (Gazi Med J.	Capecitabine	41-53	H3 histone pseudogene 6	Homo sapiens	251-254
34211587-1	2021	Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial.	Capecitabine	78-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
34141791-1	2021	BACKGROUND: Capecitabine is used in combination with lapatinib as palliative treatment for human epidermal growth factor receptor 2 - positive metastatic breast cancer.	Capecitabine	12-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-131
34150608-12	2021	Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy.	Capecitabine	241-253	nuclear receptor subfamily 4 group A member 1	Homo sapiens	156-158
34150608-12	2021	Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy.	Capecitabine	241-253	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172
35124703-3	2022	We evaluated the BRCA1-like DNA copy number signature, indicative of homologous recombination deficiency, as a predictive biomarker for capecitabine benefit in the TNBC subgroup of the FinXX trial.	Capecitabine	136-148	BRCA1 DNA repair associated	Homo sapiens	17-22
35124703-9	2022	CONCLUSION: Based on our data, patients with non-BRCA1-like TNBC appear to benefit from the addition of capecitabine to adjuvant chemotherapy.	Capecitabine	104-116	BRCA1 DNA repair associated	Homo sapiens	49-54
35429901-7	2022	In the wild-type ESR1 population, OS was 37.2 months for palbociclib plus ET and 34.8 months for capecitabine (aHR 1.06, 95% CI 0.81-1.37, P = 0.683).	Capecitabine	97-109	estrogen receptor 1	Homo sapiens	17-21
34503209-0	2021	Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
34214937-0	2021	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).	Capecitabine	188-200	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
34430592-0	2021	A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.	Capecitabine	44-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-89
34430592-1	2021	Background: This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer (BC).	Capecitabine	79-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-178
34430592-1	2021	Background: This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer (BC).	Capecitabine	79-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-185
34430592-14	2021	Conclusions: Capecitabine and lobaplatin combination therapy was effective and well tolerated among patients with advanced HER-2 negative BC.	Capecitabine	13-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
34067631-8	2021	In addition, capecitabine can remarkably downregulate the expression of CTLA-4 in SW480 cells.	Capecitabine	13-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-78
34067631-9	2021	Collectively, capecitabine can inhibit the expression of CTLA-4 in CRC cells and might bridge the immunotherapy approaches with chemotherapy.	Capecitabine	14-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
34268965-5	2021	RESULTS: At 3 months after treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment in both group, and they were lower in Capecitabine group than those in Control group after treatment.	Capecitabine	262-274	CEA cell adhesion molecule 3	Homo sapiens	58-82
34268965-5	2021	RESULTS: At 3 months after treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment in both group, and they were lower in Capecitabine group than those in Control group after treatment.	Capecitabine	262-274	CEA cell adhesion molecule 3	Homo sapiens	84-87
34268965-5	2021	RESULTS: At 3 months after treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment in both group, and they were lower in Capecitabine group than those in Control group after treatment.	Capecitabine	262-274	vascular endothelial growth factor A	Homo sapiens	129-163
34268965-5	2021	RESULTS: At 3 months after treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and vascular endothelial growth factor (VEGF) were significantly lower than those before treatment in both group, and they were lower in Capecitabine group than those in Control group after treatment.	Capecitabine	262-274	vascular endothelial growth factor A	Homo sapiens	165-169
34722814-2	2021	We report a case of a 65-year-old man who underwent proton beam therapy (PBT) with concurrent capecitabine and hormonal therapy for his synchronously found prostate (intermediate-risk) and rectal (cT2, N2b, stage IIIB) cancers; he also received low anterior resection.	Capecitabine	94-106	cancer/testis antigen 2	Homo sapiens	197-200
35534752-2	2022	METHODS: Using a Markov model, the clinical effectiveness of managing HR+, HER2- MBC in postmenopausal women with either a CDK4/6i (either ribociclib or palbociclib) and fulvestrant, fulvestrant alone, and chemotherapy (single-agent paclitaxel or capecitabine) was measured in terms of quality-adjusted life-years (QALYs).	Capecitabine	247-259	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
35534752-2	2022	METHODS: Using a Markov model, the clinical effectiveness of managing HR+, HER2- MBC in postmenopausal women with either a CDK4/6i (either ribociclib or palbociclib) and fulvestrant, fulvestrant alone, and chemotherapy (single-agent paclitaxel or capecitabine) was measured in terms of quality-adjusted life-years (QALYs).	Capecitabine	247-259	cyclin dependent kinase 4	Homo sapiens	123-130
35489750-2	2022	Proton pump inhibitors (PPIs) reportedly exert anti-inflammatory effects; however, the impact of PPIs on capecitabine-induced HFS needs to be clarified in the clinical setting.	Capecitabine	105-117	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
35467766-0	2022	Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.	Capecitabine	49-61	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	21-28
35473510-7	2022	CONCLUSION: Upfront testing of DPYD variants appears to reduce the toxicity burden of Capecitabine and 5-FU in cancer patients and can lead to substantial hospital cost savings, only if the dose management of the drugs in response to variants detected is standardised and regulated.	Capecitabine	86-98	dihydropyrimidine dehydrogenase	Homo sapiens	31-35
35467766-9	2022	rs6783836 at ST6GAL1 was associated with HFS in patients treated with XELOX (OR=3.1, 95%CI=2.1-4.6, P=4.3x10-8 ) and was borderline significant in patients receiving capecitabine from QUASAR2, but with an opposite allele effect (OR=0.66, 95% CI=0.42-1.03, P=0.05).	Capecitabine	166-178	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	13-20
35405660-8	2022	This report describes a patient with metastatic estrogen receptor-positive, HER2-nonamplified breast cancer with an activating HER2 mutation whose tumor became resistant to neratinib as well as capecitabine, but whose subsequent leptomeningeal disease had a dramatically successful response to tucatinib plus capecitabine.	Capecitabine	194-206	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
35449546-4	2022	Methods/Design: The ACO/ARO/AIO-21 is an investigator-driven, prospective, open-labeled phase I drug-repurposing trial assessing the maximum tolerated dose (MTD) of capecitabine administered concurrently to standard preoperative radiotherapy (45 Gy in 25 fractions followed by 9 Gy boost in 5 fractions) in combination with fixed doses of the IL1-RA anakinra (100 mg, days -10 to 30).	Capecitabine	165-177	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	24-27
35449546-4	2022	Methods/Design: The ACO/ARO/AIO-21 is an investigator-driven, prospective, open-labeled phase I drug-repurposing trial assessing the maximum tolerated dose (MTD) of capecitabine administered concurrently to standard preoperative radiotherapy (45 Gy in 25 fractions followed by 9 Gy boost in 5 fractions) in combination with fixed doses of the IL1-RA anakinra (100 mg, days -10 to 30).	Capecitabine	165-177	interleukin 1 alpha	Homo sapiens	343-346
35449143-0	2022	Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.	Capecitabine	30-42	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
35449143-1	2022	The association between capecitabine efficacy and proton pump inhibitors (PPIs) is controversial.	Capecitabine	24-36	ATPase H+/K+ transporting subunit alpha	Homo sapiens	50-61
35405660-8	2022	This report describes a patient with metastatic estrogen receptor-positive, HER2-nonamplified breast cancer with an activating HER2 mutation whose tumor became resistant to neratinib as well as capecitabine, but whose subsequent leptomeningeal disease had a dramatically successful response to tucatinib plus capecitabine.	Capecitabine	309-321	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
35368874-0	2022	Capecitabine Regulates HSP90AB1 Expression and Induces Apoptosis via Akt/SMARCC1/AP-1/ROS Axis in T Cells.	Capecitabine	0-12	heat shock protein 90 alpha family class B member 1	Homo sapiens	23-31
35218209-3	2022	We aimed to investigate the differences in efficacy and safety between bevacizumab combined with capecitabine maintenance therapy and capecitabine monotherapy for RAS-mutant mCRC (as defined by mutations in KRAS and NRAS exons 2-4)controlled by bevacizumab plus FOLFIRI chemotherapy for at least 12 weeks.	Capecitabine	134-146	KRAS proto-oncogene, GTPase	Homo sapiens	207-211
35218209-3	2022	We aimed to investigate the differences in efficacy and safety between bevacizumab combined with capecitabine maintenance therapy and capecitabine monotherapy for RAS-mutant mCRC (as defined by mutations in KRAS and NRAS exons 2-4)controlled by bevacizumab plus FOLFIRI chemotherapy for at least 12 weeks.	Capecitabine	134-146	NRAS proto-oncogene, GTPase	Homo sapiens	216-220
35352176-0	2022	A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.	Capecitabine	69-81	thymocyte selection associated high mobility group box	Homo sapiens	87-90
35368874-0	2022	Capecitabine Regulates HSP90AB1 Expression and Induces Apoptosis via Akt/SMARCC1/AP-1/ROS Axis in T Cells.	Capecitabine	0-12	AKT serine/threonine kinase 1	Homo sapiens	69-72
35368874-0	2022	Capecitabine Regulates HSP90AB1 Expression and Induces Apoptosis via Akt/SMARCC1/AP-1/ROS Axis in T Cells.	Capecitabine	0-12	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1	Homo sapiens	73-80
35368874-0	2022	Capecitabine Regulates HSP90AB1 Expression and Induces Apoptosis via Akt/SMARCC1/AP-1/ROS Axis in T Cells.	Capecitabine	0-12	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-85
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	insulin like growth factor 1	Homo sapiens	212-217
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	mitogen-activated protein kinase 14	Mus musculus	0-8
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	10-19
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	signal transducer and activator of transcription 3	Mus musculus	29-34
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	interleukin 6	Mus musculus	110-123
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	chemokine (C-X-C motif) ligand 15	Mus musculus	127-140
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	mitogen-activated protein kinase 14	Mus musculus	13-21
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	23-32
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	signal transducer and activator of transcription 3	Mus musculus	42-47
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	interleukin 6	Mus musculus	111-114
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	chemokine (C-X-C motif) ligand 15	Mus musculus	118-121
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	growth hormone 1	Homo sapiens	224-238
35306539-2	2022	Patients carrying Dihydropyrimidine Dehydrogenase (DPYD) variant alleles associated with decreased enzymatic function are at a greater risk of early/severe 5-fluorouracil/capecitabine toxicity.	Capecitabine	171-183	dihydropyrimidine dehydrogenase	Homo sapiens	18-49
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	growth hormone 1	Homo sapiens	240-242
35306539-2	2022	Patients carrying Dihydropyrimidine Dehydrogenase (DPYD) variant alleles associated with decreased enzymatic function are at a greater risk of early/severe 5-fluorouracil/capecitabine toxicity.	Capecitabine	171-183	dihydropyrimidine dehydrogenase	Homo sapiens	51-55
33950403-8	2021	The sensitivity to capecitabine was consistent with the clinical treatment response of this patient for capecitabine and with the sequencing results that reported MTHFR gene polymorphism mutation and TYMS -6bp/-6bp polymorphism mutation indicating effectiveness to fluorouracil.	Capecitabine	19-31	methylenetetrahydrofolate reductase	Homo sapiens	163-168
35479584-1	2022	Background: Capecitabine is used as a first-line treatment for gastrointestinal (GI) tract cancers.	Capecitabine	12-24	G protein subunit alpha i1	Homo sapiens	81-83
35479584-5	2022	Methods: The electronic medical records of patients receiving first-line capecitabine-containing regimens for GI malignancies were reviewed.	Capecitabine	73-85	G protein subunit alpha i1	Homo sapiens	110-112
35154427-0	2022	Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway.	Capecitabine	0-12	TNF superfamily member 11	Homo sapiens	126-131
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	35-47	TNF superfamily member 11	Homo sapiens	98-103
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	35-47	TNF receptor superfamily member 11b	Homo sapiens	108-111
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	35-47	TNF superfamily member 11	Homo sapiens	192-197
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	143-155	TNF superfamily member 11	Homo sapiens	98-103
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	143-155	TNF receptor superfamily member 11b	Homo sapiens	108-111
35154427-8	2022	Additionally, it was observed that capecitabine treatment reduced the protein expression of RANK, RANKL and OPG in HT29 cells, suggesting that capecitabine has a repressive effect on the RANK/RANKL pathway.	Capecitabine	143-155	TNF superfamily member 11	Homo sapiens	192-197
35154427-11	2022	These findings suggest that the regulatory role of capecitabine is at least partially mediated through the RANK/RANKL pathway in colorectal cancer.	Capecitabine	51-63	TNF superfamily member 11	Homo sapiens	112-117
35154427-12	2022	The present study demonstrated that capecitabine-induced repression of CRC is exerted by inhibiting the RANK/RANKL pathway, where this new mechanism potentially provides a novel therapeutic target.	Capecitabine	36-48	TNF superfamily member 11	Homo sapiens	109-114
35356252-0	2022	Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.	Capecitabine	16-28	prolactin	Homo sapiens	126-135
35356252-0	2022	Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.	Capecitabine	16-28	insulin like growth factor 1	Homo sapiens	137-142
35356252-0	2022	Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.	Capecitabine	16-28	growth hormone 1	Homo sapiens	148-162
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	prolactin	Homo sapiens	165-174
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	prolactin	Homo sapiens	176-179
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	insulin like growth factor 1	Homo sapiens	182-210
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	insulin like growth factor 1	Homo sapiens	212-217
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	growth hormone 1	Homo sapiens	224-238
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	44-56	growth hormone 1	Homo sapiens	240-242
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	prolactin	Homo sapiens	165-174
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	prolactin	Homo sapiens	176-179
35356252-1	2022	Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels.	Capecitabine	58-61	insulin like growth factor 1	Homo sapiens	182-210
35085506-0	2022	Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-86
35085506-16	2022	INTERPRETATION: To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population.	Capecitabine	120-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154
34656072-0	2022	Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.	Capecitabine	77-89	ATPase H+/K+ transporting subunit alpha	Homo sapiens	14-25
34656072-1	2022	Retrospective data suggest that gastric acid reduction by proton pump inhibitors (PPIs) impairs the dissolution and subsequent absorption of capecitabine, and thus potentially reduces the capecitabine exposure.	Capecitabine	141-153	ATPase H+/K+ transporting subunit alpha	Homo sapiens	58-69
34656072-1	2022	Retrospective data suggest that gastric acid reduction by proton pump inhibitors (PPIs) impairs the dissolution and subsequent absorption of capecitabine, and thus potentially reduces the capecitabine exposure.	Capecitabine	188-200	ATPase H+/K+ transporting subunit alpha	Homo sapiens	58-69
35155188-10	2021	She started to receive third-line treatment of irinotecan (200 mg d1) and capecitabine (60 mg bid) plus pyrotinib (400 mg/day).	Capecitabine	74-86	BH3 interacting domain death agonist	Homo sapiens	94-97
35040365-0	2022	Hepatitis B reactivation after oral capecitabine treatment in a rectum cancer patient with isolated anti-HBc IgG positivity.	Capecitabine	36-48	keratin 88, pseudogene	Homo sapiens	105-108
35040365-2	2022	Herein we present a case of HBV reactivation after oral capecitabine treatment in a patient with rectum cancer and isolated anti-HBc IgG positivity.	Capecitabine	56-68	keratin 88, pseudogene	Homo sapiens	129-132
35040365-11	2022	DISCUSSION: To the best of our knowledge, this is the first case report describing HBV reactivation after chemotherapy with capecitabine for rectal cancer in a patient with isolated anti-HBc IgG positivity.	Capecitabine	124-136	keratin 88, pseudogene	Homo sapiens	187-190
34037241-1	2021	BACKGROUND: Retrospective analyses suggest that capecitabine may carry superior activity in hormone receptor-positive relative to hormone receptor-negative metastatic breast cancer.	Capecitabine	48-60	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
34037241-12	2021	In the metastatic setting, the effect of capecitabine was heterogenous between hormone receptor-positive and -negative tumours.	Capecitabine	41-53	nuclear receptor subfamily 4 group A member 1	Homo sapiens	79-95
34037241-15	2021	This was largely accounted for by a moderate improvement in PFS for inclusion of capecitabine in hormone receptor-positive cancers (HR 0.82, 95% CI 0.73 to 0.91; 7 studies, 1594 participants; moderate-certainty evidence) compared to no difference in PFS for hormone receptor-negative cancers (HR 0.96, 95% CI 0.83 to 1.10; 7 studies, 1122 participants; moderate-certainty evidence).	Capecitabine	81-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	97-113
33950403-8	2021	The sensitivity to capecitabine was consistent with the clinical treatment response of this patient for capecitabine and with the sequencing results that reported MTHFR gene polymorphism mutation and TYMS -6bp/-6bp polymorphism mutation indicating effectiveness to fluorouracil.	Capecitabine	19-31	thymidylate synthetase	Homo sapiens	200-204
33586000-0	2021	Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.	Capecitabine	117-129	carboxylesterase 1	Homo sapiens	0-18
33586000-8	2021	CONCLUSIONS: The identified CES1 polymorphisms might provide guide for the identification of gastroenteric cancer patients who were likely to benefit from capecitabine-based chemotherapy.	Capecitabine	155-167	carboxylesterase 1	Homo sapiens	28-32
33755863-1	2021	BACKGROUND: Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone.	Capecitabine	71-83	Fas activated serine/threonine kinase	Homo sapiens	172-176
33996589-1	2021	Introduction: Pyrotinib plus capecitabine has been approved in China for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).	Capecitabine	29-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-113
33909203-0	2021	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >= 2 prior HER2-directed regimens.	Capecitabine	12-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
33909203-0	2021	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >= 2 prior HER2-directed regimens.	Capecitabine	12-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-140
33903667-5	2021	Repeated administration of capecitabine (200 mg/kg, p.o., five times a week for 3 weeks) increased fluid content, redness, and tumor necrosis factor (TNF)-alpha substance of the mice hind paw.	Capecitabine	27-39	tumor necrosis factor	Mus musculus	127-160
33996589-1	2021	Introduction: Pyrotinib plus capecitabine has been approved in China for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).	Capecitabine	29-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
33852121-0	2021	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).	Capecitabine	29-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
33995628-8	2021	In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, the positive expression of LC3 correlated with worse OS compared to patients who did not express LC3.	Capecitabine	36-48	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	132-135
33995628-8	2021	In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, the positive expression of LC3 correlated with worse OS compared to patients who did not express LC3.	Capecitabine	52-64	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	132-135
33995628-8	2021	In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, the positive expression of LC3 correlated with worse OS compared to patients who did not express LC3.	Capecitabine	52-64	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	202-205
33874986-5	2021	5"-deoxy-5-fluorocytidine (5"-DFCR) is a cytidine analogue (metabolite of capecitabine), which is converted by CDA and subsequently by TYMP into 5-fluorouracil, a chemotherapeutic agent frequently used to treat solid tumors.	Capecitabine	74-86	cytidine deaminase	Homo sapiens	111-114
33874986-5	2021	5"-deoxy-5-fluorocytidine (5"-DFCR) is a cytidine analogue (metabolite of capecitabine), which is converted by CDA and subsequently by TYMP into 5-fluorouracil, a chemotherapeutic agent frequently used to treat solid tumors.	Capecitabine	74-86	thymidine phosphorylase	Homo sapiens	135-139
34037241-15	2021	This was largely accounted for by a moderate improvement in PFS for inclusion of capecitabine in hormone receptor-positive cancers (HR 0.82, 95% CI 0.73 to 0.91; 7 studies, 1594 participants; moderate-certainty evidence) compared to no difference in PFS for hormone receptor-negative cancers (HR 0.96, 95% CI 0.83 to 1.10; 7 studies, 1122 participants; moderate-certainty evidence).	Capecitabine	81-93	nuclear receptor subfamily 4 group A member 1	Homo sapiens	258-274
34037241-27	2021	AUTHORS" CONCLUSIONS: In summary, a moderate PFS benefit by including capecitabine was seen only in hormone receptor-positive cancers in metastatic studies.	Capecitabine	70-82	nuclear receptor subfamily 4 group A member 1	Homo sapiens	100-116
34037241-29	2021	In contrast, the addition of capecitabine in the adjuvant setting led to improved outcomes for OS and DFS in hormone receptor-negative cancer.	Capecitabine	29-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	109-125
33709051-1	2021	Background: Capecitabine is a pyrimidine antimetabolite that inhibits thymidylate synthase and is commonly used in the treatment of colorectal cancer.	Capecitabine	12-24	thymidylate synthetase	Homo sapiens	70-90
33869031-10	2021	In PDX models with mutated p53 status, there was significant tumor growth inhibition from the combination of AZD1775 with irinotecan or capecitabine (P <= 0.03), while PDX models with wild type p53 did not show anti-tumor synergy from the same combinations (P >= 0.08).	Capecitabine	136-148	tumor protein p53	Homo sapiens	27-30
32559325-0	2021	Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: implications for dosing recommendations.	Capecitabine	85-97	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	14-17
33688205-0	2021	Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.	Capecitabine	35-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
33688205-0	2021	Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.	Capecitabine	35-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
33688205-6	2021	The small-molecule pan-HER family irreversible inhibitor pyrotinib combined with capecitabine has shown a promising effect in the treatment of HER2 mutation-induced resistance, but the molecular mechanism and efficacy need to be further verified.	Capecitabine	81-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
33538958-0	2021	Trastuzumab +- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
33581774-16	2021	INTERPRETATION: Pyrotinib plus capecitabine significantly improved progression-free survival compared with that for lapatinib plus capecitabine, with manageable toxicity, and can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy.	Capecitabine	31-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	243-247
33644953-1	2021	BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) with capecitabine was suggested to be associated with poor outcomes in gastrointestinal cancers.	Capecitabine	66-78	ATPase H+/K+ transporting subunit alpha	Homo sapiens	31-42
33538958-12	2021	CONCLUSION: Trastuzumab maintenance +- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.	Capecitabine	39-51	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
32757270-0	2021	Regulatory CDH4 genetic variants associate with risk to develop capecitabine-induced hand-foot syndrome.	Capecitabine	64-76	cadherin 4	Homo sapiens	11-15
33285053-0	2021	Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.	Capecitabine	40-52	thymidylate synthetase	Homo sapiens	17-21
33249761-13	2021	Capecitabine/bevacizumab can be selected as a subsequent maintenance therapy without irinotecan and oxaliplatin because FTD/TPI has no cross-resistance with 5-fluorouracil.	Capecitabine	0-12	triosephosphate isomerase 1	Homo sapiens	124-127
33285053-2	2021	As the target enzyme for capecitabine, thymidylate synthase (TYMS) plays a key role for 5-fluorouracil metabolism and has been associated with some side effects caused by capecitabine.	Capecitabine	25-37	thymidylate synthetase	Homo sapiens	39-59
33285053-2	2021	As the target enzyme for capecitabine, thymidylate synthase (TYMS) plays a key role for 5-fluorouracil metabolism and has been associated with some side effects caused by capecitabine.	Capecitabine	25-37	thymidylate synthetase	Homo sapiens	61-65
33285053-2	2021	As the target enzyme for capecitabine, thymidylate synthase (TYMS) plays a key role for 5-fluorouracil metabolism and has been associated with some side effects caused by capecitabine.	Capecitabine	171-183	thymidylate synthetase	Homo sapiens	39-59
33285053-2	2021	As the target enzyme for capecitabine, thymidylate synthase (TYMS) plays a key role for 5-fluorouracil metabolism and has been associated with some side effects caused by capecitabine.	Capecitabine	171-183	thymidylate synthetase	Homo sapiens	61-65
32933338-8	2021	Our data indicate that IP6 and INS enhanced the effect of capecitabine on CRC growth in mice by modulating the expression of inflammatory factors, intercellular adhesion molecules, and vimentin.	Capecitabine	58-70	vimentin	Mus musculus	185-193
33490146-7	2020	For HER2 positive unresectable, locally advanced or metastatic patients progressed after trastuzumab therapy pyrotinib plus capecitabine ranked the highest surface under the cumulative ranking area (SUCRA) in PFS, ORR and its SUCRA in OS was higher than Trastuzumab emtansine (T-DM1).	Capecitabine	124-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8
33490146-11	2020	Conclusions: The results indicated that for HER2 positive breast cancer with previous trastuzumab therapy pyrotinib plus capecitabine was probably more efficacious in PFS and ORR.	Capecitabine	121-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
33197222-0	2020	All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.	Capecitabine	91-103	dihydropyrimidine dehydrogenase	Homo sapiens	27-31
33154776-8	2020	Multivariate analysis revealed that the line of lapatinib-based treatment and its combination with capecitabine or a different agent were independent prognostic factors for the median PFS in patients with HER2+ MBC.	Capecitabine	99-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	205-209
33035787-6	2020	In the capecitabine group, the MTHFR rs1801131 CC genotype was associated with asthenia (OR = 3.48; p = 0.009).	Capecitabine	7-19	methylenetetrahydrofolate reductase	Homo sapiens	31-36
32891715-1	2020	Trifluridine/tipiracil (FTD/TPI; marketed as Lonsurf ) has shown clinically relevant activity after fluoropyrimidine failure in colorectal cancer and may thus be of increased efficacy compared with current standard capecitabine chemoradiation.	Capecitabine	215-227	triosephosphate isomerase 1	Homo sapiens	28-31
32999176-2	2021	PATIENTS AND METHODS: We retrospectively evaluated efficacy of chemotherapy with capecitabine and bevacizumab for patients with poor PS (PS 3).	Capecitabine	81-93	taste 2 receptor member 6 pseudogene	Homo sapiens	137-141
28520372-0	2012	Capecitabine Therapy and DPYD Genotype Capecitabine is a chemotherapy agent that belongs to the drug class of fluoropyrimidines.	Capecitabine	39-51	dihydropyrimidine dehydrogenase	Homo sapiens	25-29
28520372-4	2012	Individuals who are carriers of non-functional DPYD variants, such as DPYD*2A, may not be able to metabolize capecitabine at normal rates, and are at risk of potentially life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity.	Capecitabine	109-121	dihydropyrimidine dehydrogenase	Homo sapiens	47-51
28520372-4	2012	Individuals who are carriers of non-functional DPYD variants, such as DPYD*2A, may not be able to metabolize capecitabine at normal rates, and are at risk of potentially life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity.	Capecitabine	109-121	dihydropyrimidine dehydrogenase	Homo sapiens	70-74
28520372-4	2012	Individuals who are carriers of non-functional DPYD variants, such as DPYD*2A, may not be able to metabolize capecitabine at normal rates, and are at risk of potentially life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity.	Capecitabine	187-199	dihydropyrimidine dehydrogenase	Homo sapiens	47-51
28520372-4	2012	Individuals who are carriers of non-functional DPYD variants, such as DPYD*2A, may not be able to metabolize capecitabine at normal rates, and are at risk of potentially life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity.	Capecitabine	187-199	dihydropyrimidine dehydrogenase	Homo sapiens	70-74
28520372-6	2012	The FDA-approved drug label for capecitabine states that no capecitabine dose has been proven safe in patients with absent DPD activity, and that there is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test (1).	Capecitabine	32-44	dihydropyrimidine dehydrogenase	Homo sapiens	123-126
32907836-11	2020	SIGNIFICANCE: Preclinical and clinical trial data suggest that the combination of CB-839 with capecitabine could serve as an effective treatment for PIK3CA-mutant colorectal cancers.	Capecitabine	94-106	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	149-155
32966231-0	2020	Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin.	Capecitabine	130-142	dihydropyrimidine dehydrogenase	Homo sapiens	21-25
32966231-15	2020	Conclusions DPYD*9A polymorphism had a significant influence on the plasma levels of 5-FU after capecitabine administration.	Capecitabine	96-108	dihydropyrimidine dehydrogenase	Homo sapiens	12-16
32951006-9	2020	In addition, knockdown of circFoxp1 significantly sensitized colon cancer cells to Capecitabine in vitro and vivo through regulating Foxp1.	Capecitabine	83-95	forkhead box P1	Homo sapiens	30-35
33042632-4	2020	We conducted a clinical study to evaluate the efficacy and safety of trastuzumab in combination with docetaxel+capecitabine (DX) in patients with HER2-positive AGC.	Capecitabine	111-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
32847480-11	2021	CONCLUSIONS: Among breast cancer patients, higher TYMP expression was associated with sensitivity to capecitabine.	Capecitabine	101-113	thymidine phosphorylase	Homo sapiens	50-54
33065805-3	2020	Pyrotinib combined with capecitabine is widely used to treat HER2-positive metastatic breast cancer in patients who have been previously treated with anthracyclines, taxanes, and trastuzumab.	Capecitabine	24-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
32436244-0	2020	A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?	Capecitabine	51-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-72
32862744-7	2020	EXPERT OPINION: Neratinib plus capecitabine is a valid treatment option for patients with advanced HER2-positive breast cancer, after progression to at least two anti-HER2-based regimens.	Capecitabine	31-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
32770940-0	2020	CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients.	Capecitabine	62-74	Fc gamma receptor IIIa	Homo sapiens	0-4
32468955-0	2020	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.	Capecitabine	71-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	107-111
33117504-0	2020	Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine.	Capecitabine	104-116	thymidylate synthetase	Homo sapiens	36-40
32905036-7	2020	Tyrosine kinase overexpression can be treated with lapatinib, which has also been approved for improving survival and is used in combination with capecitabine.	Capecitabine	146-158	TXK tyrosine kinase	Homo sapiens	0-15
32770940-6	2020	RESULTS: The expression level of CD16 on neutrophils was down-regulated in capecitabine-resistant CRC patients.	Capecitabine	75-87	Fc gamma receptor IIIa	Homo sapiens	33-37
32770940-7	2020	Patients with CD16low/-neutrophils after capecitabine therapy had adverse clinical features.	Capecitabine	41-53	Fc gamma receptor IIIa	Homo sapiens	14-18
32770940-9	2020	RNA sequencing revealed that CD16low/-neutrophils in capecitabine-resistant patients had lower expression level of neutrophil-related genes, compared to CD16+neutrophils in capecitabine-sensitive patients, suggesting this CD16low/-population might be immature neutrophils.	Capecitabine	53-65	Fc gamma receptor IIIa	Homo sapiens	29-33
32770940-9	2020	RNA sequencing revealed that CD16low/-neutrophils in capecitabine-resistant patients had lower expression level of neutrophil-related genes, compared to CD16+neutrophils in capecitabine-sensitive patients, suggesting this CD16low/-population might be immature neutrophils.	Capecitabine	173-185	Fc gamma receptor IIIa	Homo sapiens	29-33
32770940-10	2020	Furthermore, the expression level of CD16 on neutrophils in patients with capecitabine treatment was positively correlated with the number of anti-tumor immune cell subsets, such as CD8+T cell, CD4+T cell, NK cell and monocyte.	Capecitabine	74-86	Fc gamma receptor IIIa	Homo sapiens	37-41
32770940-11	2020	CONCLUSIONS: Our findings indicated that CD16 expression on neutrophils in peripheral blood was a good prognostic marker for predicting efficacy of capecitabine in CRC patients.	Capecitabine	148-160	Fc gamma receptor IIIa	Homo sapiens	41-45
32584367-9	2020	Main Outcomes and Measures: The phase 1 primary objective was to identify the MTD of capecitabine plus T-DM1.	Capecitabine	85-97	metallothionein 1E	Homo sapiens	78-81
32399998-0	2020	Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.	Capecitabine	73-85	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	32-38
32584367-12	2020	The capecitabine MTD was identified as 700 mg/m2 in 11 patients with mBC and 6 patients with LA/mGC evaluable for dose-limiting toxic effects.	Capecitabine	4-16	metallothionein 1E	Homo sapiens	17-20
32314029-1	2020	PURPOSE: This study investigated the influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer (CRC) patients who received capecitabine-based adjuvant chemotherapy in real world.	Capecitabine	153-165	CD274 molecule	Homo sapiens	50-55
32756099-2	2020	PATIENT CONCERNS: We herein report on a patient affected by HR+ HER2- MBC treated with radical surgery after neoadjuvant chemotherapy, who relapsed early on adjuvant tamoxifen, progressed rapidly on first line anastrozole, and failed treatment with third line capecitabine.	Capecitabine	260-272	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
32733788-4	2020	Methods: The fecal samples of HER2-negative metastatic breast cancer patients treated with capecitabine as maintenance chemotherapy were collected and analyzed by 16S ribosome RNA gene sequencing.	Capecitabine	91-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34
32694997-1	2020	The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity.	Capecitabine	131-143	ret proto-oncogene	Homo sapiens	4-28
32923881-0	2020	Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing.	Capecitabine	7-19	dihydropyrimidine dehydrogenase	Homo sapiens	52-56
32458030-3	2020	Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine.	Capecitabine	83-95	carboxylesterase 1	Homo sapiens	33-37
32458030-10	2020	Higher CES1 activity expressed as a metabolic ratio (AUC of capecitabine/sum of three AUCs of each metabolite) lower than its mean was associated with higher 5"-DFUR AUC/dose and lower RDI, indicating essential roles of CES1 in capecitabine activation to produce 5"-DFUR.	Capecitabine	60-72	carboxylesterase 1	Homo sapiens	7-11
32458030-10	2020	Higher CES1 activity expressed as a metabolic ratio (AUC of capecitabine/sum of three AUCs of each metabolite) lower than its mean was associated with higher 5"-DFUR AUC/dose and lower RDI, indicating essential roles of CES1 in capecitabine activation to produce 5"-DFUR.	Capecitabine	228-240	carboxylesterase 1	Homo sapiens	7-11
32458030-11	2020	However, the association between CES1 variants and capecitabine pharmacokinetics and toxicity was not significant.	Capecitabine	51-63	carboxylesterase 1	Homo sapiens	33-37
31479512-7	2020	Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit.	Capecitabine	346-358	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	87-92
31479512-7	2020	Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit.	Capecitabine	346-358	DNA topoisomerase II alpha	Homo sapiens	152-157
31776320-0	2020	Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" therapy) for HER-2 negative breast cancer, as retrospective study in our institute.	Capecitabine	28-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
31776320-1	2020	BACKGROUND: We have modified and performed neoadjuvant chemotherapy (NAC) using capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" ) for HER-2 negative breast cancer.	Capecitabine	80-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-164
32382808-13	2020	TS activity was induced and DPD activity demonstrated circadian rhythmicity during capecitabine treatment.	Capecitabine	83-95	thymidylate synthetase	Homo sapiens	0-2
32382808-13	2020	TS activity was induced and DPD activity demonstrated circadian rhythmicity during capecitabine treatment.	Capecitabine	83-95	dihydropyrimidine dehydrogenase	Homo sapiens	28-31
32546132-1	2020	BACKGROUND: 5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine derivatives that mainly metabolized with dihydropyrimidine dehydrogenase enzyme (DPD).	Capecitabine	38-50	dihydropyrimidine dehydrogenase	Homo sapiens	153-156
32192349-8	2020	Two clinical trials have shown improved outcomes with post-operative capecitabine and ado-trastuzumab emtansine treatment in patients with either TN or HER2-positive breast cancer, respectively, who had residual disease after neoadjuvant chemotherapy.	Capecitabine	69-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
33354548-14	2020	Three patients with ERBB3 mutations showed response to lapatinib-capecitabine.	Capecitabine	65-77	erb-b2 receptor tyrosine kinase 3	Homo sapiens	20-25
32314029-12	2020	CONCLUSION: The prognosis of R0 resection CRC patients received capecitabine-based adjuvant chemotherapy in real world may be influenced by PD-L1 901T>C polymorphism through mediation of the mRNA expression of PD-L1.	Capecitabine	64-76	CD274 molecule	Homo sapiens	140-145
32314029-12	2020	CONCLUSION: The prognosis of R0 resection CRC patients received capecitabine-based adjuvant chemotherapy in real world may be influenced by PD-L1 901T>C polymorphism through mediation of the mRNA expression of PD-L1.	Capecitabine	64-76	CD274 molecule	Homo sapiens	210-215
32204315-0	2020	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.	Capecitabine	51-63	WEE1 G2 checkpoint kinase	Homo sapiens	0-4
32193619-0	2020	SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.	Capecitabine	79-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	12-17
32193619-0	2020	SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.	Capecitabine	79-91	prostaglandin E synthase	Homo sapiens	18-22
32193619-0	2020	SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.	Capecitabine	79-91	epiregulin	Homo sapiens	23-25
31838939-0	2020	Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.	Capecitabine	47-59	KRAS proto-oncogene, GTPase	Homo sapiens	77-81
32231738-0	2020	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine.	Capecitabine	124-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
32231738-1	2020	Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (ABC) patients.	Capecitabine	127-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	223-257
32231738-1	2020	Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (ABC) patients.	Capecitabine	127-139	erb-b2 receptor tyrosine kinase 2	Homo sapiens	259-263
32231738-8	2020	In HER2-positive ABC patients initiating lapatinib plus capecitabine, consideration should be given to more closely monitoring patients at risk of nausea and vomiting, while rash and hand foot syndrome are AE associated with improved survival.	Capecitabine	56-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
32131770-9	2020	CONCLUSION: Our results provide moderate quality evidence that bevacizumab-taxanes-capecitabine maybe the most effective bevacizumab plus chemotherapy on PFS and ORR in HER2-negative metastatic breast cancer, however it should be also considered that bevacizumab may add toxicity to chemotherapy and whether improve overall survival (OS) or not.	Capecitabine	83-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
32168252-0	2020	Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.	Capecitabine	78-90	insulin	Homo sapiens	31-38
32066801-1	2020	Capecitabine is selectively converted from 5"-DFUR to 5-fluorouracil (5-FU) in tumours by thymidine phosphorylase (TP).	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	90-113
32066801-1	2020	Capecitabine is selectively converted from 5"-DFUR to 5-fluorouracil (5-FU) in tumours by thymidine phosphorylase (TP).	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	115-117
32309387-1	2020	Background: Lapatinib is approved for the treatment of metastatic HER2-overexpressed breast cancer with capecitabine after progress on anthracycline, taxane, and trastuzumab in China.	Capecitabine	104-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
32062671-1	2020	BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer.	Capecitabine	118-130	KRAS proto-oncogene, GTPase	Homo sapiens	180-185
32175106-2	2020	We evaluated the safety and efficacy of the aminopeptidase inhibitor tosedostat with capecitabine in advanced PDAC.	Capecitabine	85-97	carboxypeptidase Q	Homo sapiens	44-58
31941523-0	2020	CApecitabine plus Radium-223 (Xofigo ) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.	Capecitabine	0-12	syntaxin 8	Homo sapiens	87-93
32060053-0	2020	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.	Capecitabine	36-48	nuclear receptor subfamily 4 group A member 1	Homo sapiens	73-89
32060053-0	2020	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.	Capecitabine	36-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
31941523-6	2020	METHODS/DESIGN: CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to establish the feasibility and safety of combining radium-223 given on a 6-weekly schedule in combination with orally administered capecitabine followed by a randomised extension phase to further characterise the safety profile and provide preliminary estimation of efficacy.	Capecitabine	242-254	syntaxin 8	Homo sapiens	16-22
32964213-12	2020	Conclusion: This is the first case series that reports the safety and feasibility of s-MOX in patients with mCRC who developed cardiac toxicity to 5-FU or capecitabine.	Capecitabine	155-167	monooxygenase DBH like 1	Homo sapiens	87-90
32720808-8	2020	Our findings suggest that trastuzumab, pertuzumab, and xeloda combined therapy, following the schedule and posology handled in this study, can be a good treatment for recurrent HER2+ breast cancer with signs of supraclavicular lymphadenopathy and severe inflammatory BCA component with erythema and thickening of the skin.	Capecitabine	55-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
32187596-2	2020	METHODS: The process of HER2-negative locally recurrent or metastatic breast cancer treated with bevacizumab combined with paclitaxel or bevaciz-umab combined with capecitabine made up the decision model in our analysis.	Capecitabine	164-176	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-28
31526900-6	2020	Twenty-two patients were treated with concurrent capecitabine, most frequently at 500mg BID.	Capecitabine	49-61	BH3 interacting domain death agonist	Homo sapiens	88-91
31274208-0	2019	Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.	Capecitabine	46-58	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	65-71
31547963-11	2019	Among those treated with capecitabine-based regimens, survival was longer for patients with KRAS WT status (hazard ratio, 0.47; 95% confidence interval, 0.23-0.95; P < .0001) when compared with those with mutant status.	Capecitabine	25-37	KRAS proto-oncogene, GTPase	Homo sapiens	92-96
32156946-6	2019	Since HER2 was overexpressed in the primary tumor, he was treated with capecitabine, CDDP, and trastuzumab(XPT)therapy.	Capecitabine	71-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
32157048-1	2019	We report a case in which recurrent partial HER2-positive gastric cancer showed complete clinical response to capecitabine (Cape)/oxaliplatin(L-OHP/OX)(CapeOX)plus trastuzumab(Tmab)combined chemotherapy for 32months.	Capecitabine	110-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
32157048-1	2019	We report a case in which recurrent partial HER2-positive gastric cancer showed complete clinical response to capecitabine (Cape)/oxaliplatin(L-OHP/OX)(CapeOX)plus trastuzumab(Tmab)combined chemotherapy for 32months.	Capecitabine	124-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	44-48
31274208-1	2019	This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate celecoxib, with implications for coadministration of fluoropyrimidines with CYP2C9 substrates such as warfarin.	Capecitabine	97-109	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	118-143
31274208-1	2019	This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate celecoxib, with implications for coadministration of fluoropyrimidines with CYP2C9 substrates such as warfarin.	Capecitabine	97-109	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	230-236
31897343-1	2019	Purpose: To study the efficacy of capecitabine or S-1 plus oxaliplatin (CAPOX or SOX) for treating thymidine phosphorylase (TP)- or dihydropyrimidine dehydrogenase (DPD)-positive advanced gastric cancer.	Capecitabine	34-46	dihydropyrimidine dehydrogenase	Homo sapiens	165-168
31601265-0	2019	Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.	Capecitabine	40-52	methylenetetrahydrofolate reductase	Homo sapiens	17-22
31601265-0	2019	Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.	Capecitabine	40-52	thymidylate synthetase	Homo sapiens	27-31
31601265-13	2019	CONCLUSIONS: We have identified four potentially useful pharmacogenetic markers, TYMS rs2606241, TYMS rs2853741, MTHFR rs3737964, and MTHFR rs4846048 to predict capecitabine-induced HFS in MBC patients.	Capecitabine	161-173	methylenetetrahydrofolate reductase	Homo sapiens	134-139
31430226-9	2019	CONCLUSION: In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.	Capecitabine	149-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
31339827-12	2019	With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (HR, 0.66; P = .02), but not among hormone receptor-positive patients (HR, 0.89; P = .43).	Capecitabine	65-77	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-100
31339827-15	2019	CONCLUSION: With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease.	Capecitabine	98-110	nuclear receptor subfamily 4 group A member 1	Homo sapiens	140-156
31138588-13	2019	CONCLUSIONS: In a population largely naive to HER2-targeted therapy, pyrotinib in combination with capecitabine was well-tolerated and demonstrates promising antitumor activity in patients with HER2-positive MBC.	Capecitabine	99-111	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-198
31212179-2	2019	Herein, in view of the importance of this drug in chemotherapy, interaction mechanism between Capecitabine (CAP) and human serum albumin (HSA) as a major transport protein in the blood circulatory system has been investigated by using a combination of spectroscopic and molecular modeling methods.	Capecitabine	94-106	albumin	Homo sapiens	123-142
31212179-3	2019	The fluorescence spectroscopic results revealed that capecitabine could effectively quench the intrinsic fluorescence of HSA through a static quenching mechanism.	Capecitabine	53-65	albumin	Homo sapiens	121-124
31212179-10	2019	Molecular docking studies suggested that CAP binds mainly to the subdomain IIA of HSA, which were compatible with those obtained by experimental data.	Capecitabine	41-44	albumin	Homo sapiens	82-85
31267973-4	2019	Two important clinical trials, CREATE-X (UMIN000000843) and KATHERINE (NCT01772472), have shown improved disease-free survival with postoperative capecitabine and ado-trastuzumab emtansine in patients with either triple-negative or HER2-positive breast cancer who had residual disease after neoadjuvant chemotherapy.	Capecitabine	146-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	232-236
31531249-1	2019	Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
31531249-1	2019	Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
31312030-13	2019	CONCLUSIONS: A combination of binimetinib and capecitabine shows acceptable tolerability and promising antitumor efficacy for gemcitabine-pretreated BTC, especially in patients with RAS/RAF/MEK/ERK pathway mutations.	Capecitabine	46-58	mitogen-activated protein kinase 1	Homo sapiens	194-197
31012034-0	2019	Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?	Capecitabine	37-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
31517852-3	2019	PATIENT CONCERNS: We report the case of a 49-year-old woman with ER+ HER2- metastatic breast cancer who experienced an exceptionally long response to capecitabine administered as second-line therapy following a first-line anthracycline-based chemotherapy.	Capecitabine	150-162	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-73
31517852-7	2019	LESSONS: In ER+HER2- metastatic breast cancer patients, capecitabine monochemotherapy in second line may be associated with a particularly satisfactory PFS and no impact in terms of QoL.	Capecitabine	56-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
31312030-13	2019	CONCLUSIONS: A combination of binimetinib and capecitabine shows acceptable tolerability and promising antitumor efficacy for gemcitabine-pretreated BTC, especially in patients with RAS/RAF/MEK/ERK pathway mutations.	Capecitabine	46-58	mitogen-activated protein kinase kinase 7	Homo sapiens	190-193
30649964-1	2019	INTRODUCTION: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted to 5FU by a series of reactions catalyzed by different enzymes, the last of the enzymes being thymidine phosphorylase (TP).	Capecitabine	14-26	thymidine phosphorylase	Homo sapiens	184-207
31348323-6	2019	Symptoms of diarrhea at any grade were more prevalent (95% CI: 1.21-2.29; P = .002) in patients treated with S-1, while hand-foot syndrome (HFS) at any grade (95% CI: 0.24-0.48; P &lt; .0001) or high grade (95% CI: 0.09-0.48; P &lt; .0001) was more frequent in capecitabine group.	Capecitabine	261-273	proteasome 26S subunit, non-ATPase 1	Homo sapiens	109-112
30746637-0	2019	Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.	Capecitabine	60-72	dihydropyrimidine dehydrogenase	Homo sapiens	41-45
30746637-1	2019	PURPOSE: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities.	Capecitabine	163-175	dihydropyrimidine dehydrogenase	Homo sapiens	54-58
30746637-1	2019	PURPOSE: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities.	Capecitabine	163-175	dihydropyrimidine dehydrogenase	Homo sapiens	94-125
30746637-1	2019	PURPOSE: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities.	Capecitabine	163-175	dihydropyrimidine dehydrogenase	Homo sapiens	127-130
30746637-8	2019	Five (8.4%) patients were found to carry DPYD genetic polymorphisms associated with reduced DPD activity; of these, two received dose-reduced capecitabine.	Capecitabine	142-154	dihydropyrimidine dehydrogenase	Homo sapiens	41-45
30877365-0	2019	CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.	Capecitabine	112-124	methylenetetrahydrofolate reductase	Homo sapiens	8-13
30877365-2	2019	METHODS: We tested 322 consecutive patients treated with capecitabine-based chemotherapy for CDA and MTHFR polymorphisms.	Capecitabine	57-69	methylenetetrahydrofolate reductase	Homo sapiens	101-106
30877365-5	2019	In addition, a shorter PFS was also observed in patients with MTHFR 1298 A>C (rs1801131) CC genotype than the patients with AC or AA genotype after capecitabine-based chemotherapy (P = 0.002).	Capecitabine	148-160	methylenetetrahydrofolate reductase	Homo sapiens	62-67
30628914-0	2019	Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.	Capecitabine	16-28	dihydropyrimidine dehydrogenase	Homo sapiens	95-99
30628914-2	2019	Dose reductions of the fluoropyrimidine prodrug capecitabine are recommended for patients carrying these DPYD variants to prevent toxicities.	Capecitabine	48-60	dihydropyrimidine dehydrogenase	Homo sapiens	105-109
30628914-5	2019	We implemented a protocol for tolerance-guided capecitabine dosing in DPYD variant carriers and aimed to explore its effect on toxicity of treatment.	Capecitabine	47-59	dihydropyrimidine dehydrogenase	Homo sapiens	70-74
30628914-7	2019	Capecitabine doses were reduced in case of a DPYD variant (DPYD*2A, c.2846A>T, DPYD*13, or c.1236G>A) and subsequently adjusted on the basis of tolerance.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	45-49
30628914-7	2019	Capecitabine doses were reduced in case of a DPYD variant (DPYD*2A, c.2846A>T, DPYD*13, or c.1236G>A) and subsequently adjusted on the basis of tolerance.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	59-63
30628914-7	2019	Capecitabine doses were reduced in case of a DPYD variant (DPYD*2A, c.2846A>T, DPYD*13, or c.1236G>A) and subsequently adjusted on the basis of tolerance.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	59-63
30628914-9	2019	Results were compared with a cohort of capecitabine-treated DPYD wild-type patients.	Capecitabine	39-51	dihydropyrimidine dehydrogenase	Homo sapiens	60-64
30282452-10	2019	CONCLUSION: This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.	Capecitabine	98-110	thymidylate synthetase	Homo sapiens	39-41
31528467-0	2019	A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine.	Capecitabine	141-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-79
31528467-9	2019	Conclusion: We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine.	Capecitabine	119-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
31217818-0	2019	An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.	Capecitabine	60-72	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	158-164
30927036-3	2019	The aim of this trial was to explore the potential activity and safety of capecitabine, oxaliplatin (XELOX) and trastuzumab in patients with HER-2 positive advanced gastric cancer.	Capecitabine	74-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-146
30860945-0	2019	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-116
31124962-8	2019	According to the disease stage, he started an adjuvant therapy with XELOX using capecitabine at 50% of total dose, because of his DPYD IVS14+1G&gt;A variant, detected before the treatment.	Capecitabine	80-92	dihydropyrimidine dehydrogenase	Homo sapiens	130-134
31005204-0	2019	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.	Capecitabine	76-88	cancer/testis antigen 2	Homo sapiens	166-169
31005204-0	2019	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.	Capecitabine	76-88	cancer antigen 1	Homo sapiens	179-182
30957209-5	2019	Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS.	Capecitabine	128-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
30875351-4	2019	TYMS gene encodes for the human thymidylate synthase, and is considered a candid factor for toxicity and efficacy of 5-FU and capecitabine.	Capecitabine	126-138	thymidylate synthetase	Homo sapiens	0-4
30875351-4	2019	TYMS gene encodes for the human thymidylate synthase, and is considered a candid factor for toxicity and efficacy of 5-FU and capecitabine.	Capecitabine	126-138	thymidylate synthetase	Homo sapiens	32-52
30875351-5	2019	However, TYMS polymorphism has been associated previously with capecitabine-induced neurotoxicity.	Capecitabine	63-75	thymidylate synthetase	Homo sapiens	9-13
30875351-13	2019	To the best of our knowledge, this is the first patient in the literature who developed acute cerebellar syndrome following capecitabine and was found to have mutations of TYMS.	Capecitabine	124-136	thymidylate synthetase	Homo sapiens	172-176
30649964-1	2019	INTRODUCTION: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted to 5FU by a series of reactions catalyzed by different enzymes, the last of the enzymes being thymidine phosphorylase (TP).	Capecitabine	14-26	thymidine phosphorylase	Homo sapiens	209-211
30315927-0	2019	A molecular basis for the synergy between 17-allylamino-17-demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.	Capecitabine	87-99	matrix metallopeptidase 9	Homo sapiens	165-170
28942723-3	2019	Dihydropyrimidine dehydrogenase and thymidylate synthase play a major role in fluorouracil and capecitabine activity and toxicity.	Capecitabine	95-107	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
28942723-3	2019	Dihydropyrimidine dehydrogenase and thymidylate synthase play a major role in fluorouracil and capecitabine activity and toxicity.	Capecitabine	95-107	thymidylate synthetase	Homo sapiens	36-56
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	hypoxia inducible factor 1, alpha subunit	Mus musculus	137-147
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	chemokine (C-X-C motif) receptor 4	Mus musculus	161-166
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	matrix metallopeptidase 2	Mus musculus	168-173
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	vascular endothelial growth factor A	Mus musculus	175-179
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	thymoma viral proto-oncogene 1	Mus musculus	187-190
30789971-6	2019	In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group.	Capecitabine	7-19	thymoma viral proto-oncogene 1	Mus musculus	205-208
30315927-7	2019	Among double combination groups only Cap/17-AAG showed significant differences in MMP-9 and VEGF genes expression and wound healing assay.	Capecitabine	37-40	matrix metallopeptidase 9	Homo sapiens	82-87
30315927-7	2019	Among double combination groups only Cap/17-AAG showed significant differences in MMP-9 and VEGF genes expression and wound healing assay.	Capecitabine	37-40	vascular endothelial growth factor A	Homo sapiens	92-96
30683047-0	2019	Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.	Capecitabine	0-12	KRAS proto-oncogene, GTPase	Homo sapiens	103-107
30418178-0	2019	A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.	Capecitabine	76-88	kinase insert domain receptor	Homo sapiens	29-34
30592773-7	2019	The results of the current study suggest that the plasma UH2 /Ura ratio temporarily increases following administration of capecitabine, possibly related to the DPD activity levels.	Capecitabine	122-134	dihydropyrimidine dehydrogenase	Rattus norvegicus	160-163
30592773-0	2019	Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity.	Capecitabine	44-56	dihydropyrimidine dehydrogenase	Rattus norvegicus	136-167
30361875-9	2019	CONCLUSIONS: Metronomic oral capecitabine combined with AIs showed good efficacy, minimal toxicities, and good tolerance in HR-positive patients with ABC.	Capecitabine	29-41	nuclear receptor subfamily 4 group A member 1	Homo sapiens	124-126
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Capecitabine	171-183	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Capecitabine	171-183	NRAS proto-oncogene, GTPase	Homo sapiens	42-46
30307354-2	2019	CASE PRESENTATION: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models.	Capecitabine	171-183	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	47-51
30893699-1	2019	BACKGROUND: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence.	Capecitabine	123-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-64
30893699-1	2019	BACKGROUND: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence.	Capecitabine	123-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
30692485-5	2018	Based on overexpression of the human epidermal growth factor receptor 2(HER2)protein in the primary tumor, we selected capecitabine plus cisplatin plus trastuzumab as the combination chemotherapy.	Capecitabine	119-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-71
30692485-5	2018	Based on overexpression of the human epidermal growth factor receptor 2(HER2)protein in the primary tumor, we selected capecitabine plus cisplatin plus trastuzumab as the combination chemotherapy.	Capecitabine	119-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
30538384-2	2018	In the present study, attempt was made to see the effect and safety profile of single-agent oral capecitabine in inoperable CaGB in presence of low levels of jaundice post-single-catheter transhepatic external biliary drainage.	Capecitabine	97-109	S100 calcium binding protein A9	Homo sapiens	124-128
30538384-9	2018	To the best of our knowledge, this is the first study to establish that single-agent capecitabine can be safely given in CaGB in presence of jaundice.	Capecitabine	85-97	S100 calcium binding protein A9	Homo sapiens	121-125
30115736-2	2018	BACKGROUND: We performed a phase II study to evaluate the safety and efficacy of capecitabine plus cisplatin in comparison with S-1 plus cisplatin for first-line treatment of human epidermal growth receptor 2 (HER2)-negative advanced gastric cancer in Japan.	Capecitabine	81-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	210-214
30115736-10	2018	The higher incidence of severe adverse events with capecitabine-cisplatin suggests that S-1-cisplatin should remain the standard first-line chemotherapy for HER2-negative advanced gastric cancer in Japan.	Capecitabine	51-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
30592773-8	2019	The plasma UH2 /Ura ratio might assist in monitoring the alteration of DPD activity levels in capecitabine treatments.	Capecitabine	94-106	dihydropyrimidine dehydrogenase	Rattus norvegicus	71-74
30440137-1	2018	Objective: To investigate the association between Thymidine phosphorylase(TYMP)genetic variation and clinical outcomes of postoperative gastric cancer (GC) patients received capecitabine based regimens.	Capecitabine	174-186	thymidine phosphorylase	Homo sapiens	74-78
28916944-2	2018	However, incomplete COI statements continue to be prevalent in the medical community, as appears to have occurred in the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) trial, which was recently published in the New England Journal of Medicine.	Capecitabine	121-133	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	20-23
30440137-13	2018	Conclusion: The polymorphism rs11479 of TYMP have favorable influence on the clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy treatment through changing the mRNA expression of TYMP.	Capecitabine	131-143	thymidine phosphorylase	Homo sapiens	40-44
30440137-13	2018	Conclusion: The polymorphism rs11479 of TYMP have favorable influence on the clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy treatment through changing the mRNA expression of TYMP.	Capecitabine	131-143	thymidine phosphorylase	Homo sapiens	222-226
30085142-2	2018	Case: A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasizing to the liver.	Capecitabine	144-156	proopiomelanocortin	Homo sapiens	55-59
30341682-2	2018	Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy.	Capecitabine	132-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	166-170
30349384-0	2018	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene.	Capecitabine	19-31	dihydropyrimidine dehydrogenase	Homo sapiens	85-116
30349384-0	2018	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene.	Capecitabine	19-31	dihydropyrimidine dehydrogenase	Homo sapiens	118-122
29273261-11	2018	CONCLUSION: A higher dose of weekly irinotecan in combination with capecitabine-based CRT is feasible under the guidance of the UGT1A1*28 genotype.	Capecitabine	67-79	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	128-134
29488122-0	2018	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.	Capecitabine	20-32	proteasome 26S subunit, non-ATPase 1	Homo sapiens	120-123
29488122-4	2018	METHODS: HER2-negative gastric cancer patients treated with adjuvant chemotherapy including S-1 for more than 12 weeks and relapsed within 6 months were treated with capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 on day 1 of a 3-week cycle.	Capecitabine	166-178	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
29845393-10	2018	CONCLUSION: Genetic polymorphism in DPYD seems to be associated with DFS in CRC patients receiving an adjuvant regimen of 5-FU/capecitabine-based chemotherapy.	Capecitabine	127-139	dihydropyrimidine dehydrogenase	Homo sapiens	36-40
30061234-0	2018	Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.	Capecitabine	29-41	protein tyrosine kinase 2	Homo sapiens	86-107
30061234-3	2018	In this study, we investigated the possibility of improving the antitumor effect of capecitabine against CRC by destabilizing focal adhesion kinase (FAK) signaling.	Capecitabine	84-96	protein tyrosine kinase 2	Homo sapiens	126-147
30061234-3	2018	In this study, we investigated the possibility of improving the antitumor effect of capecitabine against CRC by destabilizing focal adhesion kinase (FAK) signaling.	Capecitabine	84-96	protein tyrosine kinase 2	Homo sapiens	149-152
30061234-8	2018	RESULTS: The addition of LCS to capecitabine treatment led to an increase in the proteolysis of the FAK signaling cascade components, including SRC proto-oncogene, non-receptor tyrosine kinase; AKT serine/threonine kinase 1; and nuclear factor-kappa B, resulting in a decrease in the viability and clonogenic ability of CRC cells.	Capecitabine	32-44	protein tyrosine kinase 2	Homo sapiens	100-103
30061234-8	2018	RESULTS: The addition of LCS to capecitabine treatment led to an increase in the proteolysis of the FAK signaling cascade components, including SRC proto-oncogene, non-receptor tyrosine kinase; AKT serine/threonine kinase 1; and nuclear factor-kappa B, resulting in a decrease in the viability and clonogenic ability of CRC cells.	Capecitabine	32-44	AKT serine/threonine kinase 1	Homo sapiens	194-197
30170406-0	2018	miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.	Capecitabine	72-84	miR-17-92a-1 cluster host gene	Homo sapiens	0-9
30008904-13	2018	Trastuzumab combined with oxaliplatin and capecitabine as a conversion therapy regime for ERBB2-overexpressing advanced gastric adenocarcinoma increased the likelihood of successful surgical resection, and prolonged progression-free survival.	Capecitabine	42-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
29845287-6	2018	These results indicate that the synergistic antitumor effects exhibited by combinatory treatment of lapatinib with capecitabine may be induced via the suppression of E2F1-mediated TS expression.	Capecitabine	115-127	E2F transcription factor 1	Homo sapiens	166-170
29451302-1	2018	According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer.	Capecitabine	93-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-205
29451302-1	2018	According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer.	Capecitabine	93-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	207-211
29902974-10	2018	Subsequently the molecular inhibition of specific isoforms of ALDH by ALDH1A1 or ALDH1A3 siRNA led to sensitizing of cell lines HT-29/eGFP, HCT-116/eGFP to capecitabine and 5-FU.	Capecitabine	156-168	aldehyde dehydrogenase 1 family member A1	Homo sapiens	62-66
29902974-10	2018	Subsequently the molecular inhibition of specific isoforms of ALDH by ALDH1A1 or ALDH1A3 siRNA led to sensitizing of cell lines HT-29/eGFP, HCT-116/eGFP to capecitabine and 5-FU.	Capecitabine	156-168	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	70-77
29902974-10	2018	Subsequently the molecular inhibition of specific isoforms of ALDH by ALDH1A1 or ALDH1A3 siRNA led to sensitizing of cell lines HT-29/eGFP, HCT-116/eGFP to capecitabine and 5-FU.	Capecitabine	156-168	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	81-88
29582557-0	2018	Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.	Capecitabine	126-138	APC membrane recruitment protein 1	Homo sapiens	140-143
31149530-2	2018	Dihydropyrimidine dehydrogenase (DPD) is an enzyme encoded by the DPYD gene, which is responsible for the rate-limiting step in pyrimidine catabolism and breaks down more than 80% of standard doses of 5-fluorouracil (5-FU) and capecitabine, an oral prodrug of 5-FU.	Capecitabine	227-239	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
31149530-2	2018	Dihydropyrimidine dehydrogenase (DPD) is an enzyme encoded by the DPYD gene, which is responsible for the rate-limiting step in pyrimidine catabolism and breaks down more than 80% of standard doses of 5-fluorouracil (5-FU) and capecitabine, an oral prodrug of 5-FU.	Capecitabine	227-239	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
31149530-2	2018	Dihydropyrimidine dehydrogenase (DPD) is an enzyme encoded by the DPYD gene, which is responsible for the rate-limiting step in pyrimidine catabolism and breaks down more than 80% of standard doses of 5-fluorouracil (5-FU) and capecitabine, an oral prodrug of 5-FU.	Capecitabine	227-239	dihydropyrimidine dehydrogenase	Homo sapiens	66-70
29582557-1	2018	We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5-fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2-positive disease) and to evaluate 5-year disease-free survival (DFS) associated with this preoperative regimen.	Capecitabine	119-131	erb-b2 receptor tyrosine kinase 2	Homo sapiens	242-246
29483209-11	2018	Serial ctDNA evaluation in an illustrative patient treated with capecitabine demonstrated emergence of a new TP53 alteration after progression.	Capecitabine	64-76	tumor protein p53	Homo sapiens	109-113
29463559-0	2018	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	41-45
29463559-0	2018	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.	Capecitabine	0-12	RB transcriptional corepressor 1	Homo sapiens	50-53
29463559-9	2018	Transcriptomic and IHC analyses of 32 TNBC PDX, including both residual tumors and treatment-naive derived tumors, identified RB1 and TYMP proteins as predictive biomarkers for capecitabine response.	Capecitabine	177-189	RB transcriptional corepressor 1	Homo sapiens	126-129
29463559-9	2018	Transcriptomic and IHC analyses of 32 TNBC PDX, including both residual tumors and treatment-naive derived tumors, identified RB1 and TYMP proteins as predictive biomarkers for capecitabine response.	Capecitabine	177-189	thymidine phosphorylase	Homo sapiens	134-138
29463559-10	2018	Finally, RB1 knockdown in a cell line established from a capecitabine-responder PDX decreased sensitivity to 5-FU treatment.Conclusions: We identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes, and platins.	Capecitabine	57-69	RB transcriptional corepressor 1	Homo sapiens	9-12
29463559-10	2018	Finally, RB1 knockdown in a cell line established from a capecitabine-responder PDX decreased sensitivity to 5-FU treatment.Conclusions: We identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes, and platins.	Capecitabine	151-163	RB transcriptional corepressor 1	Homo sapiens	9-12
29463559-11	2018	RB1 positivity and high expression of TYMP were significantly associated with capecitabine response.	Capecitabine	78-90	RB transcriptional corepressor 1	Homo sapiens	0-3
29463559-11	2018	RB1 positivity and high expression of TYMP were significantly associated with capecitabine response.	Capecitabine	78-90	thymidine phosphorylase	Homo sapiens	38-42
29505962-0	2018	Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients.	Capecitabine	60-72	inducible T cell costimulator	Homo sapiens	21-25
29707135-0	2018	Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells.	Capecitabine	0-12	vascular endothelial growth factor A	Homo sapiens	45-49
29707135-9	2018	Capecitabine treatment also reversed inhibition of both antitumor angiogenesis and tumor growth under anti-VEGF antibody treatment, and this effect partially inhibited in tumors implanted in mice deficient in both PyNPases.	Capecitabine	0-12	vascular endothelial growth factor A	Mus musculus	107-111
29174919-8	2018	Thus, the present case suggests that AFP and HER2 positive gastric cancer can be effectively treated with, capecitabine, cisplatin, and trastuzumab combination therapy.	Capecitabine	107-119	alpha fetoprotein	Homo sapiens	37-40
29174919-8	2018	Thus, the present case suggests that AFP and HER2 positive gastric cancer can be effectively treated with, capecitabine, cisplatin, and trastuzumab combination therapy.	Capecitabine	107-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
29505962-0	2018	Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients.	Capecitabine	60-72	CD28 molecule	Homo sapiens	26-30
29505962-0	2018	Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients.	Capecitabine	60-72	inducible T cell costimulator ligand	Homo sapiens	31-36
28827188-0	2018	Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.	Capecitabine	122-134	carboxylesterase 2	Homo sapiens	48-52
29152729-1	2018	The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine).	Capecitabine	234-246	dihydropyrimidine dehydrogenase	Homo sapiens	91-122
29152729-1	2018	The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine).	Capecitabine	234-246	dihydropyrimidine dehydrogenase	Homo sapiens	124-128
29242966-0	2018	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.	Capecitabine	183-195	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-6
29231164-0	2018	Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review : .	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
29231164-4	2018	The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine.	Capecitabine	79-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
28827188-12	2018	Since particular SNPs in CDA and CES2 were associated with benefit from the addition of capecitabine to AT, their predictive value should be explored in a higher number of patients.	Capecitabine	88-100	carboxylesterase 2	Homo sapiens	33-37
28929491-0	2018	Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.	Capecitabine	0-12	dihydropyrimidine dehydrogenase	Homo sapiens	55-59
28782476-7	2018	When the patient recovered with drug treatment, capecitabine was restarted at a lower dose (1g bid).	Capecitabine	48-60	BH3 interacting domain death agonist	Homo sapiens	95-98
29526981-8	2018	Therefore, he was diagnosed with DPD deficiency, based on DPD protein or urinary pyrimidine levels, which caused serious adverse effects of capecitabine.	Capecitabine	140-152	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
29210644-4	2018	CES2 plays crucial roles in the metabolic activation of many prodrugs including anticancer agents capecitabine and CPT-11.	Capecitabine	98-110	carboxylesterase 2	Homo sapiens	0-4
29241084-12	2018	CONCLUSIONS: Combining sorafenib and standard chemoradiotherapy with capecitabine is highly active in patients with KRAS-mutated LARC with acceptable toxicity and deserves further investigation.	Capecitabine	69-81	KRAS proto-oncogene, GTPase	Homo sapiens	116-120
29241084-12	2018	CONCLUSIONS: Combining sorafenib and standard chemoradiotherapy with capecitabine is highly active in patients with KRAS-mutated LARC with acceptable toxicity and deserves further investigation.	Capecitabine	69-81	C-C motif chemokine ligand 20	Homo sapiens	129-133
29045513-8	2017	Based on the critical appraisal of currently available data, adjusting the labels of capecitabine and 5-FU by including recommendations on pre-emptive screening for DPYD variants and DPYD genotype-guided dose adjustments should be the new standard of care.	Capecitabine	85-97	dihydropyrimidine dehydrogenase	Homo sapiens	165-169
30285552-1	2018	The enzyme thymidine phosphorylase (TP) is important for activation of capecitabine and 5-fluorouracil.	Capecitabine	71-83	thymidine phosphorylase	Homo sapiens	11-34
30285552-1	2018	The enzyme thymidine phosphorylase (TP) is important for activation of capecitabine and 5-fluorouracil.	Capecitabine	71-83	thymidine phosphorylase	Homo sapiens	36-38
29045513-8	2017	Based on the critical appraisal of currently available data, adjusting the labels of capecitabine and 5-FU by including recommendations on pre-emptive screening for DPYD variants and DPYD genotype-guided dose adjustments should be the new standard of care.	Capecitabine	85-97	dihydropyrimidine dehydrogenase	Homo sapiens	183-187
29204180-9	2017	Drug interactions were analyzed using Chou-Talalay method to calculate the combination index (CI).The data revealed that 17-AAG shows a potent synergistic interaction (CI &lt; 1) with oxaliplatin and capecitabine in double combinations (0.5 x IC50) in both cell lines.	Capecitabine	200-212	N-methylpurine DNA glycosylase	Homo sapiens	124-127
29030673-0	2017	PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.	Capecitabine	53-65	dihydropyrimidine dehydrogenase	Homo sapiens	44-47
28830796-0	2017	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.	Capecitabine	111-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
28744157-0	2017	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.	Capecitabine	146-158	ATP binding cassette subfamily B member 7	Homo sapiens	4-8
28139840-0	2017	Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.	Capecitabine	72-84	carboxylesterase 1	Homo sapiens	26-44
29394602-0	2017	[A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab].	Capecitabine	155-167	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
29394666-0	2017	[The Case of HER2 Positive Advanced Gastric Cancer with Para-Aorta Lymph Node Recurrence Responding to Capecitabine plus CDDP plus Trastuzumab Chemotherapy].	Capecitabine	103-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
29394666-3	2017	Since HER2 protein was overexpressed in primary tumor immunostaining, he was treated with capecitabine plus CDDP plus trastuzumab therapy.After the chemotherapy, CEA levels decreased to the normal range and the enlarged lymph node was remarkably decreased in size in May, 2015.T he patient is alive 24 months after the chemotherapy with no evidence of recurrence.	Capecitabine	90-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
29394666-3	2017	Since HER2 protein was overexpressed in primary tumor immunostaining, he was treated with capecitabine plus CDDP plus trastuzumab therapy.After the chemotherapy, CEA levels decreased to the normal range and the enlarged lymph node was remarkably decreased in size in May, 2015.T he patient is alive 24 months after the chemotherapy with no evidence of recurrence.	Capecitabine	90-102	pregnancy specific beta-1-glycoprotein 2	Homo sapiens	162-165
28810186-0	2017	The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.	Capecitabine	30-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-51
28810186-3	2017	We conducted a systematic review to determine the efficacy of L, singly or in combination with capecitabine (C), as a treatment for HER-2+ BMs.	Capecitabine	95-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-137
29180853-0	2017	New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center.	Capecitabine	154-166	centrosomal protein 43	Homo sapiens	83-86
29180853-4	2017	Therefore, we initiated a pilot study to expand the literature on FOP/FCR in CRC outpatients receiving capecitabine and to generate hypotheses for future investigations.	Capecitabine	103-115	centrosomal protein 43	Homo sapiens	66-69
29180853-16	2017	Discussion: FOP/FCR occurred frequently in more than one in three patients, but was mostly untreated in this sample of consecutive outpatients with CRC receiving oral capecitabine.	Capecitabine	167-179	centrosomal protein 43	Homo sapiens	12-15
28127745-1	2017	BACKGROUND AND PURPOSE: 5-fluorouracil (5FU) and its prodrug, capecitabine, can damage endothelial cells, whilst endothelial integrity is preserved by glucagon-like peptide 1 (GLP-1).	Capecitabine	62-74	glucagon	Homo sapiens	151-174
28127745-1	2017	BACKGROUND AND PURPOSE: 5-fluorouracil (5FU) and its prodrug, capecitabine, can damage endothelial cells, whilst endothelial integrity is preserved by glucagon-like peptide 1 (GLP-1).	Capecitabine	62-74	glucagon	Homo sapiens	176-181
28127745-13	2017	5FU-triggered senescence was prevented by GLP-1, raising the possibility of using GLP-1 analogues and degradation inhibitors to treat 5FU and capecitabine vascular toxicity.	Capecitabine	142-154	glucagon	Homo sapiens	42-47
28127745-13	2017	5FU-triggered senescence was prevented by GLP-1, raising the possibility of using GLP-1 analogues and degradation inhibitors to treat 5FU and capecitabine vascular toxicity.	Capecitabine	142-154	glucagon	Homo sapiens	82-87
28913549-0	2017	Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.	Capecitabine	30-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-124
28774899-3	2017	We have evaluated the ability of the PET imaging agent, 89Zr-anti-gammaH2AX-TAT, to monitor DNA damage in response to fluorouracil (5-FU), gemcitabine, or capecitabine treatment in a mouse model of pancreatic cancer.	Capecitabine	155-167	H2A.X variant histone	Mus musculus	66-75
28303362-2	2017	METHODS: AGC patients with peritoneal metastasis received XP ID, which consists of 937.5 mg/m2 of capecitabine twice daily on days 1-14, 60 mg/m2 of intravenous cisplatin on day 1, and intraperitoneal docetaxel at 3 different dose levels (60, 80, or 100 mg/m2) on day 1, every 3 weeks.	Capecitabine	98-110	forkhead box P3	Homo sapiens	58-63
28082170-2	2017	We report here the synthesis, assembly and cytotoxicity evaluation of self-assembling hybrid prodrugs containing both camptothecin (CPT) and a capecitabine (Cap) analogue.	Capecitabine	143-155	CAP	Drosophila melanogaster	157-160
29070120-3	2017	The proliferation and expression of DNMT3b gene in RPMI8226 cells intervened with capecitabine for 24 hours were detected.	Capecitabine	82-94	DNA methyltransferase 3 beta	Homo sapiens	36-42
29070120-6	2017	The expression level of DNMT3b gene was decreased after being intervened with capecitabine for 24 hours.	Capecitabine	78-90	DNA methyltransferase 3 beta	Homo sapiens	24-30
29070120-7	2017	CONCLUSION: The expression level of DNMT3b in myeloma RPMI 8226 cells increase, and capecitabine can inhibit the proliferation of RPMI 8226 and induce apoptosis by inhibiting the expression of DNMT3b gene.	Capecitabine	84-96	DNA methyltransferase 3 beta	Homo sapiens	193-199
28628925-3	2017	The aim of this study was to investigate the effects of Scrophularia oxysepala extract on Caco-2 cells and explore the possible role of caspase 3 pathway in inducing cell death in this cancer cells in compare with chemotherapy agents of cisplatin and capecitabine.	Capecitabine	251-263	caspase 3	Homo sapiens	136-145
28765596-0	2017	A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.	Capecitabine	55-67	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Capecitabine	185-197	ATP binding cassette subfamily C member 4	Homo sapiens	75-116
28765596-4	2017	Statistical analysis showed that a polymorphism rs3742106 in the 3"-UTR of ATP-binding cassette subfamily C member 4 (ABCC4) gene was significantly associated with the efficacy of 5-FU/capecitabine-based chemotherapy in CRC.	Capecitabine	185-197	ATP binding cassette subfamily C member 4	Homo sapiens	118-123
29088787-0	2017	Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.	Capecitabine	35-47	microRNA 1307	Homo sapiens	95-103
29088787-0	2017	Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.	Capecitabine	35-47	thymidylate synthetase	Homo sapiens	111-115
29088787-6	2017	We identified a polymorphism rs7911488 T&gt;C in pre-miR-1307 to be significantly associated with the efficacy of capecitabine chemotherapy in colon cancer patients.	Capecitabine	114-126	microRNA 1307	Homo sapiens	53-61
28744157-4	2017	As add-on to current standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and the added EMT occurring as a response to current treatment modalities.	Capecitabine	45-57	ATP binding cassette subfamily B member 7	Homo sapiens	59-63
28744157-6	2017	ABC7 uses standard doses of capecitabine as used in treating breast cancer today.	Capecitabine	28-40	ATP binding cassette subfamily B member 7	Homo sapiens	0-4
28602775-0	2017	Adjuvant capecitabine for HER2-negative breast cancer.	Capecitabine	9-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
28607065-6	2017	The nontoxic, low dose of the orally active prodrug capecitabine was able to sustain the anti-VEGF-induced vessel regression for long periods.	Capecitabine	52-64	vascular endothelial growth factor A	Homo sapiens	94-98
27771885-0	2017	Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	60-64
28126414-3	2017	hCE1 is known to play crucial roles in the metabolism of a wide variety of endogenous esters, clinical drugs and insecticides, while hCE2 plays a key role in the metabolic activation of anticancer agents including irinotecan and capecitabine.	Capecitabine	229-241	carboxylesterase 1	Homo sapiens	0-4
28161133-0	2017	New Data About First-line All-oral Vinorelbine and Capecitabine in HER2-negative Metastatic Breast Cancer Confirms Results of Meta-analysis.	Capecitabine	51-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
28564564-11	2017	CONCLUSIONS: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing.	Capecitabine	121-133	erb-b2 receptor tyrosine kinase 2	Homo sapiens	242-246
28481884-0	2017	New advances in DPYD genotype and risk of severe toxicity under capecitabine.	Capecitabine	64-76	dihydropyrimidine dehydrogenase	Homo sapiens	16-20
28481884-3	2017	The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and toxicity in advanced breast cancer patients receiving capecitabine.	Capecitabine	206-218	dihydropyrimidine dehydrogenase	Homo sapiens	134-138
28481884-12	2017	CONCLUSIONS: Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3-4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V.	Capecitabine	230-242	dihydropyrimidine dehydrogenase	Homo sapiens	54-58
28481884-12	2017	CONCLUSIONS: Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3-4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V.	Capecitabine	230-242	dihydropyrimidine dehydrogenase	Homo sapiens	96-100
28088627-0	2017	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.	Capecitabine	100-112	telomeric repeat binding factor 2	Homo sapiens	29-33
28088627-9	2017	Our study provides a new mechanism of metronomic chemotherapy i.e. TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.	Capecitabine	138-150	telomeric repeat binding factor 2	Homo sapiens	67-71
28045335-8	2017	CONCLUSION: Adding erlotinib to capecitabine increased TTP by 3.2 months in KRAS-WT patients.	Capecitabine	32-44	KRAS proto-oncogene, GTPase	Homo sapiens	76-80
28262261-3	2017	This review presents the usefulness of pharmacogenetic tests for some key applications: dihydropyrimidine dehydrogenase (DPYD) genotyping for fluoropyrimidine (5-fluorouracil, capecitabine), UDP glucuronosylstransferase (UGT1A1) for irinotecan and thiopurine S-methyltransferase (TPMT) for thiopurine drugs.	Capecitabine	176-188	dihydropyrimidine dehydrogenase	Homo sapiens	88-119
28262261-3	2017	This review presents the usefulness of pharmacogenetic tests for some key applications: dihydropyrimidine dehydrogenase (DPYD) genotyping for fluoropyrimidine (5-fluorouracil, capecitabine), UDP glucuronosylstransferase (UGT1A1) for irinotecan and thiopurine S-methyltransferase (TPMT) for thiopurine drugs.	Capecitabine	176-188	dihydropyrimidine dehydrogenase	Homo sapiens	121-125
29063053-8	2017	Tyrosine kinase inhibitors are more capable of crossing into the brain and they have been shown to be beneficial for treating BM in HER2-positive patients, especially lapatinib combined with capecitabine.	Capecitabine	191-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
28126414-3	2017	hCE1 is known to play crucial roles in the metabolism of a wide variety of endogenous esters, clinical drugs and insecticides, while hCE2 plays a key role in the metabolic activation of anticancer agents including irinotecan and capecitabine.	Capecitabine	229-241	carboxylesterase 2	Homo sapiens	133-137
28234911-0	2017	Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
28246483-2	2017	METHODS: We performed a feasibility study of a modified docetaxel, cisplatin and capecitabine (DCX) regimen for stage IV gastric cancer.	Capecitabine	81-93	doublecortin	Homo sapiens	95-98
28005247-0	2017	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.	Capecitabine	32-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
28211921-5	2017	The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357-0.829; p  =0.005) compared to patients receiving BSC alone.	Capecitabine	109-121	cytochrome c oxidase subunit 8A	Homo sapiens	36-39
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Capecitabine	252-264	KRAS proto-oncogene, GTPase	Homo sapiens	37-41
28280649-0	2017	First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism.	Capecitabine	40-52	thymidylate synthetase	Homo sapiens	71-91
29349087-6	2017	Streptozotocin-based chemotherapy has been used for inoperable or progressing pancreatic NENs but the orally administered combination of capecitabine/temozolomide is becoming more popular due to its better tolerability and potential effect in other GEP-NENs.	Capecitabine	137-149	granulin precursor	Homo sapiens	249-252
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Capecitabine	252-264	NRAS proto-oncogene, GTPase	Homo sapiens	43-47
28040715-4	2017	This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline.	Capecitabine	252-264	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	53-57
28478451-0	2017	Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.	Capecitabine	106-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	8-12
27752847-0	2016	Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control?	Capecitabine	57-69	structural maintenance of chromosomes 2	Mus musculus	71-76
27752847-2	2016	PURPOSE: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients.	Capecitabine	101-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183
27628555-3	2016	Owing to a HER2 immunohistochemistry tumor score of 3+, we initiated capecitabine plus CDDP plus trastuzumab chemotherapy.	Capecitabine	69-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
27776843-0	2016	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.	Capecitabine	150-162	IKAROS family zinc finger 3	Homo sapiens	252-255
27557140-0	2016	The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.	Capecitabine	67-79	thymidylate synthetase	Homo sapiens	4-8
27569869-4	2016	Capecitabine is activated to 5-FU by CES, CDA and TYMP, of which SNPs in CDA and CES2 were found to be associated with efficacy and toxicity.	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	50-54
27569869-4	2016	Capecitabine is activated to 5-FU by CES, CDA and TYMP, of which SNPs in CDA and CES2 were found to be associated with efficacy and toxicity.	Capecitabine	0-12	carboxylesterase 2	Homo sapiens	81-85
27569869-5	2016	In addition, variants in genes of the 5-FU metabolic pathway, including TYMS, MTHFR and DPYD also influenced capecitabine efficacy and toxicity.	Capecitabine	109-121	thymidylate synthetase	Homo sapiens	72-76
27569869-5	2016	In addition, variants in genes of the 5-FU metabolic pathway, including TYMS, MTHFR and DPYD also influenced capecitabine efficacy and toxicity.	Capecitabine	109-121	methylenetetrahydrofolate reductase	Homo sapiens	78-83
27569869-5	2016	In addition, variants in genes of the 5-FU metabolic pathway, including TYMS, MTHFR and DPYD also influenced capecitabine efficacy and toxicity.	Capecitabine	109-121	dihydropyrimidine dehydrogenase	Homo sapiens	88-92
27121793-9	2016	Patients with unmethylated WRN showed a significantly longer PFS when treated with CAPIRI compared with capecitabine alone (HR = 0.48; 95% CI, 0.32-0.70; P = 0.0001).	Capecitabine	104-116	WRN RecQ like helicase	Homo sapiens	27-30
28478451-1	2017	OBJECTIVE: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estrogen receptor (ER) status in trastuzumab-refractory HER2-positive advanced breast cancer.	Capecitabine	191-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-116
27994652-11	2016	In subgroups with response for capecitabine plus RAD001, there is significant overexpression of 6 genes among 519 kinase gene such as EPHA2 (P = 0.0025), PIM1 (P = 0.0031), KSR1 (P = 0.0033), and EIF2AK4 (P = 0.0046) that are related to the activation of mTOR signalling.	Capecitabine	31-43	EPH receptor A2	Homo sapiens	134-139
27994652-11	2016	In subgroups with response for capecitabine plus RAD001, there is significant overexpression of 6 genes among 519 kinase gene such as EPHA2 (P = 0.0025), PIM1 (P = 0.0031), KSR1 (P = 0.0033), and EIF2AK4 (P = 0.0046) that are related to the activation of mTOR signalling.	Capecitabine	31-43	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	154-158
27994652-11	2016	In subgroups with response for capecitabine plus RAD001, there is significant overexpression of 6 genes among 519 kinase gene such as EPHA2 (P = 0.0025), PIM1 (P = 0.0031), KSR1 (P = 0.0033), and EIF2AK4 (P = 0.0046) that are related to the activation of mTOR signalling.	Capecitabine	31-43	kinase suppressor of ras 1	Homo sapiens	173-177
27994652-11	2016	In subgroups with response for capecitabine plus RAD001, there is significant overexpression of 6 genes among 519 kinase gene such as EPHA2 (P = 0.0025), PIM1 (P = 0.0031), KSR1 (P = 0.0033), and EIF2AK4 (P = 0.0046) that are related to the activation of mTOR signalling.	Capecitabine	31-43	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	196-203
27994652-11	2016	In subgroups with response for capecitabine plus RAD001, there is significant overexpression of 6 genes among 519 kinase gene such as EPHA2 (P = 0.0025), PIM1 (P = 0.0031), KSR1 (P = 0.0033), and EIF2AK4 (P = 0.0046) that are related to the activation of mTOR signalling.	Capecitabine	31-43	mechanistic target of rapamycin kinase	Homo sapiens	255-259
27751167-0	2016	Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: 18F-FAU, 18F-FMAU, and 18F-FLT.	Capecitabine	11-23	FAU ubiquitin like and ribosomal protein S30 fusion	Homo sapiens	111-114
27615706-4	2016	Next-generation sequencing revealed an actionable mTOR pathway STK11 mutation in a woman with adrenocorticotropic hormone-secreting pituitary carcinoma refractory to six resections, radiation and CAPecitabine and TEMozolomide.	Capecitabine	196-208	mechanistic target of rapamycin kinase	Homo sapiens	50-54
27615706-4	2016	Next-generation sequencing revealed an actionable mTOR pathway STK11 mutation in a woman with adrenocorticotropic hormone-secreting pituitary carcinoma refractory to six resections, radiation and CAPecitabine and TEMozolomide.	Capecitabine	196-208	serine/threonine kinase 11	Homo sapiens	63-68
27760940-1	2016	We reported a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer with multiple liver metastases that responded well to a combination of trastuzumab, capecitabine, and cisplatin(T-XP therapy)as first-line chemotherapy.	Capecitabine	186-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-62
27760940-1	2016	We reported a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer with multiple liver metastases that responded well to a combination of trastuzumab, capecitabine, and cisplatin(T-XP therapy)as first-line chemotherapy.	Capecitabine	186-198	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-67
27501767-18	2016	INTERPRETATION: Bevacizumab plus capecitabine represents a valid first-line treatment option for HER2-negative locally recurrent or metastatic breast cancer, offering good tolerability without compromising overall survival compared with bevacizumab plus paclitaxel.	Capecitabine	33-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
27390048-4	2016	METHODS: We developed the phenytoin-capecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration- dependent manner.	Capecitabine	36-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	119-144
27350037-7	2016	Capecitabine treatment significantly increased the intratumoral VEGF level compared with the control group; however, the combination with bevacizumab neutralized the VEGF.	Capecitabine	0-12	vascular endothelial growth factor A	Homo sapiens	64-68
27325685-14	2016	The association of elevated HER3 and RR warrants further investigation as an important player for HER-targeted regimens in combination with capecitabine.	Capecitabine	140-152	erb-b2 receptor tyrosine kinase 3	Homo sapiens	28-32
26920887-8	2016	PIK3CA mutations were associated with shorter median PFS (mutant vs. wild type: 4.3 vs. 6.4 months) and OS (17.3 vs. 27.8 months) in capecitabine plus lapatinib-treated patients, but not in T-DM1-treated patients (PFS, 10.9 vs. 9.8 months; OS, not reached in mutant or wild type).	Capecitabine	133-145	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	0-6
27608899-0	2016	Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment.	Capecitabine	72-84	protein tyrosine phosphatase non-receptor type 12	Homo sapiens	24-30
27350037-8	2016	Among angiogenic factors other than VEGF, intratumoral galectin-3, which reportedly promotes angiogenesis both dependent on, and independently of VEGF, was significantly decreased in the capecitabine group and the combination group compared with the control group.	Capecitabine	187-199	galectin 3	Homo sapiens	55-65
27350037-8	2016	Among angiogenic factors other than VEGF, intratumoral galectin-3, which reportedly promotes angiogenesis both dependent on, and independently of VEGF, was significantly decreased in the capecitabine group and the combination group compared with the control group.	Capecitabine	187-199	vascular endothelial growth factor A	Homo sapiens	146-150
27350037-9	2016	In an in vitro experiment, 5-fluorouracil (5-FU), an active metabolite of capecitabine, inhibited galectin-3 production by HT-29 cells.	Capecitabine	74-86	galectin 3	Homo sapiens	98-108
27350037-10	2016	These results suggested that capecitabine has a dual mode of action: namely, inhibition of tumor cell growth and inhibition of galectin-3 production by tumor cells.	Capecitabine	29-41	galectin 3	Homo sapiens	127-137
26983912-0	2016	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).	Capecitabine	96-108	fibroblast growth factor receptor 2	Homo sapiens	9-14
26753626-5	2016	A simulation was conducted to examine the impact of using different model structures on cost-effectiveness results in the context of a combination therapy of lapatinib and capecitabine for the treatment of HER2-positive ABC.	Capecitabine	172-184	erb-b2 receptor tyrosine kinase 2	Homo sapiens	206-210
27323902-0	2016	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.	Capecitabine	125-137	erb-b2 receptor tyrosine kinase 2	Homo sapiens	165-169
27306816-2	2016	The clinical stage was determined to be T4b, N1, M0, Stage IIIB, and a neoadjuvant chemotherapy (NAC)regimen of capecitabine/CDDP plus trastuzumab was selected for treatment.	Capecitabine	112-124	X-linked Kx blood group	Homo sapiens	97-100
27323902-0	2016	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.	Capecitabine	125-137	BRCA1 DNA repair associated	Homo sapiens	141-146
27284470-1	2016	BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) enzyme is the rate limiting step in the metabolism of capecitabine, and its deficiency leads to severe toxicities and rarely, death.	Capecitabine	104-116	dihydropyrimidine dehydrogenase	Homo sapiens	12-43
27284470-1	2016	BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) enzyme is the rate limiting step in the metabolism of capecitabine, and its deficiency leads to severe toxicities and rarely, death.	Capecitabine	104-116	dihydropyrimidine dehydrogenase	Homo sapiens	45-48
26691173-4	2016	However, the efficacy of the substitution of 5-FU for capecitabine in anal SCC needs confirmation.	Capecitabine	54-66	serpin family B member 3	Homo sapiens	75-78
27181275-0	2016	Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.	Capecitabine	91-103	dihydropyrimidine dehydrogenase	Homo sapiens	53-57
26793992-4	2016	Our aim was to analyze miR-20b, miR-27a and miR-181a expression with respect to (epirubicin/oxaliplatin/capecitabine (EOX)) chemotherapy regimen in a set of GC patients, in order to investigate whether miRNAs deregulation may influence GC MDR also via hypoxia signaling modulation.	Capecitabine	104-116	microRNA 20b	Homo sapiens	23-30
27284358-6	2016	The patient exhibited an elevated serum HER2 level, which prompted a reevaluation of the tissue by IHC, using an alternative antibody, and FISH; re-biopsy analyses confirmed the case as HER2-positive, and trastuzumab was subsequently added to the combination chemotherapy with capecitabine and cisplatin.	Capecitabine	277-289	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44
27224517-0	2016	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.	Capecitabine	36-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-79
27154293-0	2016	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.	Capecitabine	110-122	GNAS complex locus	Homo sapiens	0-4
26988358-1	2016	Capecitabine 1000 mg/m(2) bid x 14 days every 21 days (14/21) has been reported to have similar efficacy but more favorable toxicity profile than the approved dosage of 1250 mg/m(2).	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	26-29
26988358-3	2016	We performed a systematic review and meta-analysis to compare a safety profile between capecitabine starting dose of 1000 and 1250 mg/m(2) bid.	Capecitabine	87-99	BH3 interacting domain death agonist	Homo sapiens	139-142
26988358-10	2016	Capecitabine monotherapy at 1000 mg/m(2) bid (14/21) has a clinically meaningful and significantly better toxicity profile compared to 1250 mg/m(2) bid (14/21).	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	41-44
26980172-0	2016	[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].	Capecitabine	73-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
26755510-9	2016	For AC, as CrCl increased, the odds of nonhematologic toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased, the odds of experiencing toxicity of any type also increased (P = .035).	Capecitabine	97-109	CRCL	Homo sapiens	114-118
26998056-10	2016	miRNA levels increased with cancer progression, and lapatinib and 5-fluorouracil (5-FU; the active form of capecitabine) treatment increased the miRNA levels (specifically miR-210 and miR-221) in the treatment-resistant pancreatic cancer PANC-1 and MIA PaCa-2 cell lines.	Capecitabine	107-119	microRNA 210	Homo sapiens	172-179
26998056-10	2016	miRNA levels increased with cancer progression, and lapatinib and 5-fluorouracil (5-FU; the active form of capecitabine) treatment increased the miRNA levels (specifically miR-210 and miR-221) in the treatment-resistant pancreatic cancer PANC-1 and MIA PaCa-2 cell lines.	Capecitabine	107-119	microRNA 221	Homo sapiens	184-191
26691173-16	2016	CONCLUSIONS: Capecitabine can safely substitute infusional 5-FU in the standard chemoradiation regimen for SCC of the anal cancer, with a locoregional control of 86% in 6 months (CI 95% 0.72-0.94).	Capecitabine	13-25	serpin family B member 3	Homo sapiens	107-110
26706729-8	2016	MTD was capecitabine 750 mg/m(2).	Capecitabine	8-20	metallothionein 1E	Homo sapiens	0-3
27026843-1	2016	Capecitabine, a fluoropyrimidine prodrug, has been a frequently chosen ligand for the last one and half decades to inhibit thymidylate synthase (TYMS) for treatment of colorectal cancer.	Capecitabine	0-12	thymidylate synthetase	Homo sapiens	123-143
27026843-1	2016	Capecitabine, a fluoropyrimidine prodrug, has been a frequently chosen ligand for the last one and half decades to inhibit thymidylate synthase (TYMS) for treatment of colorectal cancer.	Capecitabine	0-12	thymidylate synthetase	Homo sapiens	145-149
27026843-8	2016	The drugs were superimposed on the resolved crystal structure (at 1.9 A) of ZD1694/dUMP/TYMS system to shed light on similarity of the binding of capecitabine, and its modifiers, to that of ZD1694.	Capecitabine	146-158	thymidylate synthetase	Homo sapiens	88-92
26735339-0	2016	Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.	Capecitabine	53-65	thymidine phosphorylase	Homo sapiens	128-151
26735339-2	2016	Capecitabine, which is commonly used for metastatic breast cancer in different settings, is an inactive prodrug that takes advantage of elevated levels of thymidine phosphorylase (TP), a key enzyme that is required for its conversion to 5-fluororacil, in tumors.	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	155-178
26735339-2	2016	Capecitabine, which is commonly used for metastatic breast cancer in different settings, is an inactive prodrug that takes advantage of elevated levels of thymidine phosphorylase (TP), a key enzyme that is required for its conversion to 5-fluororacil, in tumors.	Capecitabine	0-12	thymidine phosphorylase	Homo sapiens	180-182
26735339-5	2016	The combined treatment with capecitabine and HDACi, including valproic acid (VPA), resulted in synergistic/additive antiproliferative and pro-apoptotic effects in breast cancer cells but not in TP-knockout cells, both in vitro and in vivo, highlighting the crucial role of TP in the synergism observed.	Capecitabine	28-40	thymidine phosphorylase	Homo sapiens	273-275
26706729-14	2016	CONCLUSION: The MTD for the combination of capecitabine and erlotinib is 750 mg/m(2) BD, 14/21 days, and 100 mg daily, respectively, which is lower than predicted.	Capecitabine	43-55	metallothionein 1E	Homo sapiens	16-19
27057810-5	2016	This changed markedly over the last decade with the approval of irinotecan, oxaliplatin, capecitabine, humanized monoclonal antibodies that target either vascular endothelial growth factor (bevacizumab, aflibercept, and ramucirumab) or the epidermal growth factor receptor (cetuximab and panitumumab), and, most recently, regorafenib and trifluridine/tipiracil.	Capecitabine	89-101	vascular endothelial growth factor A	Homo sapiens	154-188
26721701-4	2016	Patient eligibility criteria included: ABCP who progressed to anthracyclines, taxanes and capecitabine, &lt;=4 chemotherapy schemes, with good performance status.	Capecitabine	90-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-43
26433876-7	2016	CONCLUSION: Eribulin plus capecitabine with standard or weekly dosing schedules is feasible in patients with early-stage, HER2-negative, ER-positive breast cancer.	Capecitabine	26-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
26433876-7	2016	CONCLUSION: Eribulin plus capecitabine with standard or weekly dosing schedules is feasible in patients with early-stage, HER2-negative, ER-positive breast cancer.	Capecitabine	26-38	estrogen receptor 1	Homo sapiens	123-125
27057810-5	2016	This changed markedly over the last decade with the approval of irinotecan, oxaliplatin, capecitabine, humanized monoclonal antibodies that target either vascular endothelial growth factor (bevacizumab, aflibercept, and ramucirumab) or the epidermal growth factor receptor (cetuximab and panitumumab), and, most recently, regorafenib and trifluridine/tipiracil.	Capecitabine	89-101	epidermal growth factor receptor	Homo sapiens	240-272
26722076-0	2016	Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.	Capecitabine	16-28	Mix paired-like homeobox	Homo sapiens	30-33
26623720-3	2016	Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine.	Capecitabine	98-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
26722076-1	2016	BACKGROUND/AIM: The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine.	Capecitabine	286-298	Mix paired-like homeobox	Homo sapiens	85-88
26659366-8	2016	An exploratory endpoint was to assess thymidylate synthase (TS) and thymidine phosphorylase (TP) expression, as biomarkers predictive for clinical outcomes of capecitabine treatment.	Capecitabine	159-171	thymidylate synthetase	Homo sapiens	38-58
26696550-0	2016	TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.	Capecitabine	64-76	tumor protein p53	Homo sapiens	0-4
26696550-1	2016	BACKGROUND AND AIMS: The present study analyzed the relationship between TP53 codon 72 polymorphisms and the clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel chemotherapy.	Capecitabine	172-184	tumor protein p53	Homo sapiens	73-77
26696550-5	2016	RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000).	Capecitabine	108-120	tumor protein p53	Homo sapiens	34-38
26811188-5	2016	CONCLUSIONS: The risk of febrile neutropenia, all-grade and high-grade neutropenia and leucopenia is less in S-1-based therapy than in non fluoropyrimidine regimens; yet comparable to the risk associated with infusional 5FU or capecitabine-based regimens.	Capecitabine	227-239	proteasome 26S subunit, non-ATPase 1	Homo sapiens	109-112
26696550-7	2016	CONCLUSIONS: TP53 codon 72 polymorphisms was effective in predicting the response to chemotherapy and correlate with PFS and OS in patients with advanced gastric cancer treated with paclitaxel and capecitabine chemotherapy.	Capecitabine	197-209	tumor protein p53	Homo sapiens	13-17
26586093-12	2016	CONCLUSION: Metronomic capecitabine and thalidomide after RFA significantly reduced recurrence of HCC and extended PFS, especially for HCC outside the Milan criteria, perhaps via reduction of serum CECs and VEGF levels and inhibition of tumour angiogenesis.	Capecitabine	23-35	vascular endothelial growth factor A	Homo sapiens	207-211
27610130-12	2016	This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy.	Capecitabine	113-125	epidermal growth factor receptor	Homo sapiens	51-56
27610130-12	2016	This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy.	Capecitabine	113-125	marker of proliferation Ki-67	Homo sapiens	61-66
26651493-1	2016	DPD is the rate-limiting enzyme involved in the metabolism of 5-fluorouracil and its prodrugs, capecitabine and tegafur.	Capecitabine	95-107	dihydropyrimidine dehydrogenase	Homo sapiens	0-3
27180793-17	2016	The combination of fulvestrant and low-dose capecitabine is promising because of its efficacy and tolerability for the treatment of patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.	Capecitabine	44-56	estrogen receptor 1	Homo sapiens	146-163
27180793-17	2016	The combination of fulvestrant and low-dose capecitabine is promising because of its efficacy and tolerability for the treatment of patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.	Capecitabine	44-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-214
26651493-7	2016	Since the toxicity profile was compatible with capecitabine administration, complete exon sequencing of DPYD was carried out and the patient was found to be compound heterozygous for the rare mutation c.257C&gt;T in exon 4, c.496A&gt;G in exon 6, the new variant c.1850C&gt;T in exon 14 and c.2194G&gt;A in exon 18.	Capecitabine	47-59	dihydropyrimidine dehydrogenase	Homo sapiens	104-108
26632544-8	2015	Randomized controlled trial for adjuvant chemotherapy in China showed that capecitabine could reduce the risk of recurrence and improve postoperative survival of HCC.	Capecitabine	75-87	HCC	Homo sapiens	162-165
27454530-0	2016	Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).	Capecitabine	54-66	dihydropyrimidine dehydrogenase	Homo sapiens	13-17
27454530-1	2016	BACKGROUND: Sequencing of DPYD exome was conducted in a prospective cohort of advanced breast cancer patients receiving capecitabine.	Capecitabine	120-132	dihydropyrimidine dehydrogenase	Homo sapiens	26-30
27454530-12	2016	CONCLUSIONS: Present data establish the impact of consensual variants on capecitabine toxicity and reveal the existence of a novel DPYD variant, F100L, associated with G4 toxicity.	Capecitabine	73-85	dihydropyrimidine dehydrogenase	Homo sapiens	131-135
26384789-1	2015	Lapatinib plus capecitabine (lap+cap) is approved as treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), who have progressed on prior trastuzumab in the metastatic setting.	Capecitabine	15-27	LAP	Homo sapiens	29-32
26384789-1	2015	Lapatinib plus capecitabine (lap+cap) is approved as treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), who have progressed on prior trastuzumab in the metastatic setting.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-121
26482716-0	2015	Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.	Capecitabine	9-21	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
26482716-13	2015	CONCLUSIONS: Low-dose capecitabine plus trastuzumab is effective and well tolerated in elderly patients with HER2-positive AGC.	Capecitabine	22-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
26242222-1	2015	PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5"-DFUR, 5"-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR).	Capecitabine	59-71	thymidylate synthetase	Homo sapiens	261-281
26242222-1	2015	PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5"-DFUR, 5"-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR).	Capecitabine	59-71	methylenetetrahydrofolate reductase	Homo sapiens	286-321
26242222-1	2015	PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5"-DFUR, 5"-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR).	Capecitabine	59-71	methylenetetrahydrofolate reductase	Homo sapiens	323-328
26242222-10	2015	For the MTHFR C677T (rs1801133) genotype, an increasing number of 677C alleles showed borderline correlation with an increasing elimination half-life of capecitabine (p = 0.043).	Capecitabine	153-165	methylenetetrahydrofolate reductase	Homo sapiens	8-13
26242222-12	2015	A possible, probably indirect role of the MTHFR genotype in pharmacokinetics of capecitabine and/or 5-FU should be investigated in further studies.	Capecitabine	80-92	methylenetetrahydrofolate reductase	Homo sapiens	42-47
25997855-7	2015	In multivariate analysis, ER positivity and single-organ metastasis retained a significant association with better PFS to capecitabine monotherapy (hazard ratio [HR], 0.51; P &lt; .001 and HR, 0.62; P = .004).	Capecitabine	122-134	estrogen receptor 1	Homo sapiens	26-28
25997855-8	2015	CONCLUSION: Our data suggest that ER positivity and single-organ metastasis can be useful predictive markers for better PFS to second- or greater-line palliative capecitabine monotherapy in anthracycline- and taxane-pretreated MBC patients.	Capecitabine	162-174	estrogen receptor 1	Homo sapiens	34-36
26252060-8	2015	Serum AMH was correlated with increased FSH and T and decreased inhibin-B in gonadotoxic protocols (cisplatin or busulfan) and remained unchanged in nongonadotoxic protocols (capecitabine).	Capecitabine	175-187	anti-Mullerian hormone	Homo sapiens	6-9
26489577-0	2015	[A Case of HER-2 Positive Advanced Gastric Cancer Responding to Capecitabine+Cisplatin+Trastuzumab Chemotherapy].	Capecitabine	64-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-16
26622896-1	2015	The present study aimed to analyze the efficacy of maintenance therapy with single agent capecitabine for human epidermal growth factor receptor (HER2) negative metastatic breast cancer (MBC) patients following disease control with 6 cycles of docetaxel plus capecitabine chemotherapy as the first-line treatment.	Capecitabine	89-101	epidermal growth factor receptor	Homo sapiens	112-144
26622896-1	2015	The present study aimed to analyze the efficacy of maintenance therapy with single agent capecitabine for human epidermal growth factor receptor (HER2) negative metastatic breast cancer (MBC) patients following disease control with 6 cycles of docetaxel plus capecitabine chemotherapy as the first-line treatment.	Capecitabine	89-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
26622896-8	2015	The results of the present study indicate that maintenance with single agent capecitabine therapy is an effective and tolerable treatment option for HER2 negative MBC patients in which disease control with 6 cycles of docetaxel plus capecitabine chemotherapy is achieved in the first-line setting.	Capecitabine	77-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
26711981-0	2015	[Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer].	Capecitabine	50-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
26711981-1	2015	OBJECTIVE: To evaluate the efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2-positive metastatic breast cancer patients who have previously received anthracyclines and taxanes.	Capecitabine	67-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-111
26711981-12	2015	CONCLUSION: Trastuzumab plus capecitabine is an effective and safe regimen as first-line treatment for HER-2-positive metastatic breast cancer patients whose cancer is resistant to treatment with anthracyclines and taxanes.	Capecitabine	29-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-108
26623038-6	2015	In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5-FU from capecitabine in tumor tissues.	Capecitabine	181-193	thymidine phosphorylase	Homo sapiens	107-130
26623038-1	2015	In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial).	Capecitabine	193-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
26623038-6	2015	In this model, treatment with trastuzumab alone or trastuzumab plus oxaliplatin enhanced the expression of thymidine phosphorylase (TP), a key enzyme in the generation of 5-FU from capecitabine in tumor tissues.	Capecitabine	181-193	thymidine phosphorylase	Homo sapiens	132-134
25748080-3	2015	In this Review Chemotherapy regimens combined to anti-HER2 blockade are discussed, focusing in particular the role of anthracyclines, taxanes and capecitabine.	Capecitabine	146-158	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
25871911-0	2015	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.	Capecitabine	159-171	estrogen receptor 1	Homo sapiens	68-85
25871911-11	2015	Our findings suggest that mutations that inactivate homologous recombination and/or chromatin remodeling genes within ER-positive, HER2-negative breast cancers may predict for highly durable responses to capecitabine.	Capecitabine	204-216	estrogen receptor 1	Homo sapiens	118-120
25871911-11	2015	Our findings suggest that mutations that inactivate homologous recombination and/or chromatin remodeling genes within ER-positive, HER2-negative breast cancers may predict for highly durable responses to capecitabine.	Capecitabine	204-216	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
26313797-0	2015	A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.	Capecitabine	78-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106
26313797-1	2015	A combination of trastuzumab and cisplatin or trastuzumab and capecitabine has been confirmed to be effective for treating adverse effects in with HER2-positive advanced gastric cancer (AGC) patients.	Capecitabine	62-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
25924969-10	2015	A subgroup analysis of 70 patients on treatment with capecitabine for at least three cycles showed similar results (TTF2: 8.3 vs. 4.4 months, HR 0.53, p = 0.010; OS: 10.4 vs. 6.7 months, HR 0.62, p = 0.056).	Capecitabine	53-65	transcription termination factor 2	Homo sapiens	116-120
26321717-3	2015	The cancer was HER2-positive; therefore, the patient was administered trastuzumab, capecitabine, and cisplatin combination therapy.	Capecitabine	83-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
26321717-7	2015	In Japan, trastuzumab, capecitabine, and cisplatin combination therapy is currently recommended as the standard therapy for unresectable advanced/recurrent HER2-positive gastric cancer, and the findings of the present case suggest that it may also be useful as neoadjuvant chemotherapy.	Capecitabine	23-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
25953439-0	2015	Efficacy of capecitabine monotherapy as the first-line  treatment of metastatic HER2-negative breast cancer.	Capecitabine	12-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
26710505-2	2015	Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer.	Capecitabine	0-12	vascular endothelial growth factor A	Homo sapiens	180-184
25953439-2	2015	The purpose of this study was to investigate the efficacy and safety of capecitabine monotherapy as a first-line treatment in human epidermal receptor 2 (HER2)-negative patients with MBC.	Capecitabine	72-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	154-158
25953439-7	2015	First-line capecitabine treatment for HER2-negative MBC was more effective in the estrogen receptor (ER)-positive patient population compared to the ER-negative group (median PFS 9 vs 4 months (p = 0.002), median OS 33 vs 21 months (p = 0.01)).	Capecitabine	11-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
25953439-7	2015	First-line capecitabine treatment for HER2-negative MBC was more effective in the estrogen receptor (ER)-positive patient population compared to the ER-negative group (median PFS 9 vs 4 months (p = 0.002), median OS 33 vs 21 months (p = 0.01)).	Capecitabine	11-23	estrogen receptor 1	Homo sapiens	82-99
25953439-7	2015	First-line capecitabine treatment for HER2-negative MBC was more effective in the estrogen receptor (ER)-positive patient population compared to the ER-negative group (median PFS 9 vs 4 months (p = 0.002), median OS 33 vs 21 months (p = 0.01)).	Capecitabine	11-23	estrogen receptor 1	Homo sapiens	39-41
25953439-10	2015	CONCLUSIONS: Capecitabine monotherapy is an effective and safe regimen for ER-positive, HER2-negative patients with MBC.	Capecitabine	13-25	estrogen receptor 1	Homo sapiens	75-77
25953439-10	2015	CONCLUSIONS: Capecitabine monotherapy is an effective and safe regimen for ER-positive, HER2-negative patients with MBC.	Capecitabine	13-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
25862350-6	2015	Median PFS (progression-free survival) was 1.2 years for capecitabine and 1.3 years for S-1, with a hazard ratio (S-1/capecitabine) of 0.85 (95 % confidence interval [CI] 0.52-1.38) (P = 0.48 by log-rank).	Capecitabine	118-130	proteasome 26S subunit, non-ATPase 1	Homo sapiens	88-91
25915935-0	2015	Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.	Capecitabine	72-84	dihydropyrimidinase	Homo sapiens	25-44
25899086-6	2015	Furthermore, CD19(+) B cells were more sensitive to capecitabine plus oxaliplatin stimulation in vitro than other immune cells, displaying higher frequency of apoptosis in a dose-dependent way.	Capecitabine	52-64	CD19 molecule	Homo sapiens	13-17
25800061-4	2015	TYMS VNTR 2R and TYMS-3"-UTR 6-bp ins-del variants were associated with global toxicity in capecitabine-treated patients.	Capecitabine	91-103	thymidylate synthetase	Homo sapiens	0-4
25800061-4	2015	TYMS VNTR 2R and TYMS-3"-UTR 6-bp ins-del variants were associated with global toxicity in capecitabine-treated patients.	Capecitabine	91-103	thymidylate synthetase	Homo sapiens	17-21
25681512-13	2015	Of the patients that received capecitabine over the course of their treatment, those with Smad4 loss (n=13) had significantly worse DFS (p=0.003) and OS (p=0.0007).	Capecitabine	30-42	SMAD family member 4	Homo sapiens	90-95
26112944-1	2015	BACKGROUND: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2(+)BC) after progression on trastuzumab based therapy.	Capecitabine	72-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
26112944-1	2015	BACKGROUND: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2(+)BC) after progression on trastuzumab based therapy.	Capecitabine	72-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-164
25815774-8	2015	RESULTS: In patients receiving capecitabine monotherapy, rs4702484, located in ADCY2 and close to MTRR, was associated with slightly reduced PFS for homozygous wild-type patients (CC 6.2 vs. CT 8.0 months; P=0.018).	Capecitabine	31-43	adenylate cyclase 2	Homo sapiens	79-84
25815774-8	2015	RESULTS: In patients receiving capecitabine monotherapy, rs4702484, located in ADCY2 and close to MTRR, was associated with slightly reduced PFS for homozygous wild-type patients (CC 6.2 vs. CT 8.0 months; P=0.018).	Capecitabine	31-43	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	98-102
26298900-4	2015	Most of the time surgery is associated with external beam radiotherapy often combined with concurrent chemotherapy (capecitabine) according to the neoadjuvant regimen CAP 50 (5 weeks long).	Capecitabine	116-128	annexin A11	Homo sapiens	167-173
25495470-4	2015	AREAS COVERED: Among the antimetabolites, a small but widely prescribed number of drugs (i.e., gemcitabine, capecitabine, cytarabine, azacytidine) share a same metabolic pattern driven by a liver enzyme, cytidine deaminase (CDA), coded by a gene displaying several genetic and epigenetic polymorphisms.	Capecitabine	108-120	cytidine deaminase	Homo sapiens	204-222
25495470-4	2015	AREAS COVERED: Among the antimetabolites, a small but widely prescribed number of drugs (i.e., gemcitabine, capecitabine, cytarabine, azacytidine) share a same metabolic pattern driven by a liver enzyme, cytidine deaminase (CDA), coded by a gene displaying several genetic and epigenetic polymorphisms.	Capecitabine	108-120	cytidine deaminase	Homo sapiens	224-227
25691056-10	2015	Polymorphisms in ABCB1, CDA, ENOSF1,and TYMS could help to predict specific and overall severe adverse reactions to capecitabine.	Capecitabine	116-128	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
25677447-0	2015	Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.	Capecitabine	112-124	thymidylate synthetase	Homo sapiens	9-13
25677447-9	2015	CONCLUSIONS: Germline polymorphisms of DPYD, TYMS and GSTP1 have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for advanced colorectal or gastroesophageal cancer.	Capecitabine	141-153	dihydropyrimidine dehydrogenase	Homo sapiens	39-43
25677447-9	2015	CONCLUSIONS: Germline polymorphisms of DPYD, TYMS and GSTP1 have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for advanced colorectal or gastroesophageal cancer.	Capecitabine	141-153	thymidylate synthetase	Homo sapiens	45-49
25677447-9	2015	CONCLUSIONS: Germline polymorphisms of DPYD, TYMS and GSTP1 have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for advanced colorectal or gastroesophageal cancer.	Capecitabine	141-153	glutathione S-transferase pi 1	Homo sapiens	54-59
25960662-3	2015	The purpose of this study was to determine the clinical correlation between TP expression in tumor tissue and the clinical outcome of capecitabine-based therapy in patients with locally advanced (stage III) or metastatic breast cancer (stage IV).	Capecitabine	134-146	thymidine phosphorylase	Homo sapiens	76-78
25691056-10	2015	Polymorphisms in ABCB1, CDA, ENOSF1,and TYMS could help to predict specific and overall severe adverse reactions to capecitabine.	Capecitabine	116-128	enolase superfamily member 1	Homo sapiens	29-35
25691056-10	2015	Polymorphisms in ABCB1, CDA, ENOSF1,and TYMS could help to predict specific and overall severe adverse reactions to capecitabine.	Capecitabine	116-128	thymidylate synthetase	Homo sapiens	40-44
25034007-8	2015	Mitochondrial dysfunction subsequently initiates downstream events that trigger caspase-3 activation, and our results showed that 5-FU and capecitabine activated caspase-3 which leads to apoptosis or necrosis.	Capecitabine	139-151	caspase 3	Rattus norvegicus	80-89
25691056-0	2015	Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.	Capecitabine	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	20-25
25691056-5	2015	The ABCB1*1 haplotype was associated with a high risk of delay in administration or reduction in the dose of capecitabine, diarrhea, and overall toxicity.	Capecitabine	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	4-9
25691056-7	2015	TYMS rs45445694 was associated with a high risk of delay in administration or reduction in the dose of capecitabine, HFS &gt;1 and HFS &gt;2.	Capecitabine	103-115	thymidylate synthetase	Homo sapiens	0-4
25691056-9	2015	A score based on ABCB1-CDA polymorphisms efficiently predicts patients at high risk of severe overall toxicity (PPV, 54%; sensitivity, 43%) in colorectal cancer patients treated with regimens containing capecitabine.	Capecitabine	203-215	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
25026457-0	2015	EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.	Capecitabine	81-93	epidermal growth factor receptor	Homo sapiens	0-4
26126066-0	2015	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.	Capecitabine	131-143	SLC9A3 regulator 1	Homo sapiens	41-47
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Capecitabine	193-205	SLC9A3 regulator 1	Homo sapiens	62-68
25596694-2	2015	Very few reports of adverse ocular reactions caused by capecitabine, a fluorinated pyrimidine antineoplastic agent like S-1, exist, and consequently, the mechanism underlying these reactions is not well understood.	Capecitabine	55-67	proteasome 26S subunit, non-ATPase 1	Homo sapiens	120-123
25637137-2	2015	BACKGROUND: A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC).	Capecitabine	152-164	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	166-169
25812508-0	2015	[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].	Capecitabine	74-86	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
25812508-1	2015	We report a case of human epidermal growth factor receptor 2 (HER2) -positive advanced gastric cancer effectively treated via capecitabine, cisplatin, and trastuzumab (XPT) chemotherapy followed by curative gastrectomy.	Capecitabine	126-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-60
25812508-1	2015	We report a case of human epidermal growth factor receptor 2 (HER2) -positive advanced gastric cancer effectively treated via capecitabine, cisplatin, and trastuzumab (XPT) chemotherapy followed by curative gastrectomy.	Capecitabine	126-138	erb-b2 receptor tyrosine kinase 2	Homo sapiens	62-66
25681367-7	2015	Phenytoin is metabolized in the liver, primarily by the CYP2C9 isozyme, which can be competitively inhibited by capecitabine.	Capecitabine	112-124	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	56-62
26434843-1	2015	BACKGROUND: Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy.	Capecitabine	99-111	estrogen receptor 1	Homo sapiens	115-132
26434843-1	2015	BACKGROUND: Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy.	Capecitabine	99-111	estrogen receptor 1	Homo sapiens	134-136
24647007-0	2015	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.	Capecitabine	26-38	dihydropyrimidine dehydrogenase	Homo sapiens	113-117
24647007-0	2015	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.	Capecitabine	26-38	enolase superfamily member 1	Homo sapiens	142-148
24647007-0	2015	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.	Capecitabine	26-38	thymidylate synthetase	Homo sapiens	161-165
25590835-15	2015	Erlotinib/capecitabine chemotherapy was significantly better in patients with EGFR mutations and in those with thymidine phosphorylase-negative tumors.	Capecitabine	10-22	epidermal growth factor receptor	Homo sapiens	78-82
25034007-8	2015	Mitochondrial dysfunction subsequently initiates downstream events that trigger caspase-3 activation, and our results showed that 5-FU and capecitabine activated caspase-3 which leads to apoptosis or necrosis.	Capecitabine	139-151	caspase 3	Rattus norvegicus	162-171
25034007-13	2015	Our findings showed that the cytotoxic action of 5-FU and capecitabine on cardiomyocytes are mediated by oxidative stress and subsequent mitochondrial dysfunction which causes caspase-3 activation and cell death.	Capecitabine	58-70	caspase 3	Rattus norvegicus	176-185
25459393-1	2014	BACKGROUND: The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response rate (ORR) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC).	Capecitabine	57-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	215-219
25459393-14	2014	INTERPRETATION: In patients with HER2-negative LR/MBC, addition of capecitabine to paclitaxel and bevacizumab significantly improved PFS, ORR and response duration.	Capecitabine	67-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37
25294797-2	2014	The aim of this study is to investigate efficacy and tolerability of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metastases (BCBM).	Capecitabine	102-114	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-127
24647007-5	2015	RESULTS: We identified the first common DPYD polymorphisms to be consistently associated with capecitabine toxicity, rs12132152 (toxicity allele frequency (TAF)=0.031, OR=3.83, p=4.31x10(-6)) and rs12022243 (TAF=0.196, OR=1.69, p=2.55x10(-5)).	Capecitabine	94-106	dihydropyrimidine dehydrogenase	Homo sapiens	40-44
24647007-10	2015	We found that polymorphism rs2612091, which lies within an intron of ENOSF1, was also associated with capecitabine toxicity (TAF=0.532, OR=1.59, p=5.28x10(-6)).	Capecitabine	102-114	enolase superfamily member 1	Homo sapiens	69-75
24647007-14	2015	CONCLUSIONS: DPYD harbours rare and common capecitabine toxicity variants.	Capecitabine	43-55	dihydropyrimidine dehydrogenase	Homo sapiens	13-17
25421252-5	2014	In preclinical studies, our group showed that the addition of HDACi, including VPA, to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase (TP), the key enzyme converting capecitabine to 5-FU, and by downregulating thymidylate synthase (TS), the 5-FU target.	Capecitabine	87-99	thymidylate synthetase	Homo sapiens	257-277
25185651-0	2014	Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.	Capecitabine	116-128	thymidylate synthetase	Homo sapiens	34-54
25185651-3	2014	The objective of this article is to investigate whether TS expression is associated with clinical outcome in advanced GC receiving capecitabine alone chemotherapy.	Capecitabine	131-143	thymidylate synthetase	Homo sapiens	56-58
25185651-12	2014	The present study demonstrates that TS expression is associated with chemotherapy response, PFS, and OS in advanced GC patients treated with capecitabine alone chemotherapy.	Capecitabine	141-153	thymidylate synthetase	Homo sapiens	36-38
25421252-5	2014	In preclinical studies, our group showed that the addition of HDACi, including VPA, to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase (TP), the key enzyme converting capecitabine to 5-FU, and by downregulating thymidylate synthase (TS), the 5-FU target.	Capecitabine	87-99	thymidylate synthetase	Homo sapiens	279-281
25421252-7	2014	Also, a randomized phase-2 study will be performed to explore whether the addition of VPA and/or capecitabine to preoperative SCRT might increase pathologic complete tumor regression (TRG1) rate.	Capecitabine	97-109	tRNA-Gly (anticodon CCC) 1-1	Homo sapiens	184-188
25421252-8	2014	A sample size of 86 patients (21-22/arm) was calculated under the hypothesis that the addition of capecitabine or VPA to SCRT can improve the TRG1 rate from 5% to 20%, with one-sided alpha = 0.10 and 80% power.Several biomarkers will be evaluated comparing normal mucosa with tumor (TP, TS, VEGF, RAD51, XRCC1, Histones/proteins acetylation, HDAC isoforms) and on blood samples (polymorphisms of DPD, TS, XRCC1, GSTP1, RAD51 and XRCC3, circulating endothelial and progenitors cells; PBMCs-Histones/proteins acetylation).	Capecitabine	98-110	tRNA-Gly (anticodon CCC) 1-1	Homo sapiens	142-146
25270122-1	2014	This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC).	Capecitabine	120-132	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-163
23335064-0	2014	Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.	Capecitabine	58-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
25434447-3	2014	Owing to a HER2 immunohistochemistry (IHC) tumor score of 3+, we initiated capecitabine plus cisplatin (CDDP) plus trastuzumab chemotherapy.	Capecitabine	75-87	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
25731506-1	2014	We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection.	Capecitabine	162-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-60
25731506-1	2014	We report a case of human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer successfully treated with combination therapy of trastuzumab, capecitabine, and cisplatin, followed by a curative resection.	Capecitabine	162-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
25731522-9	2014	We identified a case of gastric cancer showing response to first-line capecitabine/CDDP therapy after lymph node recurrence following the administration of S-1 as postoperative adjuvant chemotherapy.	Capecitabine	70-82	proteasome 26S subunit, non-ATPase 1	Homo sapiens	156-159
25731522-10	2014	Since capecitabine and S-1 differ in their mechanisms of action and as predictive factors for therapeutic effect, capecitabine may be an efficient option in cases of S-1 failure.	Capecitabine	114-126	proteasome 26S subunit, non-ATPase 1	Homo sapiens	23-26
25731522-11	2014	The present case suggests that capecitabine/CDDP therapy may be an effective treatment for S-1 pretreated patients with advanced or metastatic gastric cancer.	Capecitabine	31-43	proteasome 26S subunit, non-ATPase 1	Homo sapiens	91-94
25364262-1	2014	BACKGROUND: We present a retrospective analysis of metronomic capecitabine in metastatic gastroenteropancreatic neuroendrocrine tumors (GEP-NETs).	Capecitabine	62-74	granulin precursor	Homo sapiens	136-139
25731304-7	2014	After 7 courses of capecitabine plus oxaliplatin (XELOX) treatment, the right #283 lymph node increased to 8 mm in October 2011 and the patient was diagnosed with a re-recurrence of the original tumor (CEA level, 4.6).	Capecitabine	19-31	CEA cell adhesion molecule 3	Homo sapiens	202-205
24590654-9	2014	CONCLUSION: A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above.	Capecitabine	46-58	dihydropyrimidine dehydrogenase	Homo sapiens	119-123
25232326-0	2014	Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months" Remission with Lapatinib plus Capecitabine.	Capecitabine	100-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-24
25114575-2	2014	In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer.	Capecitabine	98-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
25114575-4	2014	In pivotal phase III trials, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression compared to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer.	Capecitabine	60-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-178
24899084-0	2014	A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.	Capecitabine	50-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-94
24923572-1	2014	BACKGROUND: We modified 3-week XELOX regimen with oxaliplatin to 85 mg/m 2 on Day 1 and capecitabine 1000 mg/m 2 BID for 10 days every 14 days to be more practical in clinical practice for advanced gastric cancer.	Capecitabine	88-100	BH3 interacting domain death agonist	Homo sapiens	113-116
24424115-2	2014	Treatment with lapatinib plus capecitabine for HER2-positive metastatic breast cancer (MBC) with primary or acquired resistance to trastuzumab was analyzed retrospectively.	Capecitabine	30-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
24464780-0	2014	A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.	Capecitabine	33-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-85
25216762-1	2014	Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC).	Capecitabine	14-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-56
24112786-0	2014	Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
25232273-10	2014	Trastuzumab as perioperative and adjuvant medication, in combination with oxaliplatin and capecitabine for a HER2-overexpressing advanced gastric adenocarcinoma, led to recurrence-free survival of at least 18 mo after surgery.	Capecitabine	90-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
24967516-3	2014	Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.	Capecitabine	297-309	immunoglobulin heavy diversity 1-7	Homo sapiens	192-195
24374727-6	2014	"Low" tumor VEGF-A level was predictive of better ORR for bevacizumab [ORR (low) 53% vs. (high) 19%, interaction p = 0.03] but not for PFS [hazard ratio, HR (low) 0.73 vs. (high) 0.62, interaction p = 0.68] in the comparison of capecitabine (C) versus C and bevacizumab (CB) and CB plus mitomycin (M).	Capecitabine	228-240	vascular endothelial growth factor A	Homo sapiens	12-18
24746899-4	2014	Metronomic capecitabine or CTX chemotherapy decreased vascular endothelial growth factor (VEGF) but elevated thrombospondin-1 (TSP-1) expression, reduced CEP levels and decreased microvessel density (MVD).	Capecitabine	11-23	vascular endothelial growth factor A	Homo sapiens	54-88
24746899-4	2014	Metronomic capecitabine or CTX chemotherapy decreased vascular endothelial growth factor (VEGF) but elevated thrombospondin-1 (TSP-1) expression, reduced CEP levels and decreased microvessel density (MVD).	Capecitabine	11-23	vascular endothelial growth factor A	Homo sapiens	90-94
24746899-4	2014	Metronomic capecitabine or CTX chemotherapy decreased vascular endothelial growth factor (VEGF) but elevated thrombospondin-1 (TSP-1) expression, reduced CEP levels and decreased microvessel density (MVD).	Capecitabine	11-23	thrombospondin 1	Homo sapiens	109-125
24746899-4	2014	Metronomic capecitabine or CTX chemotherapy decreased vascular endothelial growth factor (VEGF) but elevated thrombospondin-1 (TSP-1) expression, reduced CEP levels and decreased microvessel density (MVD).	Capecitabine	11-23	thrombospondin 1	Homo sapiens	127-132
24908435-19	2014	CONCLUSIONS: The combination of capecitabine and erlotinib with radiotherapy in locally advanced pancreatic cancer is well tolerated and feasible at the dose level of capecitabine 925 mg/m2 bid and erlotinib 100 mg daily.	Capecitabine	32-44	BH3 interacting domain death agonist	Homo sapiens	190-193
24915461-9	2014	In Scenario 3, we obtained a list of disease-related genes from the disease-related GEP (liver cancer) and the drug (Capecitabine) on the PharmGKB website, resulting in twenty-two hidden connections.	Capecitabine	117-129	granulin precursor	Homo sapiens	84-87
24590654-9	2014	CONCLUSION: A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above.	Capecitabine	46-58	thymidylate synthetase	Homo sapiens	128-132
24803897-5	2014	Because immunohistochemical staining for HER2 was strong in both components, combination chemotherapy with capecitabine, cisplatin, and trastuzumab was initiated.	Capecitabine	107-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-45
24362621-2	2014	Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data.	Capecitabine	28-40	NK6 homeobox 2	Homo sapiens	42-45
24233024-9	2014	Overall, our results demonstrate that simvastatin can enhance the effects of capecitabine through suppression of NF-kappaB-regulated markers of proliferation, invasion, angiogenesis, and metastasis.	Capecitabine	77-89	nuclear factor kappa B subunit 1	Homo sapiens	113-122
24598096-4	2014	Her platelet count increased to approximately 10.0x10(4)/muL during chemotherapy with oxaliplatin plus capecitabine, and she developed deep venous thrombosis requiring inferior vena cava filter placement and anticoagulation.	Capecitabine	103-115	tripartite motif containing 37	Homo sapiens	57-60
24396465-10	2014	Topical retinoids may have the potential to effectively treat capecitabine-induced HFS by increasing HB-EGF expression and decreasing cutaneous side-effects.	Capecitabine	62-74	heparin binding EGF like growth factor	Homo sapiens	101-107
24292263-6	2014	In a separate cohort of 21 patients treated with gemcitabine and capecitabine together with concurrently administered GV1001 vaccine with adjuvant GM-CSF, the MDSC% fell in 18/21 patients and there was a significant difference in the trajectory of MDSCs between those receiving GV1001 and GM-CSF in combination with chemotherapy and those receiving chemotherapy alone.	Capecitabine	65-77	colony stimulating factor 2	Homo sapiens	289-295
25374186-0	2014	Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.	Capecitabine	53-65	doublecortin	Homo sapiens	67-70
26609545-1	2014	Interfering with anaplerotic utilization of glutamine (Gln) was recently reported to sensitize KRAS-driven cancer cells to the cytotoxic effects of capecitabine and paclitaxel.	Capecitabine	148-160	KRAS proto-oncogene, GTPase	Homo sapiens	95-99
25427581-0	2014	Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.	Capecitabine	78-90	zinc fingers and homeoboxes 2	Homo sapiens	148-151
25374186-4	2014	In the present study, the efficacy and toxicity of a regimen with a modified dose of docetaxel and cisplatin in combination with oral capecitabine (DCX) was evaluated in untreated patients with HER2-negative advanced gastric cancer.	Capecitabine	134-146	doublecortin	Homo sapiens	148-151
24219283-8	2013	In addition, our in vitro cytotoxicity results showed that RCC cell lines differed in their response to 5-FU and DFUR and prior treatment with IFN-alpha potentiated cytotoxic response to metabolites of capecitabine.	Capecitabine	202-214	interferon alpha 1	Homo sapiens	143-152
23907440-5	2013	Randomized, phase III clinical trials indicate targeted HER2 treatment with lapatinib and capecitabine in brain metastases from breast cancer increases the time to progression and decreases the frequency of CNS involvement at progression.	Capecitabine	90-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
23959266-0	2013	ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.	Capecitabine	31-43	epidermal growth factor receptor	Homo sapiens	16-20
24007821-3	2013	On the basis of high epidermal growth factor receptor expression of biliary tract cancers this study aims to investigate the efficacy of cetuximab, gemcitabine and capecitabine in an exploratory phase 2 trial.	Capecitabine	164-176	epidermal growth factor receptor	Homo sapiens	21-53
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	Capecitabine	34-46	epidermal growth factor receptor	Homo sapiens	53-57
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	Capecitabine	34-46	epidermal growth factor receptor	Homo sapiens	213-217
24013510-3	2013	METHODS: HER2-positive MBC with brain metastasis not previously treated with whole-brain radiotherapy received first-line combination of lapatinib and capecitabine in a phase II study.	Capecitabine	151-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	Capecitabine	34-46	epidermal growth factor receptor	Homo sapiens	213-217
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	Capecitabine	181-193	epidermal growth factor receptor	Homo sapiens	53-57
24135868-0	2013	High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.	Capecitabine	72-84	alpha-1-microglobulin/bikunin precursor	Homo sapiens	20-24
24114122-0	2013	UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.	Capecitabine	69-81	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
24135868-9	2013	Our data indicated that the high level of serum AMBP could predict the poor response of the AGC patients treated with the paclitaxel-capecitabine chemotherapy, which could be used as a potential biomarker to identify patients who would benefit from this chemotherapeutic regimen.	Capecitabine	133-145	alpha-1-microglobulin/bikunin precursor	Homo sapiens	48-52
23975242-1	2013	PURPOSE: Capecitabine (CAP), a prodrug, needs to be converted to 5-fluorouracil by several key enzymes, including thymidine phosphorylase (TP).	Capecitabine	9-21	thymidine phosphorylase	Mus musculus	114-137
23975242-1	2013	PURPOSE: Capecitabine (CAP), a prodrug, needs to be converted to 5-fluorouracil by several key enzymes, including thymidine phosphorylase (TP).	Capecitabine	9-21	thymidine phosphorylase	Mus musculus	139-141
23975242-1	2013	PURPOSE: Capecitabine (CAP), a prodrug, needs to be converted to 5-fluorouracil by several key enzymes, including thymidine phosphorylase (TP).	Capecitabine	23-26	thymidine phosphorylase	Mus musculus	114-137
23975242-1	2013	PURPOSE: Capecitabine (CAP), a prodrug, needs to be converted to 5-fluorouracil by several key enzymes, including thymidine phosphorylase (TP).	Capecitabine	23-26	thymidine phosphorylase	Mus musculus	139-141
24344005-0	2013	Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
24344005-1	2013	PURPOSE: To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in anthracycline- and taxane-pretreated HER-2 negative metastatic breast carcinoma (MBC) female patients.	Capecitabine	69-81	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-151
23263912-0	2013	Polymorphism of TS 3"-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.	Capecitabine	109-121	thymidylate synthetase	Homo sapiens	16-18
24394076-0	2013	[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].	Capecitabine	92-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
24394076-1	2013	We report a case of human epidermal growth factor receptor(HER)2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin(CDDP), and trastuzumab as first-line chemotherapy.	Capecitabine	141-153	epidermal growth factor receptor	Homo sapiens	26-58
24394076-4	2013	Because overexpression of HER2 protein was observed in primary tumor immunostaining, combination therapy of capecitabine+CDDP+trastuzumab was administered as first-line chemotherapy.	Capecitabine	108-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-30
25841682-4	2013	In fact, while it showed that capecitabine may be combined with radiotherapy more safely than gemcitabine and it could be a standard regimen as a consolidation regimen after an induction chemotherapy, the LAP-07 trial showed that radiotherapy in combination with chemotherapy does not add any valuable effect to chemotherapy alone.	Capecitabine	30-42	LAP	Homo sapiens	205-208
23390054-3	2013	The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap).	Capecitabine	288-300	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	61-64
23390054-3	2013	The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap).	Capecitabine	338-350	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	61-64
23585145-1	2013	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur).	Capecitabine	128-140	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
23585145-1	2013	Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur).	Capecitabine	128-140	dihydropyrimidine dehydrogenase	Homo sapiens	33-36
24088129-2	2013	We determined the frequency of polymorphisms in the CYP2D6 gene associated with activation of tamoxifen, and those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity of paclitaxel and capecitabine.	Capecitabine	195-207	dihydropyrimidine dehydrogenase	Homo sapiens	147-151
23768086-10	2013	Subgroup analyses stratified by CTX was also performed, evident benefits of additional BEV in OS and PFS can be identified in all subgroups, except for the CTX containing capecitabine in OS.	Capecitabine	171-183	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	156-159
23629479-1	2013	Both S1 and XELOX (capecitabine+oxaliplatin) have been recommended as an adjuvant treatment for gastric cancer according to the guidelines of the National Comprehensive Cancer Network (NCCN).	Capecitabine	19-31	proteasome 26S subunit, non-ATPase 1	Homo sapiens	5-17
23263912-8	2013	CONCLUSIONS: We first reported that TS 3"-UTR ins6/ins6 genotype could predict the poor survival of advanced gastric cancer patients treated with capecitabine plus paclitaxel, which would be further verified in a large multicenter study.	Capecitabine	146-158	thymidylate synthetase	Homo sapiens	36-38
23987495-10	2013	CONCLUSION: Celecoxib can enhance the antitumor effect of capecitabine by inhibiting the expressions of COX-2 and NF-KappaB p65 in mice bearing H22 implanted tumor.	Capecitabine	58-70	cytochrome c oxidase II, mitochondrial	Mus musculus	104-109
23987495-10	2013	CONCLUSION: Celecoxib can enhance the antitumor effect of capecitabine by inhibiting the expressions of COX-2 and NF-KappaB p65 in mice bearing H22 implanted tumor.	Capecitabine	58-70	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-123
23987495-10	2013	CONCLUSION: Celecoxib can enhance the antitumor effect of capecitabine by inhibiting the expressions of COX-2 and NF-KappaB p65 in mice bearing H22 implanted tumor.	Capecitabine	58-70	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	124-127
23876062-0	2013	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.	Capecitabine	26-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	128-132
23736036-8	2013	For patients treated with capecitabine, a MTHFR c.1298CC homozygous variant genotype predicted hand-foot syndrome (P=4.1 x 10-6, OR=9.99, 95% CI: 3.84-27.8).	Capecitabine	26-38	methylenetetrahydrofolate reductase	Homo sapiens	42-47
23863740-0	2013	[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].	Capecitabine	83-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	11-15
23876062-10	2013	Capecitabine and sorafenib/placebo doses can be escalated to 1250 mg/m2 BID and 400 mg BID, respectively, as tolerated, or reduced to manage toxicity.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	72-75
23876062-10	2013	Capecitabine and sorafenib/placebo doses can be escalated to 1250 mg/m2 BID and 400 mg BID, respectively, as tolerated, or reduced to manage toxicity.	Capecitabine	0-12	BH3 interacting domain death agonist	Homo sapiens	87-90
23876062-17	2013	DISCUSSION: RESILIENCE will provide definitive PFS data for the combination of sorafenib and capecitabine in advanced HER2-negative breast cancer and better characterize the benefit-to-risk profile.	Capecitabine	93-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-122
23244709-12	2013	CONCLUSION: In patients with KRAS wild-type tumors treated with cetuximab plus capecitabine-based chemotherapy ETS &gt;= 20% is an important predictor of favorable outcome.	Capecitabine	79-91	KRAS proto-oncogene, GTPase	Homo sapiens	29-33
23749894-8	2013	These results are of importance when interpreting TYMP expression data in rectal cancer and may be of clinical interest as TYMP participates in the activation of capecitabine.	Capecitabine	162-174	thymidine phosphorylase	Homo sapiens	123-127
23595344-0	2013	A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.	Capecitabine	97-109	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	2-8
23463098-1	2013	PURPOSE: Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC).	Capecitabine	56-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133
23332349-0	2013	Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.	Capecitabine	63-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
23463098-11	2013	CONCLUSIONS: Combination of trastuzumab and paclitaxel plus capecitabine is an effective and well-tolerated regimen in the first-line therapy for women with HER2-positive MBC.	Capecitabine	60-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	157-161
23444220-11	2013	CONCLUSION: The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab.	Capecitabine	53-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-143
23647753-2	2013	MATERIAL AND METHODS: Twelve patients were treated with chemoradiotherapy to 50.4 Gy combined with capecitabine 825 mg/m(2) BID.	Capecitabine	99-111	BH3 interacting domain death agonist	Homo sapiens	124-127
23411960-0	2013	[Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].	Capecitabine	148-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
23407049-6	2013	Therefore, we analysed the association of MTHFR gene polymorphisms and the occurrence of serious toxicity of first-line capecitabine monotherapy and combination therapy.	Capecitabine	120-132	methylenetetrahydrofolate reductase	Homo sapiens	42-47
23603345-0	2013	Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.	Capecitabine	115-127	dihydropyrimidine dehydrogenase	Homo sapiens	0-31
23603345-0	2013	Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.	Capecitabine	115-127	dihydropyrimidine dehydrogenase	Homo sapiens	38-42
23603345-9	2013	Among 65 patients with toxicities due to capecitabine, nine (14%) had mutated DPYD, which was more frequent than in the control group (p=0.006).	Capecitabine	41-53	dihydropyrimidine dehydrogenase	Homo sapiens	78-82
23603345-10	2013	CONCLUSION: Mutated DPYD is frequently observed in Caucasian patients who experience toxicities while receiving 5-FU/capecitabine.	Capecitabine	117-129	dihydropyrimidine dehydrogenase	Homo sapiens	20-24
23603345-11	2013	Screening of patients for DPYD mutations prior to administration of 5-FU/capecitabine using new pharmacogenetic testing methods, may help for identify those patients who are at greatest risk for adverse effects, allowing a more individualized approach to their chemotherapy management.	Capecitabine	73-85	dihydropyrimidine dehydrogenase	Homo sapiens	26-30
24158082-0	2013	Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.	Capecitabine	66-78	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
24158082-1	2013	Lapatinib, in combination with capecitabine, has shown clinical activity in both first-line and refractory disease in patients with HER2-positive advanced breast cancer.	Capecitabine	31-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
24158082-5	2013	In advanced breast cancer patients with skin metastases overexpressing HER2, previously treated with anthracyclines, taxanes and trastuzumab, lapatinib and capecitabine may represent a very active, safe and well-tolerated treatment option.	Capecitabine	156-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75
24158083-0	2013	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.	Capecitabine	45-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
23344713-0	2013	All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.	Capecitabine	40-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
23344713-0	2013	All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.	Capecitabine	40-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-88
23344713-1	2013	PURPOSE: To evaluate the efficacy and safety of an all-oral vinorelbine and capecitabine combination therapy in anthracycline- +- taxane-pretreated HER2/Neu-negative metastatic breast cancer (MBC).	Capecitabine	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
23344713-1	2013	PURPOSE: To evaluate the efficacy and safety of an all-oral vinorelbine and capecitabine combination therapy in anthracycline- +- taxane-pretreated HER2/Neu-negative metastatic breast cancer (MBC).	Capecitabine	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-156
23344713-13	2013	CONCLUSION: These results show that the combination of oral vinorelbine and capecitabine is an effective and well-tolerated first-line regimen for HER2/Neu-negative MBC patients pretreated with anthracyclines +- taxanes.	Capecitabine	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	147-151
23344713-13	2013	CONCLUSION: These results show that the combination of oral vinorelbine and capecitabine is an effective and well-tolerated first-line regimen for HER2/Neu-negative MBC patients pretreated with anthracyclines +- taxanes.	Capecitabine	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-155
24649155-5	2013	The patient developed solitary liver metastasis one year later and was treated with trastuzumab plus capecitabine/cisplatin since results of the immunohistochemical analysis of the resected specimens demonstrated overexpression of the human epidermal growth factor receptor 2 (HER2).	Capecitabine	101-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	241-275
24649155-5	2013	The patient developed solitary liver metastasis one year later and was treated with trastuzumab plus capecitabine/cisplatin since results of the immunohistochemical analysis of the resected specimens demonstrated overexpression of the human epidermal growth factor receptor 2 (HER2).	Capecitabine	101-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	277-281
23411960-1	2013	We report a case of a trastuzumab-resistant human epidermal growth factor receptor-2(HER2)-positive breast cancer patient with extensive liver metastases and associated impaired liver function, who showed an excellent response to the combination of trastuzumab and capecitabine.	Capecitabine	265-277	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-84
23411960-1	2013	We report a case of a trastuzumab-resistant human epidermal growth factor receptor-2(HER2)-positive breast cancer patient with extensive liver metastases and associated impaired liver function, who showed an excellent response to the combination of trastuzumab and capecitabine.	Capecitabine	265-277	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89
23122784-0	2013	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	Capecitabine	15-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
23909036-1	2013	Targeted therapy (lapatinib and/or trastuzumab) in combination with chemotherapy (capecitabine) is highly effective in metastatic lesions of the brain in breast cancer patients with overexpress HER-2/neu.	Capecitabine	82-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	194-203
23229803-7	2013	The antitumor activity of capecitabine and 5"-DFUR correlated             significantly with the mRNA levels of TP and with the TP/DPD ratio, whereas the             activity of 5-FU correlated significantly with OPRT, TMPK, UMPK and CD.	Capecitabine	26-38	dihydropyrimidine dehydrogenase	Homo sapiens	131-134
23229803-8	2013	In a stepwise             regression analysis, TP and DPD were found to be independent predictive factors             of sensitivity to capecitabine and 5"-DFUR, and UMPK was predictive of sensitivity             to 5-FU.	Capecitabine	136-148	dihydropyrimidine dehydrogenase	Homo sapiens	54-57
23305997-4	2013	In HER2-positive metastatic breast cancer with brain metastases not previously treated with whole brain radiotherapy, capecitabine and lapatinib combination obtains a volumetric reponse in two thirds of patients (LANDSCAPE study).	Capecitabine	118-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	3-7
24191208-3	2013	We report a patient with breast cancer overexpressing HER-2 where brain metastases were successfully treated with radiation and a combination of lapatinib and capecitabine.	Capecitabine	159-171	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
23079156-19	2013	Interestingly, the results suggest that low DPD expression may be associated with response to capecitabine but also with increased toxicity.	Capecitabine	94-106	dihydropyrimidine dehydrogenase	Homo sapiens	44-47
23104222-6	2012	In multivariate analysis by backward elimination, significantly improved ORR (p = 0.0036), PFS (p &lt; 0.0001) and OS (p &lt; 0.0001) with capecitabine were demonstrated in patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive versus both ER and PgR-negative tumors.	Capecitabine	139-151	progesterone receptor	Homo sapiens	217-238
23104222-6	2012	In multivariate analysis by backward elimination, significantly improved ORR (p = 0.0036), PFS (p &lt; 0.0001) and OS (p &lt; 0.0001) with capecitabine were demonstrated in patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive versus both ER and PgR-negative tumors.	Capecitabine	139-151	progesterone receptor	Homo sapiens	240-243
23104222-6	2012	In multivariate analysis by backward elimination, significantly improved ORR (p = 0.0036), PFS (p &lt; 0.0001) and OS (p &lt; 0.0001) with capecitabine were demonstrated in patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive versus both ER and PgR-negative tumors.	Capecitabine	139-151	progesterone receptor	Homo sapiens	273-276
23104222-11	2012	Multivariate analyses identified greater ORR, PFS, and OS with capecitabine in patients with ER and/or PgR-positive versus ER/PgR-negative tumors.	Capecitabine	63-75	progesterone receptor	Homo sapiens	103-106
23104222-11	2012	Multivariate analyses identified greater ORR, PFS, and OS with capecitabine in patients with ER and/or PgR-positive versus ER/PgR-negative tumors.	Capecitabine	63-75	progesterone receptor	Homo sapiens	126-129
23235178-6	2012	We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy.	Capecitabine	76-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
22766748-9	2012	This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.	Capecitabine	161-173	tubulin beta 3 class III	Homo sapiens	40-45
22734012-0	2012	Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.	Capecitabine	57-69	doublecortin	Homo sapiens	71-74
22504780-0	2012	Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.	Capecitabine	100-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-29
23152018-0	2012	[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].	Capecitabine	41-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-69
23152022-0	2012	[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].	Capecitabine	31-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
22430888-16	2012	The KRAS WT is highly associated with tumor down-staging to cetuximab plus capecitabine-based CRT in patients with LARC.	Capecitabine	75-87	KRAS proto-oncogene, GTPase	Homo sapiens	4-8
22430888-16	2012	The KRAS WT is highly associated with tumor down-staging to cetuximab plus capecitabine-based CRT in patients with LARC.	Capecitabine	75-87	C-C motif chemokine ligand 20	Homo sapiens	115-119
22766748-0	2012	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.	Capecitabine	140-152	tubulin beta 3 class III	Homo sapiens	16-21
22766748-2	2012	In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine.	Capecitabine	179-191	tubulin beta 3 class III	Homo sapiens	79-84
22734012-1	2012	BACKGROUND: This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma.	Capecitabine	154-166	doublecortin	Homo sapiens	168-171
21623901-1	2012	The combination of lapatinib and capecitabine is approved in Her2+ metastatic breast cancer.	Capecitabine	33-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
22526409-0	2012	Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.	Capecitabine	46-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
21623901-5	2012	Lapatinib proved to markedly downregulate TS activity, thus suggesting a subsequent better efficacy of capecitabine.	Capecitabine	103-115	thymidylate synthetase	Homo sapiens	42-44
21623901-6	2012	Capecitabine optimized the downregulation of p-AKT and p-P42/44 expression by lapatinib.	Capecitabine	0-12	erythrocyte membrane protein band 4.2	Homo sapiens	57-60
21623901-12	2012	Besides, modulation of TS expression by lapatinib makes its association with capecitabine a promising way to overcome breast cancers resistant in relation with TS overexpression.	Capecitabine	77-89	thymidylate synthetase	Homo sapiens	23-25
21623901-12	2012	Besides, modulation of TS expression by lapatinib makes its association with capecitabine a promising way to overcome breast cancers resistant in relation with TS overexpression.	Capecitabine	77-89	thymidylate synthetase	Homo sapiens	160-162
23060925-9	2012	Treg and IL-6 levels decreased following GEM monochemotherapy, IL-17A levels decreased after GEMOX, and IL-6 levels were reduced subsequent to BEV+CAPE+RT treatment.	Capecitabine	147-151	interleukin 6	Homo sapiens	104-108
22839200-0	2012	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.	Capecitabine	118-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-25
22480411-10	2012	CONCLUSIONS: These results suggest a clinical advantage of chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone via the elevation of the TP/DPD ratio in cervical squamous cell carcinoma.	Capecitabine	82-94	dihydropyrimidine dehydrogenase	Homo sapiens	164-167
22426923-3	2012	PATIENTS AND METHODS: 79 SNPs in CYP450, whose minor allele frequency were &gt;= 10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine.	Capecitabine	157-169	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	33-39
22790050-2	2012	We encountered a case of HER2-positive breast cancer with cerebral metastasis presenting with hydrocephalus, in which VP shunting was successful, enabling continued treatment with lapatinib+capecitabine and improvement of the patient"s QOL.	Capecitabine	190-202	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-29
22534478-4	2012	RESULTS: p53 expression were associated with the significantly shorter disease-free survival (DFS) (p&lt;0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving capecitabine plus paclitaxel.	Capecitabine	218-230	tumor protein p53	Homo sapiens	9-12
22534478-6	2012	CONCLUSIONS: p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant capecitabine plus paclitaxel chemotherapy.	Capecitabine	140-152	tumor protein p53	Homo sapiens	13-16
22426923-9	2012	CONCLUSION: CYP1A1 rs1048943 A&gt;G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients.	Capecitabine	136-148	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	12-18
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Capecitabine	84-96	cyclin D1	Homo sapiens	4-13
22341133-9	2012	This finding may be explained through thymidylate synthase inhibition by capecitabine.	Capecitabine	73-85	thymidylate synthetase	Homo sapiens	38-58
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Capecitabine	84-96	cyclin D1	Homo sapiens	15-20
21989330-0	2012	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.	Capecitabine	84-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
21989330-9	2012	CONCLUSION: Our findings suggest that CCND1A870G may be useful in predicting clinical outcome in HER2-positive mBC patients treated with lapatinib plus capecitabine.	Capecitabine	152-164	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101
21373875-0	2012	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +- trastuzumab.	Capecitabine	129-141	tumor protein p53	Homo sapiens	0-4
21915635-0	2012	Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5"-DFUR, the bioactive metabolite of Xeloda.	Capecitabine	175-181	epidermal growth factor receptor	Homo sapiens	14-18
22351692-0	2012	First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway.	Capecitabine	108-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	174-183
21373875-10	2012	Capecitabine plus docetaxel in HER2-negative, and with trastuzumab in HER2-positive patients, provided a good response rate with four cycles of non-anthracycline-containing therapy.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	31-35
22444716-0	2012	Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.	Capecitabine	41-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
22444716-1	2012	BACKGROUND: We conducted a multiinstitutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)-positive (HER2(+)) metastatic breast cancer (MBC).	Capecitabine	64-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	240-244
22444716-1	2012	BACKGROUND: We conducted a multiinstitutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)-positive (HER2(+)) metastatic breast cancer (MBC).	Capecitabine	64-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	256-260
22276821-2	2012	The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by doxorubicin plus cyclophosphamide, would increase the rates of pathological complete response in the breast in women with operable, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathological complete response.	Capecitabine	73-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	289-329
22276821-2	2012	The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by doxorubicin plus cyclophosphamide, would increase the rates of pathological complete response in the breast in women with operable, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathological complete response.	Capecitabine	73-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	331-335
22430264-0	2012	A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.	Capecitabine	70-82	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	2-6
22430264-2	2012	We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria).	Capecitabine	136-148	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	20-53
22430264-2	2012	We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria).	Capecitabine	136-148	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	55-59
22741034-0	2012	Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.	Capecitabine	119-131	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
22741034-2	2012	The purpose of this study was to evaluate the prognostic role of Bax in patients with advanced gastric cancer treated with triplet chemotherapy COI regimen (capecitabine, oxaliplatin, and irinotecan).	Capecitabine	157-169	BCL2 associated X, apoptosis regulator	Homo sapiens	65-68
22412143-2	2012	A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer.	Capecitabine	87-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-175
22412143-2	2012	A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer.	Capecitabine	87-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	177-181
22412143-10	2012	CONCLUSION: Addition of sorafenib to capecitabine improved PFS in patients with HER2-negative advanced breast cancer.	Capecitabine	37-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-84
22351692-10	2012	CONCLUSIONS: Overall our results show that gamma-tocotrienol can potentiate the effects of capecitabine through suppression of NF-kappaB-regulated markers of proliferation, invasion, angiogenesis, and metastasis.	Capecitabine	91-103	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	127-136
22116464-0	2012	Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.	Capecitabine	28-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
22374460-0	2012	Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.	Capecitabine	46-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	76-80
22397399-0	2012	The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.	Capecitabine	78-90	microRNA 126	Homo sapiens	24-36
22397399-2	2012	The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC).	Capecitabine	113-125	microRNA 126	Homo sapiens	77-86
21088942-1	2012	BACKGROUND: Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM).	Capecitabine	103-115	host cell factor C1	Homo sapiens	206-211
21590447-6	2012	The DLT level was reached at oral metronomic vinorelbine 70 mg and capecitabine 1,250 mg/m(2), and the recommended MTD doses are vinorelbine 60 mg and capecitabine 1,250 mg/m(2).	Capecitabine	67-79	codanin 1	Homo sapiens	4-7
21590447-6	2012	The DLT level was reached at oral metronomic vinorelbine 70 mg and capecitabine 1,250 mg/m(2), and the recommended MTD doses are vinorelbine 60 mg and capecitabine 1,250 mg/m(2).	Capecitabine	151-163	codanin 1	Homo sapiens	4-7
22215908-0	2012	A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.	Capecitabine	35-47	natriuretic peptide A	Homo sapiens	2-5
22363067-14	2012	CONCLUSIONS: Cetuximab plus capecitabine at a dose of 1,000 mg/m2 every 12 hours may be an alternative to more aggressive regimens in elderly patients with advanced wild-type KRAS CRC.	Capecitabine	28-40	KRAS proto-oncogene, GTPase	Homo sapiens	175-179
22418569-0	2012	Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.	Capecitabine	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-63
22848366-0	2012	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	Capecitabine	89-101	erb-b2 receptor tyrosine kinase 3	Homo sapiens	33-37
22848366-0	2012	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	Capecitabine	89-101	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-109
22848366-1	2012	BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer.	Capecitabine	27-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	100-104
22396769-9	2012	Meanwhile, the subgroup analysis revealed that capecitabine improved the DFS in triple negative (HR = 0.71, 95% CI: 0.53-0.96, P = 0.028), hormone receptor negative (HR = 0.73, CI: 0.56-0.94, P = 0.017) and HER2 negative (HR = 0.81, CI: 0.67-0.98, P = 0.034) patients.	Capecitabine	47-59	nuclear receptor subfamily 4 group A member 1	Homo sapiens	139-155
22396769-9	2012	Meanwhile, the subgroup analysis revealed that capecitabine improved the DFS in triple negative (HR = 0.71, 95% CI: 0.53-0.96, P = 0.028), hormone receptor negative (HR = 0.73, CI: 0.56-0.94, P = 0.017) and HER2 negative (HR = 0.81, CI: 0.67-0.98, P = 0.034) patients.	Capecitabine	47-59	erb-b2 receptor tyrosine kinase 2	Homo sapiens	207-211
22690483-9	2012	Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2 is approved with capecitabine in trastuzumab resistant patients and in combination with letrozole in first line.	Capecitabine	78-90	epidermal growth factor receptor	Homo sapiens	47-51
23358102-8	2011	CONCLUSION: TUBB3, TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy.	Capecitabine	114-126	tubulin beta 3 class III	Homo sapiens	12-17
23358102-8	2011	CONCLUSION: TUBB3, TS and TP expressions could predict the response of advanced gastric cancer patients receiving capecitabine-based and paclitaxel-based chemotherapy.	Capecitabine	114-126	thymidylate synthetase	Homo sapiens	19-21
22397278-7	2011	The patient underwent a chemotherapy with capecitabine in total of 8 cycles before his CEA level began to rise and MSCT showed a progression in size of splenic metastasis.	Capecitabine	42-54	CEA cell adhesion molecule 3	Homo sapiens	87-90
22189229-8	2011	Early during the capecitabine treatment, grade 2 elevations in the patient"s GOT and GPT values were observed.	Capecitabine	17-29	glutamic--pyruvic transaminase	Homo sapiens	85-88
21898114-0	2012	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.	Capecitabine	26-38	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
22419903-7	2011	CONCLUSION: Treatment with capecitabine in addition to trastuzumab, which is one of the strategies applied in HER2-positive breast cancer, was effective in our patient.	Capecitabine	27-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
20567941-3	2011	This increased toxicity is probably due to the intracellular retention of polyglutamated folates induced by prior leucovorin therapy which, upon subsequent administration of capecitabine, will result in an enhanced and prolonged inhibition of the, for DNA synthesis important, enzyme thymidylate synthase, essentially creating a situation equivalent to overdosing.	Capecitabine	174-186	thymidylate synthetase	Homo sapiens	284-304
22418569-8	2012	Here, we review the available data on capecitabine as a single agent for first-line treatment of patients with human epidermal growth factor receptor 2-negative MBC.	Capecitabine	38-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-151
22467666-12	2012	The combination of bevacizumab, trastuzumab, and capecitabine was clinically active as first-line therapy for patients with HER-2-positive MBC, with an acceptable safety profile and no unexpected toxicities.	Capecitabine	49-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	124-129
21855639-1	2011	Uridine phosphorylase (UPP) catalyzes the reversible conversion of uridine to uracil and ribose-1-phosphate and plays an important pharmacological role in activating fluoropyrimidine nucleoside chemotherapeutic agents such as 5-fluorouracil and capecitabine.	Capecitabine	245-257	uridine phosphorylase 1	Homo sapiens	23-26
22190998-4	2011	Immunohistochemical staining of PAK4 protein was performed in tumor specimens of 49 metastatic gastric cancer patients who received palliative capecitabine/cisplatin as first-line treatment.	Capecitabine	143-155	p21 (RAC1) activated kinase 4	Homo sapiens	32-36
21954436-2	2011	We elucidated the effects on the metabolism and antitumor efficacy of 5-FU and capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) in our UPase knockout (UPase(-/-)) model.	Capecitabine	79-91	uridine phosphorylase 1	Mus musculus	150-176
21954436-2	2011	We elucidated the effects on the metabolism and antitumor efficacy of 5-FU and capecitabine (N(4)-pentyloxycarbonyl-5"-deoxy-5-fluorocytidine) in our UPase knockout (UPase(-/-)) model.	Capecitabine	93-141	uridine phosphorylase 1	Mus musculus	150-176
21954436-5	2011	UPase expressing colon 38 tumors implanted in UPase(-/-) mice revealed an improved therapeutic efficacy when treated with 5-FU and capecitabine because of the higher maximum tolerated dose for fluoropyrimidines achievable in UPase(-/-) mice.	Capecitabine	131-143	uridine phosphorylase 1	Mus musculus	0-5
21954436-5	2011	UPase expressing colon 38 tumors implanted in UPase(-/-) mice revealed an improved therapeutic efficacy when treated with 5-FU and capecitabine because of the higher maximum tolerated dose for fluoropyrimidines achievable in UPase(-/-) mice.	Capecitabine	131-143	uridine phosphorylase 1	Mus musculus	46-56